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Presentación 
Las macromoléculas biológicas, es decir, las proteínas, los ácidos nucleicos y los hidratos de 
carbono, son los motores principales de la célula viva. La esencia de la vida está regulada por 
las interacciones que se dan entre estas entidades, en distintos niveles de complejidad. El 
conocimiento de su estructura tridimensional, su dinámica y la manera en que se relacionan 
entre ellas y con otras moléculas más pequeñas contribuye, en gran medida, a entender el 
funcionamiento de la compleja maquinaria celular. Por otra parte, la gran cantidad de 
información genómica y estructural de la que se dispone en la actualidad requiere del uso 
de herramientas computacionales que puedan permitir llegar a conseguir una perspectiva 
global de los mecanismos, de las interacciones y de las redes subyacentes en la acción de la 
célula. 
En este sentido, la biología estructural ha prosperado en las últimas décadas como uno de 
los métodos esenciales para conseguir el conocimiento científico necesario que permita 
desentrañar los secretos de los procesos de reconocimiento a escala molecular. La biología 
estructural tiene una componente importante de métodos físicos y químicos y puede 
aplicarse para diseñar estrategias que interfieran con las interacciones moleculares a nivel 
celular y que, por tanto, puedan modificar el ciclo de la vida celular. Es decir, su importancia 
en el terreno biomédico y farmacéutico es evidente. 
Las herramientas esenciales para conseguir información a escala atómica son la 
espectroscopía de Resonancia Magnética Nuclear (RMN) y la difracción de rayos X. No 
obstante, existen una pléyade de técnicas que también proporcionan información 
estructural, a distintas escalas, como son distintas espectroscopías (IR, UV, Raman), la 
microscopía electrónica (EM) o los métodos basados en transferencia de energía de 
resonancia (FRET). Merece mención especial el desarrollo que la RMN ha experimentado en 
las dos últimas décadas. No obstante, hay que decir que todavía existe un límite en el 
tamaño de los complejos que pueden ser estudiados mediante RMN frente a aquellos que 
pueden conocerse mediante técnicas de difracción de Rayos X. Por otra parte, y en 
contraste con la cristalografía de Rayos-X, la RMN ofrece la ventaja de poder estudiar un 
sistema en disolución acuosa, y de poder caracterizar las propiedades conformacionales y  
dinámicas de las moléculas.  
En este trabajo de Tesis, se han aplicado métodos de RMN para el estudio de los 
mecanismos de reconocimiento molecular de dos sistemas biológicos relacionados con 
procesos de interés en biomedicina: a) el sistema formado por los Factores de crecimiento 
para Fibroblastos (FGF), sus receptores (FGFR), y oligosacáridos de heparina, y b) la proteína 
tubulina (en su forma no polimerizada y en su forma ensamblada formando microtúbulos) 
cuando interacciona con diversos agentes estabilizantes de microtúbulos (docetaxel, 
discodermolido y azatilona). Los métodos de RMN se han apoyado en distintas herramientas 
computacionales para proponer modelos tridimensionales de los complejos formados por 
estas moléculas. 
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1. General Introduction  
Over the last decades, advances in Nuclear Magnetic Resonance (NMR) spectroscopy both in 
hardware and pulse sequence developments have open new avenues for applications of NMR 
to study key chemical and biological problems. It is well established that knowledge about the 
structure of biomolecules may be crucial for understanding its function. Along these lines, 
NMR methods have become indispensable to gain insights into the conformational, structural 
and dynamic features at both the atomic and molecular levels. This knowledge has also 
fundamental implications in the drug discovery process, especially for structure-based drug 
design and for fragment-based drug design. 
[1-3]
  
Nowadays, NMR offers a wide variety of applications, from the classic structural 
characterization of proteins to the identification of small molecules (potential drugs) that bind 
to protein targets. Thus, NMR is widely employed as a tool for screening of large or medium 
size libraries, for exploring transient or dynamic processes, for studying functional properties 
of proteins and enzymes, and for characterizing other phenomena, such as protein folding.  
Very especially, NMR has been extensively engaged in the field of molecular recognition 
processes, from the chemical perspective to the biomedical viewpoint. As an example, in this 
Thesis, we have been paying attention to the investigation of recognition events related to 
cancer. Two different NMR-based approaches have been used for two topics, as will be 
shown below. 
 
1.1 Tubulin and the FGF/FGFR system as cancer therapy 
targets  
1.1.1 Cancer. Overview 
Cancer is one of the leading causes of death in civilized countries. It was not until the second 
half of the 20
th
 century that cancer has been more fully approached from the scientific 
perspective and its molecular and cellular basis began to be understood. Since then, anti-
cancer drugs and protocols to eradicate cancer such as chemotherapy, immunotherapy and 
radiotherapy, have been the favorite subject of interest for thousands of scientists. As a result, 
many effective treatments have been developed. However, it is still needed the development 
of novel anti-cancer drugs which show reduced side effects, higher selectivity towards tumor 
cells, and a broader spectrum of responsive tumors, implying the ability to circumvent the 
problems of resistance to current compounds. 
Cancer is a complex, multi-step process, characterized by a disturbance in cellular growth 
control. Tissue growth can be abnormal because of faults in cellular signaling cascades, which 
in turn lead to growth arrest, differentiation, or apoptosis. Also apoptosis is important during 
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normal development and maintenance of healthy organs. Indeed, abnormalities of apoptosis 
have been described in many serious pathologic conditions including cancer. Normal growth is 
tightly regulated by extracellular cues that trigger complex intracellular programs. Each cell 
has contact with neighboring cells and with the extracellular matrix. Much of the paracrine 
signaling between neighboring cells is mediated by growth factor action on their respective cell 
surface receptors. In many cases, these growth factor signals are mediated by the 
extracellular matrix, which can guide and restrict growth factor diffusion and, in some cases, 
act as a reservoir of signaling molecules. 
Cancer can be caused by several sources. Due to the complex nature of cancer development, 
it is not possible to pinpoint one specific agent as the cause of cancer. 
[4-6]
 Rather, it is most 
likely due to a number of contributing factors that include exposure to certain chemicals, action 
of viruses, exposure to radiation, and heredity. 
At present, surgery and radiation therapy continue to be the mainstays of cancer treatment.
[5, 7-
8]
 Chemotherapy, however, has also proven to be a highly effective treatment method for 
numerous cancers. Chemotherapy uses cytotoxic drugs and hormones to kill cancerous 
tumors. It is most commonly used in conjunction with surgery and radiation therapy against 
rapidly growing cancers that have spread or that are normally disseminated throughout the 
body. Examples of such cancers include the leukemias, lymphomas, and Hodgkin‟s disease. 
Multiple chemotherapeutic drugs are commonly administered at one time, to take advantage 
of synergistic effects and to combat the growing problem of resistance. This type of therapy is 
referred to as combination chemotherapy.  
1.1.2 Chemotherapeutic Agents 
Chemotherapeutic agents affect the course of cancer by taking advantage of the fact that 
cancer cells grow and reproduce faster than normal cells. 
[5, 9]
 Anticancer drugs may act at 
different levels: cancer cells, endothelium, extracellular matrix, the immune system, or host 
cells. The tumor cell can be targeted at the DNA, RNA or protein level. Most classical 
chemotherapeutic agents interact with tumor DNA, enzymes and/or substrates related to DNA 
transcription and synthesis. These drugs therefore exert their toxic and antitumor effects by 
inhibiting cells that undergo DNA synthesis at some point in their life cycle. The end result is 
either general cell death leading to necrosis, or the initiation of a controlled series of steps 
known as programmed cell death (apoptosis). 
Chemotherapeutic agents are often organized according to their origin or mechanism of 
action. 
[5, 10-11]
 These include alkylating agents which damage DNA; antimetabolites that 
replace the normal building blocks of RNA and DNA; antibiotics that interfere with the 
enzymes involved in DNA replication; topoisomerase inhibitors that inhibit either 
topoisomerase I or II, which are the enzymes involved in unwinding DNA during replication 
and transcription; mitotic inhibitors that inhibit mitosis and cell division; corticosteroids, which 
are used for the treatment of cancer and to relieve the side effects from other drugs; and other 
miscellaneous drugs, such as L-asparaginase, an enzyme used in the treatment of acute 
lymphocytic leukemia, or the proteosome inhibitor called bortezomib. (Table 1.1) 
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Nevertheless, anticancer chemotherapy has numerous problems. Due to the high inherent 
cytotoxicity of anticancer drugs and their selectivity for fast growing/reproducing cells, 
significant toxicity can be produced in a variety of normal tissues. As a result, patients 
commonly experience a host of disagreeable side effects, depending upon which tissue/organ 
or organ system is affected. Perhaps the best known and most widely experienced are intense 
nausea and hair loss, which are due to gastrointestinal and dermatological toxicity. 
Anticancer Drugs      
Alkylating 
agents 
Nitrogen mustards 
Cyclophosphamide 
(Cytoxan) 
melphalan 
clorambucil 
mechlorethamine 
 
Nitrosoureas 
carmustine 
(BCNU) 
lomustine 
Alkyl sulfonates 
Busulfan 
Triazines 
Dacarbazine 
(DTIC) 
temozolomide 
(Temodar) 
Ethylenimines 
Thiotepa 
altretamine 
(hexamethylmelamine) 
Platinum 
drugs 
Cisplatin 
carboplatin 
oxaliplatin 
 
Antimetabolites 
5-Fluorouracil 
(5-FU) 
fludarabine 
capecitabine 
(Xeloda) 
6-mercaptopurine 
(6-MP) 
methotrexate 
pemetrexed 
(Alimta) 
gemcitabine 
(Gemzar) 
cytarabine 
(Ara- C) 
Antitumor 
antibiotics 
 
 
Anthracyclines 
Daunorubicin 
doxorubicin 
(Adriamycin) 
Anthracyclines 
epirubicin 
Idarubicin 
Actinomycin-D bleomycin mitomycin-C  
Topoisomerase 
inhibitors 
 
Topoisomerase I 
Topotecan 
 irinotecan  
Topoisomerase 
II  
Etoposide  
(VP-16) 
 teniposide 
 
    
Mitotic 
inhibitors 
 
The Taxanes 
Paclitaxel (Taxol) 
docetaxel 
(Taxotere) 
 
Epothilones 
Ixabepilone 
(Ixempra) 
 
The Vinca 
alkaloids 
Vinblastine (Velban) 
Vincristine 
(Oncovin) 
 
The Vinca 
alkaloids 
vinorelbine 
(Navelbine) 
 
  
Corticosteroids 
Prednisone 
 
methylpredni-
sone 
(Solumedrol) 
dexamethasone 
Decadron 
 
   
Others 
L-asparaginase  
 
bortezomib 
(Velcade) 
Estramustine 
(Emcyt). 
 
   
 
 Table 1.1. Classification of anticancer drugs and their mechanism of action. 
 
Another emerging problem area is drug resistance. Cancer cells appear to have an unusual 
capacity for developing resistance to the effects of anticancer drugs. This is most commonly 
caused by additional genetic mutation within the cancer cell. However, other biochemical 
mechanisms can contribute, including decreased drug transport, the development of efficient 
DNA repair mechanisms, and the impairment of drug activation. 
[9]
 One major mechanism of 
multidrug resistance is linked to the overexpression of a 170 kDa plasma membrane 
glycoprotein, known as the P-glycoprotein (Pgp). This protein is proposed to function as an 
ATP-dependent efflux pump for hydrophobic drugs. 
[12]
  
The inevitable consequence of toxicity and drug resistance problems has lead to the progress 
of active research processes into new approaches. These aim to increase the specificity of 
cancer treatments, including biologically-based and targeted therapies. Immunotherapy 
utilizes the body‟s defense mechanisms by stimulating the immune response against cancer 
cells. Monoclonal antibodies (mAbs) against antigens or specific molecules expressed on the 
surface of cancer cells have been developed, and cancer vaccines that make immune cells 
recognize cancer cells and kill them are examples of biological-based treatments.  
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Targeted therapies block the growth and spread of cancer by interfering with specific 
molecules necessary for tumor growth, targeting selectively cancer cells, but not normal cells, 
and this greatly reduces the side effects associated with chemotherapy. Targeted therapies 
include anti-angiogenic drugs, various enzyme inhibitors, and antisense and gene therapy. 
This approach has been expanding to include drugs that are highly specialized, and are only 
effective for treating a narrow range of tumors. For example, the tyrosine kinase inhibitor, 
geftinib, which blocks EGFR signaling, is effective only in lung cancer patients that express the 
mutations in the tyrosine kinase domain of the EGFR gene. 
[13]
 
These targeted therapies have demonstrated considerable potential as anti-cancer agents in 
the clinic, especially when administered in combination with conventional chemotherapy 
treatment. It has been shown, for instance, that suramin, an inhibitor of multiple growth factors 
including aFGF and bFGF, enhances the in vitro antitumor activity of several anticancer drugs, 
such as paclitaxel. 
[14]
 Therefore, angiogenesis inhibitors and targeted therapies can act as 
effective adjuvants for improving the efficacy of the chemotherapeutic drugs. 
1.1.3 Angiogenesis Inhibitors 
Sustained angiogenesis is a hallmark of cancer. 
[15]
 The study of the mechanisms by which 
tumors promote new blood-vessels formation has been a highly active area of investigation in 
cancer research over the past two decades. It is now evident that angiogenesis is essential for 
tumor growth, and for progression of cancer from one site to other distant organs or tissues 
(metastasis). 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It is a complex 
process consisting of different sequential steps, which include the release of proteases from 
endothelial cells with subsequent degradation of the basement membrane surrounding the 
pre-existing vessels, migration of endothelial cells into the interstitial space, endothelial cell 
proliferation and differentiation into mature blood vessels. For these processes to proceed, an 
extensive interplay between cells, angiogenic inducers, and extracellular matrix components is 
necessary. The “basic fibroblast growth factor” (bFGF) and “vascular endothelial growth factor“ 
(VEGF) are probably the most important and best characterized pro-angiogenic factors. 
[16]
 
One of the most promising avenues in this field of cancer research is the study of a group of 
drugs called angiogenesis inhibitors (AIs). These are drugs that block the development of 
normal new blood vessels, stopping tumors from developing a blood supply, a pre-requisite for 
tumor spreading. AIs have some advantages over other forms of therapy: it is a disease-
specific therapy, since angiogenesis is a phenomenon that occurs in tumor tissue but not in 
normal tissue, and therefore should have a wide margin of safety. A second advantage is that 
anti-angiogenic therapy is directed against normal endothelial cells which, unlike tumor cells, 
are genetically stable, so it is less likely that drug resistance will develop as with 
chemotherapy agents. Bevacizumab (Avastin
®
, Genentech /Roche), a humanized monoclonal 
antibody (MAb) directed against VEGF, was the first commercially available angiogenesis 
inhibitor. Since its approval in 2004, it has been used as a treatment for metastatic colorectal 
cancer, breast and lung cancer. By binding to VEGF, Avastin blocks VEGF receptor binding, 
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inhibiting the formation of new blood vessels, thus denying tumors blood, oxygen and other 
nutrients needed for growth.  
With an exciting number of antiangiogenic agents in both preclinical and clinical development, 
targeting angiogenesis has become a promising strategy for cancer treatment, and a wide 
variety of therapies directed at interfering with this process are under development. 
[17-18]
  
Hence, the unregulated control of cell growth, cell division and angiogenesis serves an 
attractive and achievable objective for drug design as cancer therapy agents. 
1.1.4 Tubulin as chemotherapeutic target 
Over the past decades, significant progress has been made in the understanding of the 
biology of microtubule (MT) assembly into the mitotic spindle during mitosis and the molecular 
signaling and execution of the various pathways to apoptosis. Since one of the key 
components required for cell division and cell growth is the dynamic nature of the MT, 
essential for carrying out normal mitotic division, MT-targeted agents, that cause mitotic arrest, 
have been an important target for cancer treatment. 
[19-20]
  
Since 1960, MT-targeted agents obtained from natural plant or animal products, such as the 
vinca alkaloids and the taxanes, have been used as chemotherapeutic agents. Nowadays, 
paclitaxel and docetaxel, have come to occupy a central role in the treatment of a variety of 
human epithelial cancers.  
These agents can be divided into two major classes based on their effect on microtubule 
polymerization and the mass of microtubule polymers: those that inhibit polymerization (MT-
depolymerizing agents), such as the vinca alkaloids and colchicine, and those that stabilize 
microtubules (MT-polymerizing agents), such as the taxanes and epothilones. Their natural 
sources and chemical structures are remarkably diverse, making microtubules the only target 
for which such a diverse group of anti-cancer agents has been identified. (Figure 1.1) 
Microtubule depolymerizing agents 
The earliest MT-depolymerizing agents to be studied were the vinca alkaloids, extracted from 
periwinkle leaves (Catharanthus roseus). Vinca alkaloids depolymerize MTs, blocking the MT 
dynamics and leading to the suppression of cell division process. 
[21]
  Members of this group, 
which include vinblastine and vincristine, were used initially in the treatment of leukemia. And 
others semi-synthetic analogues, including vindesine, vinorelbine, and vinflunine, have been 
also found to have clinical efficacy. 
[22]
 Vinblastine and its semi-synthetic analogue, 
vinorelbine, bind to tubulin α and β-subunits and block its ability to polymerize into MTs. 
[23]
  
Microtubule polymerizing agents 
Microtubule polymerizing agents, in contrast, promote the assembly of microtubules from α,β 
tubulin heterodimers and stabilize microtubules by preventing depolymerization. This stability 
results in the inhibition of the normal dynamic reorganization of the microtubules network that 
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is essential for the vital interphase and mitotic cellular functions. 
Taxol
Epothilone A Epothilone B
Docetaxel
 
DiscodermolideDictyostatin  
Figure 1.1 Chemical structures of several natural and synthetic microtubule-polymerizing agents. 
 
Taxanes were the first-in-class microtubule-stabilizing drugs identified, and are now routinely 
used in the treatment of solid tumors, such as lung, breast and ovarian cancers. 
[24]
 Paclitaxel 
is the most important member of the clinically useful natural anticancer agents (Taxol
®
, Bristol-
Myers Squibb). Docetaxel (Taxotere
®
, Sanofi Aventis) is clinically used mainly for the 
treatment of breast, ovarian, and non-small cell lung cancer. 
[25-26]
 Epothilones are the newest 
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of the approved anti-mitotic agents that target microtubules. They are used for the treatment of 
drug-refractory advanced breast cancer and are under evaluation for the treatment of a range 
of other solid tumors. They have shown activity in a subset of paclitaxel-refractory tumors. 
[27]
 
Paclitaxel, a highly functionalized diterpenoid, was first isolated from the bark of Taxus 
brevifolia (Pacific Yew). In 1979 S. Horwitz with P. Schiff and J. Fant found the unique 
mechanism of action of taxol compared to previous anticancer drugs. 
[28]
 They discovered that 
taxol promoted the assembly of tubulin into stable microtubules and they explained the basis 
for taxol‟s known action as an antimitotic drug. Docetaxel, a semi-synthetic analogue of 
paclitaxel derived from a compound found in the European yew tree, Taxus baccata, was later 
found and considered as or even more effective than paclitaxel as a citotoxic microtubule 
agent.  
The success of the taxanes have led to a search for other natural products that enhance 
tubulin polymerization, yielding many promising compounds, including the epothilones 
(isolated from myxobacterium Sorangium cellulosum), discodermolide (isolated from the 
Caribbean sponge Discodermia dissoluta) and eleutherobins. There has been also a 
tremendous research interest in efficient approaches towards the total synthesis of taxanes 
and analogues. 
[29]
 In addition, many efforts have been done to study potential synergistic 
combinations of these compounds to overcome known mechanisms of drug resistance for the 
development of novel drugs. 
[30-32]
 
These antimitotic agents have been so successful in the treatment of cancer that no one 
would dispute that tubulin and microtubules are still a promising target for new 
chemotherapeutic agents. 
[33-34]
 However, it is still needed the development of novel anti-
cancer drugs which are able to circumvent the problem of taxol-resistance, and with better 
water-solubility properties than taxol, thus enabling the use of less problematic formulation 
vehicles for clinical application. 
1.1.5 FGF and FGFR as targets in anti-angiogenic tumor therapy 
In the 1980s, FGFs were first isolated from bovine brain extracts. The purification of pro-
angiogenic proteins led to the identification, and sequencing of the two prototypic heparin-
binding growth factors FGF1 (acidic FGF) and FGF2 (basic FGF). 
[35]
 It was shown that FGF1 
and FGF2 were very potent inducers of endothelial cell migration, proliferation in vitro, and 
also highly angiogenic in vivo. 
[36]
 Although initially conceived as FGF traps and protectors, it 
was later shown that heparan sulfate proteoglycans also participated in FGF signaling, 
although they are not absolutely required. 
[37-39]
 
Besides VEGFs, a wealth of information has recognized the involvement of different members 
of the FGF family in pathological conditions, rather related to cancer. Overexpression or 
genetic alterations lead to a deregulated activation of FGF/FGF receptor pathways in cancer 
[40]
, and elevated levels of FGFs are detected in the serum of cancer patients. 
[41]
 Sometimes, 
FGFs seem to be directly involved in tumor genesis by the autocrine, paracrine and juxtacrine 
induction of the growth of the cancer cells.  
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In addition, FGF signaling may affect processes other than growth associated to tumor 
progression. For example, they can be involved in the creation of profuse blood irrigation 
networks to sustain the intense metabolism of the tumor cells, which subsequently favor their 
dissemination throughout the organism. Tumor metastasis is additionally favored by the 
activation of enzymes that degrade the basement membrane and the enhancement of cell 
motility by FGFs. Moreover, they are also involved in inhibiting apoptosis, enhancing the 
survival of tumor cells, promoting the resistance of tumors to chemotherapeutic drugs and 
radiation, controlling tumor dormancy (a step in tumor progression), and controlling the self-
renewal of cancer stem cells. FGFs may also participate in paraneoplastic events in cancer 
patients. 
[14, 42-46]
 
Summarizing, FGFs may promote tumor growth by three different mechanisms: as angiogenic 
inducers, as mitogens for the tumor cells themselves, and as inhibitors of apoptosis. Since 
there are no documented activating mutations in FGFs themselves, the biological activities of 
FGFs in tumor growth are based on overexpression or increased availability of FGFs, due to 
release of intracellular and mobilization of the extracellular FGFs. For instance, FGFs are 
overexpressed in human pancreatic cancer and in breast cancer, in lung carcinomas or 
glioma. 
[47]
 
Thereof, blockade of the FGF pathway could inhibit tumor angiogenesis and growth. It can be 
achieved by different strategies, such as inhibition of FGFs synthesis, sequestration of FGFs, 
masking FGFRs, inhibition of FGFRs expression, and inhibition of signal transduction, as 
schematized in Figure 1.2. 
 
 
Figure 1.2 Strategies for inhibiting FGFs. Inhibitors of FGFs can act by reducing FGF production by the 
tumor (1), interfering with FGF-FGFR recognition (2,3), affecting endothelial cells expression of FGFR 
(4), inhibiting FGF-induced intracellular signaling pathways (5), or act downstream FGFs, on effectors 
of angiogenesis (6). (Figure taken from 
[48]
) 
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At present, there are more than twenty antiangiogenic agents in different stages of clinical 
development for oncology,
[49]
 a considerable number of which are polypeptides that the 
organism uses to counterbalance the effect of the positive angiogenesis regulators. 
[50]
 Among 
structurally different derivatives, potential inhibitors of fibroblast growth factors have been 
reported, such as naphthalene sulfonate derivatives,
[51]
  gentisic acid,
[52]
, modular proteins as 
thrombospondin-1 (TSP-1) 
[53-55]
 and other distinct inhibitors, including monoclonal antibodies. 
It has been shown that suramin, a non-specific FGF inhibitor, enhances the antitumor activity 
of several anticancer drugs in vitro and in vivo conditions in prostrate, bladder, pancreatic, 
lung, and breast cancer. 
[14, 56]
 
The antiangiogenic activity of suramins is based, at least in part, on their ability to disrupt the 
interaction of many growth factors with their membrane receptors, such as in the case of FGFs 
and their tyrosine kinase receptors. 
[57-60]
 Since it has been shown that heparin disrupts 
aFGF/suramin complexes 
[61]
 and counteracts the antiangiogenic effect of these 
polysulfonated ureas, 
[59-60]
 suramins are considered to act by blocking the heparin binding 
sites of FGFs. 
[62]
  
Another group of antiangiogenic and anti-tumoral compounds is comprised by the suradistas, 
a type of non-cytotoxic synthetic binaphthalene sulfonic distamycin-A derivatives. These 
compounds tightly interact with FGFs, inhibit the binding of these polypeptides to the tyrosine 
kinase cell membrane receptors, and suppress the FGF-induced angiogenesis and 
neovascularization in vivo 
[63-64]
, probably using a mechanism similar to that of the suramins. 
Gentisic acid (2,5-dihydroxybenzoic acid), a widespread plant secondary metabolite and a 
catabolite of aspirin, binds the heparin-binding site of FGF, changes the three-dimensional 
structure of the growth factor at their receptor recognizing site and is capable of dissociating 
the receptor:growth factor signaling complex. That is why has been used as a template to 
develop novel inhibitors of angiogenesis. 
[52]
 
The use of angiogenesis inhibitors is an exciting new area of cancer research, and growth 
factors have been demonstrated to be potential target for the development of new cancer 
therapies. 
 
1.2 Tubulin and Microtubules 
1.2.1 Structural features of tubulin and microtubules  
The basic structural motif of microtubule is an α/β-tubulin heterodimer, one of the most 
conserved proteins through evolution. 
[65-66]
 Tubulin heterodimers are built by the non-covalent 
bonding between the globular α-tubulin and β-tubulin subunits 
[22]
. The tubulin dimers 
polymerize, end to end, in protofilaments, which laterally interact with each other giving rise to 
a hollow cylinder- a MT (Figure 1.3).  
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In the tubulin heterodimer, the α-tubulin subunit is always bound to guanosine 5'- triphosphate 
(GTP), this site is non-exchangeable, 
[67]
 whereas the nucleotide associated with the β-subunit 
can exchange freely. The presence of non-hydrolysable GTP analogues maintains stability, 
because the GTP cap at the MT end prevents unraveling of the MTs. 
 
Figure 1.3 Microtubule structure and dynamics. MTs are intrinsically dynamic polymers that grow and 
shorten by the reversible non-covalent association and dissociation of /-tubulin heterodimers at 
their two ends. 
[68]
 The -tubulin and -tubulin subunits each has a GTP binding site, referred to as the 
nonexchangeable site in -tubulin, and the exchangeable site in -tubulin. 
[69-70]
 During the association 
of /-tubulin heterodimers to the ends of microtubules, guanosine 5'- triphosphate (GTP) in -
tubulin is hydrolyzed to guanosine 5'-diphosphate (GDP), which is unable to exchange. When the 
microtubule depolymerizes, the /-tubulin heterodimers are released and the GDP in -tubulin is 
now able to exchange to GTP. In contrast, although -tubulin also binds a GTP molecule, the GTP is 
bound at the nonexchangeable site and cannot be hydrolyzed to GDP during the addition of the 
tubulin heterodimers to the ends of microtubules. 
[71-72]
 (Figure taken from 
[73]
)  
 
MTs are highly dynamic filamentous fibers and stiff hollow cylindrical structures, composed of 
9 to at most 16 protofilaments, 
[74-75]
 that are set in parallel, which gives the MT a distinct 
polarity. Diameter of the MT is 25 nm and the thickness of the wall is 5 nm. Tubulin subunits 
assemble head-to tail in the same direction, 
[76]
 being this assembly faster at the plus end (fast 
growing) than at the minus end. 
[67]
 MT plus ends are more dynamic in nature than minus 
ends. The minus ends of MTs are located at the centrosome, which is also known as a 
microtubule organizing center (MTOC). The plus ends are located near the plasma membrane 
and are free in the cytoplasm. 
[77]
 Some MTs are entirely free in the cytoplasm rather than 
being anchored in the MTOC.  
In a first attempt, cryo-electron crystallography of zinc-induced tubulin sheets led to a low-
  Introduction 
 
 
13 
 
resolution model of taxol bound to tubulin. 
[78]
 Both α-and β-tubulin monomers (each55kDa) 
were found to be very similar, containing three main domains: 
1) a nucleotide binding domain,  
2)  an intermediate domain (which comprises the taxol binding site), 
3)  a C-terminal helical domain which is suggested to act as the interaction site for motors 
and other associated proteins. 
[78]
  
 
Further structural biology investigations 
into the taxol-tubulin interactions refined 
the electron crystallographic (EC) 
structure of the α, β-tubulin heterodimer 
bound to taxol at 3.5 Å resolution (Figure 
1.4).
[79]
 
Figure 1.4 Refined structure of α-β tubulin 
from Zn-induced sheets stabilized with taxol 
at 3.5 Å resolution. 
[79]
 (PDB code 1JFF) 
 
Docking calculations of the crystal structure of the protofilament into a 3D reconstruction of the 
microtubule obtained at 8 Å resolution allowed better understanding of the interactions 
between tubulin protofilaments as well as the dimer orientation within the microtubule. 
[80-81] 
Moreover, different computational tools were combined to obtain deeper insight into the 
presence of a putative binding site for taxanes on the outside of microtubules, 
[82-83]
 suggesting 
an additional binding site for the ligand before internalization into the known lumenal site. 
 
 In the work of Magnani et al., one intermediate site 
for taxanes and other MT-stabilizing agents was 
proposed at the so-called Type I pore of the 
microtubule (Figure 1.4). 
 
 
Figure 1.4 Microtubule wall structure model by Magnani 
et al.
[82]
 Type I pore, in magenta, was proposed as the 
external binding site of taxanes in microtubules. (Figure 
taken from 
[82]
) 
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1.2.2 Microtubule dynamics 
MTs undergo complex polymerization dynamics, which are regulated by hydrolysis of GTP. 
[67]
 
An essential feature for the activity of microtubules is their so-called „dynamic instability‟; they 
are highly-dynamic structures, comprising heterodimers that are continuously incorporated into 
the microtubule and released into solution in cells. This MT dynamic behavior is important 
during mitosis and cell division. 
[67]
  
 
Formation of protofilaments is a process which relies upon formation of short polymers of 
subunits, which are elongated with the addition of more heterodimer subunits. This process is 
defined as the nucleation-elongation pathway. 
[22, 67]
 During the elongation phase, subunits are 
added to the free ends of the existing MTs. The concentration of free tubulin declines until it 
reaches a plateau, the critical concentration, where the polymerization and depolymerization 
rates are exactly balanced. MTs known to be at equilibrium at the critical subunit 
concentrations are called treadmilling 
[76]
. Under these conditions, there are kinetically identical 
rates of addition/removal of tubulin. 
 
The addition of drugs can disrupt microtubule assembly and dynamics by three primary 
modes: (i) Substoichometric poisoning, which occurs if a drug can poison the end of a 
microtubule; (ii) Alternate polymer formation; or (iii) Microtubule stabilization. 
[84]
 
 
1.2.3 The mechanism of action of MT-binding agents 
The main effect of microtubule-targeting drugs is to block the mitotic phase at the cell cycle. 
Currently, there are four known drug-binding sites on tubulin: three that are well characterized 
(the vinca alkaloid, paclitaxel and colchicine sites). There is a fourth one that has not been 
fully established yet (laulimalide site). The names of the binding sites have been assigned 
according to the drug that was originally found to bind that specific site. The taxane binding 
site on β-tubulin, the only type that will be discussed along this Thesis, is shared by most 
drugs that stabilize microtubules (Figure 1.4). 
[79]
 
Paclitaxel binds to the β-subunit of the tubulin heterodimer in MTs and disrupts the flexible 
nature of the MT. Binding of paclitaxel promotes MT assembly, 
[24, 28]
 leading to 
hyperstabilization of the MT and consequently, blocking cells in the mitotic phase of the cell 
cycle. Paclitaxel ultimately arrests cell division and leads to apoptosis. 
[20]
 The unique 
mechanism of action as a MT stabilizing antimitotic agent is responsible by the extraordinary 
clinical success achieved by taxol and related taxanes in the treatment of a variety of cancers. 
Although taxanes are the most prominent among the known MT stabilizing agents, their 
scarceness, poor pharmacokinetic properties, high systemic toxicity, and resistance 
development have led to the identification of novel compounds having similar mechanisms of 
action. 
[28, 85-87]
 These include non-taxane MT stabilizing natural products as discodermolide, 
epothilones, and dictyostatin. These promising anticancer agents competitively inhibit the 
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binding of paclitaxel to tubulin polymers, indicating a largely overlapping binding site in the β-
tubulin cavity, which can accommodate a variety of structurally diverse MT stabilizing agents 
in unique and independent ways. 
[88-90] 
Epothilones and discodermolide 
Epothilones, whose major variants are epothilone A and epothilone B, and discodermolide are 
polyketide-based bacterial natural products, (Figure 1.1) that have shown to exhibit potent in 
vitro and in vivo antitumor activity. Their mechanism of action is similar to that of taxol, by 
stabilizing microtubules and blocking cells in the mitotic phase of the cell cycle. However, in 
contrast to taxol, epothilones and discodermolide are not substrates (or only very poor) for the 
P-gp efflux pump and therefore, exhibit virtually identical potency against drug-sensitive and 
many drug-resistant tumor cell lines (including taxol-resistant cells) in vitro. 
[87, 91]
  
In addition, both families of compounds are considerably more water-soluble than taxol 
[91-92]
, 
thus enabling the use of less problematic formulation vehicles for clinical applications. These 
physicochemical and biological characteristics have qualified these natural products as lead 
compounds for the development of new, more effective and safer anticancer agents. 
[89, 93]
 
 
1.3  The FGF/FGFR system   
1.3.1 The FGF family 
Fibroblast Growth Factors (FGFs) constitute a large family of more than twenty growth factors 
that are involved in a variety of critical biological processes such as proliferation, 
differentiation, cell migration, morphogenesis, and angiogenesis. 
[94-98]
 FGF polypeptides are 
present in the intracellular and extracellular environment of endothelial cells and blood 
vessels, and in parenchymal cells in neural, skeletal and reproductive tissues, as well as in 
major organs.  
All of FGF family members, with molecular weight ranging from 17 to 34 kDa, share a highly 
homologous central core of 28 highly conserved and 6 identical amino acids sequences 
[99-100]
. 
Ten of these highly conserved sequences are responsible for the interaction between FGF 
and its receptor, FGFR 
[100-101]
. Another similarity among FGF family members is that they all 
have a high binding affinity to heparin and heparin sulfate proteoglycans. 
[100, 102-106]
  
FGF1 and FGF2 are widely expressed in normal adult tissues, whereas other family members 
are found predominantly in embryonic and tumor tissues. FGF1 and FGF2 are involved in the 
development and function of numerous organ systems, induce cell proliferation, migration, and 
angiogenesis in vitro, and stimulate wound healing and repair 
[94, 100, 107]
. Aberrant FGF activity 
is found in pathologic conditions including Alzheimer's disease, atherosclerosis, and neoplasia 
[108]
. FGF2 may also inhibit the growth of different cells. 
[109-110]
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1.3.2 FGF receptors and FGF signaling 
The mechanism by which FGFs stimulate cellular responses concerns binding to the 
extracellular domains of their specific fibroblast growth factor receptors (FGFRs 1- 4), which 
have intrinsic tyrosine kinase activities, leading to receptor dimerization and phosphorylation of 
the cytoplasmic domain of the FGFR. 
[94, 111]
 Phosphorylation of these tyrosine kinases initiates 
the activation of signaling pathways, leading to gene transcription and diverse responses. 
[112]
 
It has been proposed that molecular association between FGF and its receptor requires direct 
involvement of heparin and heparan sulfate proteoglycans (HSPGs), thus forming a specific 
complex on the cell surface, which is essential for biological activity. 
[99, 112-113]
 The HSPGs act 
as the low affinity receptor of FGF, enhancing the binding of FGF to its high-affinity tyrosine 
kinase receptor. 
[114-115]
 
Nowadays, there are four known FGF receptors, FGFRs1-4, which share approximately 29–
72% sequence identity at the protein level. A prototypical FGFR contains three extracellular Ig-
like domains (Ig1, Ig2 and Ig3), a stretch of acidic amino acids between Ig-like domain 1 and 2 
that is unique for FGFRs, a transmembrane domain, and two intracellular domains with protein 
tyrosine kinase activity, which are responsible for activating downstream signaling and 
biological responses. Whereas Ig1 and the Ig1–Ig2 linker with a contiguous stretch of acidic 
amino acids are known to be involved in auto-inhibitory regulation, the determinants for FGF 
binding and specificity are located at Ig2 and Ig3 domains and at the linker that connects 
them. 
[116-117]
 Due to alternative splicing in the Ig-like domain 3, there are two different receptor 
isoforms, IgIIIb and IgIIIc, for FGFR1, FGFR2 and FGFR3. FGFR4 only has one possible form 
of its Ig3 domain. The seven FGFR isoforms display remarkably different ligand binding 
specificity. For example, bFGF binds FGFR1 (IIIb and IIIc), FGFR2 (IIIc), FGFR3 (IIIc) and 
FGFR4, but not FGFR2 (IIIb) or FGFR3 (IIIb), whereas aFGF has high binding affinity to 
FGFR2 (IIIb) and FGFR3 (IIIb). 
[112, 118]
 
Different binding specificities of FGFs to various FGFR subtypes and the tissue-specific 
alternative splicing may contribute to the diverse function of FGFs. FGFR expression was 
observed in a majority of human tumor cell lines. 
[119]
 However, the prevalence of the different 
FGFRs in human tumor tissues has not been systematically investigated, except that 
increased expression of the FGF2-responsive IIIc isoform during tumorigenesis of epithelial 
tumors was observed. 
[118, 120]
 Therefore, the widespread expression of FGFRs in human 
tumors suggests a possible role of FGF signaling pathway in tumor growth, malignant 
progression and FGF-mediated chemoresistance.  
1.3.3 Heparin and heparan sulfate 
Heparin and heparan sulfate (HS) are complex, highly sulfated, acidic linear polysaccharides 
that are composed of repeating disaccharide units consisting of an uronic acid 1,4‐linked to a 
ᴅ‐glucosamine unit. They belong to the glycosaminoglycan family, or GAG. The differences 
between their structures are related to the level of sulfate substitution and to the chemical 
nature of the predominant uronic acid (iduronic acid in heparin and glucuronic acid in HS). The 
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most common disaccharide unit of heparin is composed of a 2-O-sulfo--ʟ-iduronic acid 1,4-
linked to 6-O-sulfo, N-sulfo--ᴅ-glucosamine, IdoA2S-GlcNS6S (Figure 1.5). An average 
disaccharide contains 2.7 sulfate groups, thus rendering heparin one of the most acidic 
macromolecules in nature.  
A                                                                 B
ᴅ-GlcA-(14)-ᴅ-GlcNAc-(14) ʟ-IdoA2S-(14)-ᴅ-GlcNS6S-(14)  
Figure 1.5 Major repeating disaccharide units in (A) HS, (B) heparin. Heparin has a simpler structure 
with its most common disaccharide unit being 2-O-sulfo-ʟ-iduronic acid (IdoA2S) 14-linked to 6-O-
sulfo, N-sulfo-ᴅ-glucosamine (GlcNS6S), -IdoA2S(14) GlcNS6S-. HS has a similar but more highly 
variable and less sulfated structure with its most common disaccharide unit being ᴅ-glucuronic acid 
(GlcA) and N-acetyl-ᴅ-glucosamine (GlcNAc), -GlcA(14)GlcNAc-. 
 
These polysaccharide precursors may extensively vary (by epimerization, N-deacetylation, 
and N-, O-sulfation), thus creating a wide heterogeneity of GAG structures. The binding 
specificity of these GAGs is encoded in their primary structures, but ultimately depends on 
how their functional groups are presented in the three-dimensional space to interact with a 
given receptor.  
The conformation of heparin 
The molecular conformation of GAGs, especially of those containing IdoA such as heparin, 
heparan sulfate and dermatan sulfate, has been a matter of controversy for years. 
[121]
 Heparin 
exists primarily as a helical structure, 
[122]
 and it seems to display its sulfo and carboxyl groups 
in defined patterns and orientations to promote specific protein interactions. 
[123]
 Analysis of the 
conformation of individual sugars within heparin indicates that the glucosamine and glucuronic 
acid residues assume the preferred 
4
C1 conformation. 
[124]
 In contrast, the conformation of the 
flexible iduronic acid (IdoA) residue varies, depending on the substitution pattern of this 
residue and on its relative position in the chain. This conformational flexibility of the iduronic 
acid residue within heparin is believed to be responsible for the wide range of specific protein 
interactions exhibited by this family of GAGs. 
[125]
  
The availability of a number of synthetic heparin oligosaccharides 
[126]
 has permitted extensive 
studies on the conformation of IdoA (and IdoA2SO3) in different sequences, showing that three 
almost iso-energy possible conformations, 
4
C1, 
1
C4 and 
2
SO (Figure 1.6), exist when the IdoA 
is at the reducing end of the oligosaccharide. However, the internal IdoA adopts equilibrium 
between 
1
C4 and 
2
SO forms. Nevertheless, this conformational variation does not produce a 
significant conformational change in the backbone of the polysaccharide chain. 
[122]
 The 
2
SO 
form appears to be slightly favored in terms of conformational stability, as it tends to minimize 
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the unfavorable 1,3 diaxial nonbonded interactions that are expected in the 
1
C4 form, where 
four of the substituents are axially oriented and only the carboxyl group is equatorial. 
[30]
  
4C1                                                                       
1C4                                                             
2S0
 
Figure 1.6 Conformational flexibility of the iduronic acid residue in heparin. In the chair forms, atoms 
C2, C3, C5 and O5 are in one plane (the atom numbering is clockwise); in 
4
C1 form C4 is above the 
plane while C1 is below. In 
1
C4 form, C1 is above the plane while C4 is below. In 
2
SO form, a plane can 
be defined containing atoms C1, C3, C4 and C5, where C2 is above the plane while O5 is below. 
 
However, the energy barrier to the 
1
C4 form is not high and therefore, it is possible for the 
iduronate ring to change between the 
2
SO and 
1
C4 forms. This fact means that, in a putative 
bound state, either form can make favorable electrostatic interactions with basic amino acids 
at the protein surface. 
[127]
 Relative conformer populations are also affected by extrinsic 
factors, such as the type of counter ions. 
[128-129]
  
The crystal structure analysis of FGF2 bound to a heparin hexasaccharide revealed that one 
internal IdoA2S residue tightly interacting with the protein adopted the less populated 
2
SO 
geometry, whereas the other weakly interacting residue adopted the standard 
1
C4 
conformation. 
[130]
 Thus, while the iduronate rings are flexible and in equilibrium between the 
2
SO and 
1
C4 conformation in the unbound state, they can be locked into either conformation 
when bound to a protein. Indeed, whereas IdoA2SO3 residues in the NS domains of heparin 
are about 60% in the 
1
C4 and 40% in the 
2
SO conformation, 3-O-sulfation of GlcNSO3 as in the 
AT-binding domain reverses to 40:60 the population of these conformers. 
[131]
 
Heparin binding to AT III 
The earliest known biological role of heparin was as a clinical anticoagulant. Since 1936, 
heparin has been used in clinics for the prevention and treatment of thrombosis. Its main 
antithrombotic activity is explained by its ability to potentiate the activity of the serine protease 
inhibitor antithrombin III (AT-III), which inactivates a number of serine proteases such as 
thrombin and factor Xa in the coagulation cascade. 
[132]
 
It was later in the 1980s when it was deduced that a specific pentasaccharide fragment, that 
occurs in about one-third of the heparin polysaccharide chains, constituted the minimal binding 
domain for AT-III. 
[133]
 This interaction of heparin with antithrombin was the first reported 
example for a specific heparin‐protein interaction of physiological significance. The 
characteristic heparin pentasaccharide sequence, which was later synthesized as AGA*IAM 
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(Figure 1.6), displays a rare 3-O-sulfated GlcNSO3 residue, and several sulfate groups that are 
essential for high-affinity binding to AT-III (highlighted in red in Figure 1.7).  
A G A* I AM  
Figure 1.7 Synthetic pentasaccharide responsible for AT-III binding. The sequence is AGA*IAM (where A 
is GlcNSO36SO3; A*, GlcNSO33,6SO3; G, GlcA; I, IdoA2SO3). The groups highlighted in red are absolutely 
essential for the activation of AT-III, whereas the groups in blue only help to increase the biological 
activity. The 3-O-sulphate group at position A* is specific for binding to AT-III. It is clinically used as 
Fondaparinux (Arixtra®, GlaxoSmithKline) and has been approved for prophylaxis and treatment of 
deep vein thrombosis (DTV) and pulmonary embolism (PE) in certain clinical interactions. 
(www.arixtra.com) 
 
Upon binding to the pentasaccharide, AT-III undergoes a conformational change, which 
results in its activation and inhibition of thrombin and other coagulation cascade protease. This 
process has been studied in great detail 
[126, 134]
 by NMR spectroscopy 
[135]
 and X‐ray 
crystallographic 
[136-137]
 methods. 
Heparin binding to FGF/FGFR 
Over the past decade, rapid progress in the development of technology for GAG structural 
characterization has complemented whole-organism genetics, leading to a dramatic increase 
in the known important roles of GAGs in fundamental aspects of cell growth, cell-cell 
interactions, and developmental processes.  
Nowadays, it is believed that heparan sulfate proteoglycans play a key role in cell proliferation, 
because they act as co-receptors for growth factors of the FGF family. Indeed, members of the 
FGF family need to interact with both a heparin ⁄ HS chain and with their high affinity receptor 
to perform their full signaling potential. 
[138-139]
  
The interactions of heparin with fibroblast growth factors (FGFs) and their receptors (FGFRs) 
have been the subject of many studies. An emerging paradigm in this field is that unique 
heparin sequences bind to growth factors and receptors in a specific way, as it occurs for AT 
III. 
[140-141]
  
 
In Table 1.2 the principal minimal binding sequences of the heparin/HS chains preferentially 
recognized by glycosaminoglycan-binding proteins are summarized. 
[142]
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Interaction   Minimal binding sequence 
Heparin/HS – AT III A6S - G - A* - I - A 
Heparin/HS -- Lipoproteinlipase  G - ANS - G - ANS - I  
Heparin/HS -- FGF2  A - I - A - I - A - I 
Heparin/HS -- FGF1  A - I - A - I 
Heparin/HS – Herpes simplex virus 
Glycoprotein gD  
U - ANS - I - A
-
- U - ANS - I - A3S 
Table 1.2. Key binding sequences contained within the heparin chains that mediate interactions with 
GAG-binding proteins (where A is GlcNSO36SO3; A*,GlcNSO33,6SO3; ANS, GlcNSO3;  A6S,GlcNAc6SO3; 
G,GlcA; I,IdoA2SO3; U, IdoA or GlcA; A
-
, GlcNH2; A3S, GlcNH23SO3
-
) 
 
1.3.4 FGFR dimerization as a key event in FGF signaling. The FGF-heparin-
FGFR ternary complex 
Ligand-induced dimerization seems to be the key event for the activation of FGFRs, as has 
been described for other receptor tyrosine kinases (RTKs),
[143]
 and this process requires 
heparan sulfate proteoglycans. 
[111, 114-115, 144]
 Subsequently, FGF signaling occurs, with trans-
autophosphorylation at conserved tyrosine residues of the cytoplasmic domain. 
[145]
 
Defining the precise mechanism for FGFR dimerization is important, not only for the 
understanding of FGFR function, but also for the ability to manipulate FGFR signaling with 
therapeutic purposes. Thus, understanding the mechanism by which FGF and heparin/HS 
cooperate to promote FGFR dimerization has been one of the most controversial issues in 
FGF signaling.  
X-ray crystallography-based structural analysis of different combinations between the three 
components (FGFs, FGFRs, HSPGs) have been solved in different research groups. 
[130, 143, 
146-148]
 Among them, two X-ray structures of the ternary complex FGF1-heparin-FGFR2 (PDB 
entry 1E0O) 
[147]
 and FGF2-heparin-FGFR1 (PDB entry 1FQ9) 
[149]
 have permitted to explore 
two conceptually different models of FGFR dimerization. (Figure 1.8) Interestingly, there are 
striking discrepancies in the proposed topologies and stoichiometries of the two experimentally 
defined ternary complexes.  
There is a 2:1:2 FGF1:heparin:FGFR2 structure, which shows a FGF1 trans-oriented dimeric 
structure, sandwiching a HS chain, for which there are no protein-protein interactions, neither 
between FGF-FGF nor between FGFR-FGFR molecules. FGF interacts with FGFR only via 
the so-called primary site (in Ig2-Ig3), while heparin only interacts with one of the FGFR 
molecules. For this reason this model has been dubbed as “asymmetric”. Based on this 
model, the shortest biologically active HS would be an octasaccharide, although maximal 
activity would require a dodecasaccharide, because it will be long enough, such that it could 
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engage Ig2 of both FGFRs. 
[147]
 In contrast, there is also a “symmetric” model, for a 2:2:2 
FGF2:heparin:FGFR1 complex, which shows FGF-FGFR interactions not only via the primary 
site present in the asymmetric model, but also via the so-called secondary site (in Ig2). The 
HS moiety adopts a cis-type orientation when interacting with the FGF and, in addition, there 
are contacts between the two Ig2 modules of the two FGFR moieties. 
Ig2
Ig3
Ig3
Ig2
FGF
FGFR
FGFR
FGF
A                                               B
 
Figure 1.8 Proposed models for the ternary complex FGF-heparin-FGFR. A) Crystal structure of the 
complex FGF2-heparin-FGFR1 with stoichiometry 2:2:2. This model shows two FGFs dimerized by 
heparin, bringing two FGFR molecules together. B) Crystal structure of the complex FGF1-heparin-
FGFR2 with stoichiometry 2:1:2. This model shows two FGF–FGFR–heparin heterotrimers forming a 
complex via interactions of the FGFR in each complex with all three members of the other complex. 
FGFR is shown as cyan and green cartoons, FGF is shown as dark blue cartoon and heparin is shown as 
sticks, oxygen atoms colored red and sulfur atoms colored yellow.  
 
In this structure, only the first six sugar units at the non-reducing end of the decasaccharide 
are in contact with any protein (FGFR or FGF). The remaining four sugar units of one of two 
decasaccharides are disordered. In the other decasaccharide, two additional sugar units are 
visible due to the favorable crystal contacts that they make with an adjacent FGF molecule. 
Thus, based on the symmetric model, a hexasaccharide should be sufficient for dimerization 
and hence biological activity. 
[150-151] 
Summarizing, in the symmetric two-end model, heparin promotes dimerization of two FGF-
FGFR complexes by stabilizing bivalent interactions of the ligand and receptor through primary 
and secondary sites and by stabilizing direct receptor-receptor contacts. In contrast, in the 
asymmetric model, there are no protein-protein contacts between the two FGF-FGFR 
complexes, which are solely bridged by heparin. 
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1.4 Experimental NMR techniques for the study of protein-
ligand interactions 
1.4.1 Nuclear Magnetic Resonance spectroscopy. Overview 
Nuclear magnetic resonance (NMR) spectroscopy has become a powerful tool to investigate 
structural features, dynamics and interactions of biomolecules in solution, at atomic resolution. 
Challenges of this method include the need for relatively high concentrations (usually in, or 
close to, the mM range). Nevertheless, this drawback has been overcome in part by the 
development of cryogenic probes and very high field magnets, above 16 Tesla, which permit 
to run multidimensional experiments using medium to high µM concentration ranges. Still, a 
limitation of liquid-state NMR spectroscopy resides in the size of the investigated molecules. 
For large proteins, there are not only significant resolution problems due to overlapping 
signals, but also there is a severe broadening of the signals. The larger a molecule is, the 
slower it tumbles in solution. This fact in turn leads to an increase of the relaxation rates and 
thereby to line broadening and experimental efficiency problems. In addition, for ligand-
receptor complexes, chemical exchange can also lead to severe line broadening, depending 
on the exchange rate. 
The prerequisite for the NMR-based investigation of a molecule at atomic resolution is the 
assignment of the spectral resonances to the particular nuclei. In the case of 
biomacromolecules above certain size (10 kDa), the process is facilitated by the labeling of the 
molecules of interest with NMR active isotopes. Modern assignment experiments are based 
on the incorporation of 
13
C and 
15
N nuclei into the molecules and on the selective transfer of 
magnetization between 
1
H, 
13
C and 
15
N nuclei. This will be explained in detail in the Material 
and Methods section. 
A variety of NMR parameters can be used for the characterization of a molecule. Chemical 
shifts, scalar coupling constants, and particularly, vicinal (
3
J) coupling constants can report on 
molecule conformations, since they depend on the torsion angle between the connected spins. 
The relationship between coupling constants and dihedral angles is given by so-called Karplus 
relations (Figure 1.9). 
[152]
 Karplus relations exist for a large number of coupling constants, and 
report on the backbone torsion angles (, ). The homonuclear nuclear Overhauser effect 
(NOE) yields through space distance restraints up to 5-6 Å. These parameters are routinely 
used for structure calculations and are also employed for sequential assignments.  
 
Figure 1.9 Stereochemical dependence of the 
three-bond coupling constant 
3
J expressed by 
the equation proposed by Karplus. 
[152]
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NMR diffusion-ordered NMR spectroscopy (DOSY) can be used for the analysis and 
characterization of complex mixtures and aggregates, and for the study of intermolecular 
interactions, both qualitatively and quantitatively, to identify compounds that bind to a specific 
receptor. 
In the case of a protein, amide proton to deuterium exchange methods can be used to identify 
hydrogen atoms that are involved in hydrogen bonds or are buried in the protein core, since 
these protons are protected against exchange with the solvent. Hydrogen exchange rate 
determination therefore can also provide valuable information on protein folding intermediates, 
unfolded states, and kinetics.  
1.4.2 NMR in structural analysis of carbohydrates 
This part of the introduction has been condensed within the book chapter entitled: 
Carbohydrate NMR spectroscopy 
In Encyclopedia of Biophysics, to be published (2011) 
by Lidia Nieto1 and Jesús Jiménez-Barbero1 
1Chemical and Physical Biology, Centro de Investigaciones Biológicas, CSIC, Madrid  
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Chemical and Physical Biology/Centro de
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Introduction
In the past years, the application of nuclear magnetic
resonance (NMR) spectroscopy to carbohydrates has
become a powerful tool for a full understanding of the
molecular processes in which carbohydrates are
involved. Determining the three-dimensional structure
of carbohydrates is crucial since their biological func-
tion originates from their conformation. And NMR
methods have become indispensable to gain insights
into these conformational, structural, and dynamic fea-
tures at both the atomic and molecular levels,
a fundamental requirement for further successful drug
design. Given the increasing interest in the biological
roles of carbohydrates, recent advances in NMR can
offer new insights into the functional understanding of
carbohydrate interactions, which can overcome the
challenge of developing new carbohydrate-derived
therapeutics in the future.
There are several factors that have made possible
the recent advances in this topic. On the one hand, the
development of newmethods for the efficient synthesis
of carbohydrates of increasing size and complexity;
and on the other hand, the recent advances in NMR
spectroscopy, both from the hardware and software
perspectives, such as the access to spectrometers with
higher and higher magnetic field strengths and the
development of new NMR techniques, facilitating
higher sensitivity as well as increased resolution.
These features have contributed to the characterization
of very complex oligosaccharides and glycoconjugates
(Jime´nez-Barbero and Peters 2002). In addition, the
development of small molecules that may mimic the
structure and function of complex carbohydrates has
also emerged as potential source for understanding
carbohydrate recognition and has opened new avenues
from the structural and conformational viewpoints
(Ernst and Magnani 2009).
In contrast to X-ray crystallography, NMR spec-
troscopy allows one to monitor, from the qualitative
to quantitative perspectives, the intrinsic physical flex-
ibility of carbohydrates, providing information on their
geometries and dynamics. However, given the inherent
flexibility of carbohydrates, the combination of the
NMR parameters with computational chemistry tools
are usually required. Therefore, a multidisciplinary
approach is often necessary to gain insight into the
physical chemistry structural properties of carbohy-
drates. The advantages and limitations of these struc-
tural techniques have been previously reviewed
(Wormald et al. 2002).
The present chapter will briefly address some basic
features of carbohydrate NMR as well as some of the
recent methods and applications of this technique in
the rapidly evolving carbohydrate research field, from
the chemistry to the molecular recognition areas.
Structure Determination
NMR spectroscopy methods are able to provide basi-
cally all the key information necessary to completely
define the primary structure of a glycan molecule.
G.C.K. Roberts (ed.), Encyclopedia of Biophysics, DOI 10.1007/978-3-642-16712-6,
# Springer-Verlag Berlin Heidelberg 2012
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The NMR chemical shift, the simplest parameter to
access, is highly sensitive to the chemical environment
that is surrounding each NMR-sensitive atom. For
instance, the presence of an electronegative group, as
SO3
, in glycosaminoglycans produce a significant
deshielding of the chemical shift of the directly
bound protons to the corresponding carbon O-sulfation
point in the 1H NMR spectra. Due to the limited 1H
chemical shift dispersion in the NMR spectra of carbo-
hydrates, the anomeric proton resonances, found in the
shift range 4.4–5.5 ppm, can be firstly analyzed and is,
in principle, the easiest accessible nucleus. The chemi-
cal shifts of these protons, as well as those belonging to
the rest of the sugar ring, strongly depend on the struc-
ture of the carbohydrate chain and are the basis for the
concept known as structural reporter group. Some
empirical rules can be followed for the identification
and assignment of the 1H NMR spectra of oligo and
polysaccharides: (1) The anomeric protons are found
more downfield than the remaining proton resonances.
(2) In pyranose rings, the equatorial proton resonances
appear downfield than the axial ones. For instance, H-2
protons of Man moieties resonate at lower field than
those of Glc rings. For anomeric protons, H-1a reso-
nates between 5.0 and 5.8 ppm, while H-1b resonates
between 4.4 and 5.2 ppm (3) Vicinal coupling constant
between the anomeric H-1 and the H-2, 3J1,2, indicates
the relative orientation of the two protons; in the case of
D sugars and b anomers, a large coupling constant
(7–9 Hz) is observed, whereas for a anomers this J is
smaller (2–4 Hz).
A combination of experiments based on interactions
through bonds (spin–spin coupling) and interactions
through space (dipole–dipole coupling) are required
for the determination of the molecule assignment. 2D
classical NMR homo- and heteronuclear experiments,
such as homonuclear TOCSY and DQF-COSY, can
help in the identification of individual spin systems.
Given the additional dispersion in the carbon dimen-
sion, heteronuclear 1H-13C HSQC or HMQC, together
with HMBC experiments, provides important short-
and long-range correlations, respectively, the latter
often useful for the sequence assignment information.
Despite the enormous structural diversity of oligo-
saccharides, 1H and 13C chemical shifts for most
monosaccharides and variations thereof can be found
in the literature. In fact, there is detailed information
for the wide variety of component monosaccharide
residues, different anomeric configurations, ring
forms, and for disaccharides and higher oligosaccha-
rides, also for the different inter-glycosidic linkages.
There are also a variety of sugar databases, containing
chemical shift and structural features of characterized
monosaccharide, oligosaccharide, and more complex
carbohydrates, which can be very helpful for the
assignment procedure. Some of them are CarbBank,
Complex Carbohydrate Structure Database (CCSD),
and SUGARBASE. In particular, CarbBank contains
branched carbohydrates structures, while
SUGARBASE is a carbohydrate-NMR database that
combines CarbBank Complex Carbohydrate Structure
Data (CCSD) with proton and carbon chemical shift
values (Van Kuik and Vliegenthart 1993). Further-
more, GlyNest and CASPER are two independent
approaches to estimate 1H and 13C NMR shifts of
diverse glycans.
For a basic view of NMR background, methodol-
ogy, and routine applications for structural elucidation
of different molecules, the reader is referred to special-
ist books (i.e., Claridge 2009). For specific structural
characterization of carbohydrates as well as practical
considerations in this field, the reader can find more
detailed information in different books (i.e., Sinott
2007) and review articles (Duus et al. 2000; Bubb
2003).
Conformation
The conformational features of biomolecules, includ-
ing carbohydrates, are usually (but not uniquely) char-
acterized by measuring nuclear Overhauser effect in
different types of experiments, such as NOESY and
ROESY. The NOE between two nuclei depends on the
distance between them (/ r6). Because of the confor-
mational flexibility of carbohydrates around the glyco-
sidic linkages, the derivation of molecular structure
from NOE values is not straightforward. In addition
to the 1/r6 dependence of distance, the NOE has
a complex time dependence, in which the overall
molecular tumbling may interact with kinetics of the
conformational exchange involved in the internal
motion (Neuhaus and Williamson 1989). Moreover,
the NOE-based approach works well when there are
sufficient measurable NOEs that are sensitive to
molecular shape, which is not usually the case for
oligosaccharide structural analysis. In fact, one of the
major targets to derive the conformational features of
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carbohydrates is the derivation of the torsion angle
values, F and C, which define the conformation
around the O-glycosidic linkages. Very few NOEs
possess information on these values. Additionally, vic-
inal proton–proton coupling constants might also pro-
vide crucial information for determining the 3D
structure of molecules in solution, but they cannot be
employed to derive the conformation around the gly-
cosidic torsions. Nevertheless, in flexible structures
such as carbohydrate molecules, scalar coupling con-
stants may have the advantage that calculation of aver-
age values over an ensemble of conformations is
simpler than that for NOEs. Recent developments in
multidimensional NMR have made possible a number
of new methods for measurements of the
interglycosidic heteronuclear coupling constants,
which might be useful for conformational analysis.
Experiments such as HMQC-NOESY and HMQC-
TOCSY for the determination of long-range H–C and
of the HMBC-type for the determination of C–H and
C–C coupling constants permit access to explore trans-
O-glycoside scalar couplings to derive the conforma-
tion aroundF/C pairs. In any case, taking into account
the existing conformational averaging, it is worth not-
ing that combining the NMR parameters with the data
obtained from molecular mechanics (MM) and molec-
ular dynamics (MD) simulations may be necessary to
determine carbohydrate conformation (Vliegenthart
and Woods 2006). Further examples of new sophisti-
cated NMR methods for carbohydrate NMR assign-
ment as 3D homo- and heteronuclear experiments,
using 13C-enriched samples, have been carefully
described (Duus et al. 2000).
Dynamics and Recognition
Other NMR techniques, such as 13C- and 2H-based
NMR relaxation experiments, allow us to deduce
dynamic parameters through the measurement of
relaxation parameters, thus revealing important
dynamic information in oligo- and polysaccharides
(Jime´nez-Barbero and Peters 2002).
From the molecular recognition perspective, it is
well known that carbohydrate–protein interactions
are implicated in a variety of cell–cell and cell–matrix
recognition events. Along these lines, the great poten-
tial of the application of NMR technologies in the drug
discovery process is also acknowledged (Zerbe 2003).
In this context, NMR has become crucial for the study
of the specificity and molecular recognition features of
different neutral and charged (glycosaminoglycans)
carbohydrates by carbohydrate-binding proteins
(lectins, antibodies, and enzymes). These proteins spe-
cifically recognize particular carbohydrate structures,
usually with well-defined molecular topographies. In
these interaction studies, NMR offers some unique
features that make it an attractive means for monitor-
ing interactions either using single putative ligands or
even for screening of carbohydrate libraries to identify
target compounds that bind to specific proteins. By
using NMR, it is also possible to deduce the specificity
and affinity of binding, association constants, and equi-
librium thermodynamic parameters (Poveda and
Jime´nez-Barbero 1998).
Intermolecular Interactions
NMR has the key advantage of being able to detect
weak intermolecular interactions in the mM range,
which can be beneficial in the first steps of the discov-
ery procedure. Indeed, NMR is the ideal technique for
a fragment-based screening protocol (Coles et al.
2003). Basically, all NMR parameters may serve as
sensors for detecting the binding of a ligand to
a protein. Generally speaking, by using NMR, two
different approaches can be used: receptor-based and
ligand-based experiments, depending on the signals
that are chosen to monitor the interaction.
The employed protocols range from the robust and
well-known chemical shift mapping approach, from
the receptor’s viewpoint, to ligand-based techniques
that monitor changes in the nuclear spin relaxation
properties of the ligand’s nuclei upon binding, passing
to measuring the changes in the translational diffusion
coefficient of the ligand when passing from the free to
the bound states.
Starting from the ligand’s perspective, very proba-
bly, the most frequently used NMR strategies are the
saturation transfer difference experiment (STD) and, to
a lesser extent, the transferred nuclear Overhauser
spectroscopy (trNOESY) technique. Provided that the
dissociation rate is fast in the relaxation timescale,
these methods can provide detailed structural informa-
tion on the binding characteristics of particular carbo-
hydrate–protein interactions. STD experiment gives
knowledge of the binding of a ligand to the target
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receptor and, in some favorable cases, defines the
recognition epitope of the ligand. The information is
achieved by selectively saturating several resonances
that belong to the receptor. The saturation is rapidly
transferred throughout the whole protein reaching the
protons at the binding site, which are also saturated. If
the ligand binds, the saturation is transferred by cross-
relaxation to the binding compound at the ligand–
receptor interface (Mayer and Meyer 1999) thus
changing the intensities of the ligand. These changes
in intensities are easily detected by using difference
spectroscopy and permit differentiation of binding
from nonbinding entities. Also, since the first protons
of the ligand to feel the magnetization transfer are
those in closer contact with the protein, information
on the binding epitope can also be achieved. The
trNOESY experiment not only allows to deduce the
existence of binding, but also to know the conforma-
tion of the ligand in the bound state, an information
which is of paramount importance in the drug design
process. When small molecules bind to large receptor
proteins, the observed exchange-transferred NOE
cross-peaks undergo drastic changes in sign (from
positive to negative) thus providing the required infor-
mation. The observation of negative trNOESY cross-
peaks relies on the existence of very different tumbling
times tc for the free (in the picosecond timescale) and
bound (in the nanosecond timescale) molecules. Fur-
ther analysis of these experimental data with molecular
modeling programs can help to deduce and refine the
three-dimensional structure of the complex.
The final aim of the study of any molecular recog-
nition process is to know the structure–activity rela-
tionships (SARs) that regulate the interaction between
a particular glycan and its protein receptors to allow
the rational design of molecules that enhance or abol-
ish the interaction, depending on the final aim. Differ-
ent rational ligand design strategies can be envisaged
that range from the preparation of molecules that are
pre-organized in their bioactive conformation, or the
incorporation, within a given scaffold, of additional
binding sites that can lead to enhancement of the affin-
ity and to a reduced entropy cost of the binding pro-
cess. Within this context, an interesting approach in the
discovery of high-affinity ligands is the “SAR by
NMR” concept (Shuker et al. 1996). This receptor-
based approach is based in the chemical shift pertur-
bation analysis of the protein resonances (usually NH
or CH atom pairs in HSQC-type of experiments) upon
binding to different ligands. Thus, diverse ligands from
a library can be identified that bind to two neighboring
binding sites of a protein. Subsequent chemical linking
of two of these ligands through the use of the proper
spacers permit the production of high-affinity ligands.
As a consequence, glycomimetics with therapeutic
interest can be successfully designed (Ernst and
Magnani 2009).
Carbohydrate-Binding Proteins
Relaxation measurements also provide valuable infor-
mation on the extent of the motional changes that take
place at specific amino acid residues of carbohydrate-
binding proteins (from the receptor’s viewpoint) and
also of the extent of rigidification that takes place at the
oligosaccharide moieties upon binding to the receptor.
In the last decades, together with the development
of methods for isotope labeling of carbohydrates,
the increasing application of residual dipolar couplings
(RDCs) and anisotropies in carbohydrates has permit-
ted retrieval of complementary structural (global
orientational restraints) and dynamic (internal molec-
ular motion) information in anisotropic media. This
long-range type of information describes the relative
orientation of remote atoms or molecular fragments,
important information which is unavailable from J
coupling- or NOE data-analysis alone. Measurements
of both one-bond and two-bond 1H-13C and 1H-1H
RDCs provide conformational information in oligo-
saccharides and glycolipids, in a variety of alignment
media, such as bicelles, bacteriophage, polyacryl-
amide gels, and others. This approach has also been
taken for the elucidation of carbohydrate–protein inter-
actions, making possible determination of the relative
orientations of the ligand and the protein. Advances
made in alignment, data acquisition and analysis
methods, and some examples have been reviewed
(Jime´nez-Barbero and Peters 2002; Prestegard et al.
2004).
Other Methods
In addition to the use of standard 1H and 13C spectros-
copy, further NMR methods have been developed
employing other NMR-active nuclei such as 19F and
31P. In this context, 19F possesses favorable NMR
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properties: 100% natural abundance, high sensitivity
(gF/gH ¼ 0.94), and high chemical-shift dispersion.
Thus, it is not unexpected that over the last decade,
fluorinated carbohydrates have been used as NMR
probes for investigating biologically relevant systems
(Michalik et al. 2000).
Most recently, solid-state NMR applications have
been used for the study of biological molecules that
were intractable to high-resolution liquid-state NMR
techniques, based on experiments performed on static
samples or recorded under magic-angle sample spin-
ning (MAS) conditions (Zerbe 2003).
Summary
In the past years, NMR spectroscopy has been demon-
strated to be a robust tool for carbohydrate research.
The challenge, therefore, is to continue designing new
NMR methodologies to completely characterize the
structural, dynamic, and binding properties of a wide
range of carbohydrates in biological systems, with the
additional further possibility of developing carbohy-
drate-derived therapeutics in the future.
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KD  =
[𝑃][𝐿]
[𝑃𝐿]
=
koff
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kon 
 koff 
 
[P] + [L]    ⇆    [PL] 
 
1.4.3 NMR in molecular recognition processes 
NMR spectroscopy is one of the most widely used techniques to characterize molecular 
recognition events at atomic level. NMR techniques can be employed both for studying 
protein-ligand and protein-protein interaction processes. These methods, usually assisted by 
computational protocols, permit to elucidate the structural features of the binding entities, as 
well as to characterize the kinetic and thermodynamic features of the free-bound equilibrium.  
NMR techniques provide the possibility to study interaction events directly in solution, close to 
the physiological medium. Since the binding process strongly modifies the physicochemical 
properties of both partners, especially rotational and diffusion motion timescales, there are 
several NMR parameters that are influenced by the interaction process, as chemical shift, 
relaxation time and NOEs, diffusion constants, etc. 
The binding of small ligands to large receptor proteins follows a bimolecular association 
reaction 
[153]
 with second-order kinetics:    
          
         Eq 1.1 
where [P], [L] and [PL] are the equilibrium concentrations of protein, ligand and complexed 
state, respectively ([P] and [L] are also referred to as the free or non-bound states); kon is the 
association rate and koff is the dissociation rate (measured as s
-1
 M
-1
); and the dissociation 
constant (KD) can be written: 
         Eq 1.2 
 
KD has the units of concentration. Therefore a value of KD in the mM range implies an 
approximately 1:1000 ratio of free to bound states in an equimolar mixture of P and L and a KD 
in the μM range implies an approximately 1:1,000,000 ratio of these states, i.e., a much more 
stable complex with less of the „free‟ species present. kon can extensively vary in a range from 
10
4
-10
11
, being larger if the complexation process needs conformational rearrangements of 
either ligand or receptor. Diverse NMR methods can be used for the determination of the KD of 
a protein-ligand complex, as has been recently reviewed by Fielding. 
[154]
 
The binding process is, in fact, a dynamic chemical exchange between free and bound states. 
Different simulations are possible, depending of koff. The exchange may be fast in the 
chemical-shift (CS) time scale, koff >>, or display an intermediate value, koff , and also the 
exchange can be rather slow, koff <<. Δ =2Δ, is the chemical shift difference between the 
free and bound states, measured in Hz. 
A complete discussion of how chemical exchange modifies the NMR parameters (dynamic 
NMR) should include a description of the modified Bloch equation formalism of Hahn, Maxwell, 
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𝐴 = 𝑝𝑏𝑜𝑢𝑛𝑑  𝐴𝑏𝑜𝑢𝑛𝑑 + 𝑝𝑓𝑟𝑒𝑒  𝐴𝑓𝑟𝑒𝑒                             Eq. 3.2                            
and McConnell. 
[155-156]
 This formalism (HMM) provides an excellent theoretical framework to 
describe the majority of the exchange phenomena that occur in NMR screening experiments, 
under all exchange regimes. Such a treatment is beyond the scope of the present Thesis but 
can be found in a recent review by Peng et al. 
[157]
  
Slow exchange approximation 
 
For a system in slow exchange on the chemical shift time scale (in general terms this would be 
a protein–ligand system with high binding affinity and low dissociation constant, KD = μM or 
lower), resolved signals might be expected for the free and bound states, and using the ligand 
observed example, [L] and [PL] are in principle available by integration of separate resolved 
signals. In practice this is extremely difficult because of the difficulty of detecting μM signals in 
what is likely to be a complex and crowded spectrum. 
Fast exchange approximation 
The solutions to the HMM equations describe the behavior of system magnetization on 
arbitrary exchange time scales. In NMR-based screening, however, these equations are 
almost never solved, and fast exchange is simply assumed. This assumption is made for two 
reasons. First, the experimental conditions for ligand-based NMR screening are often well 
suited to fast exchange. These experiments are typically carried out with a LT/RT > 10 (where 
LT and RT refer to total ligand and total receptor concentrations, respectively) and the binding 
compounds have a KD ≥ 100μM. If kon is well approximated by a diffusion-limited value (10
7
-
10
9
 M
-1
s
-1
), then the slowest exchange rate kex values lie in the range 1000 <kex< 100,000 s
-1
. 
Ligand-based NMR screening methods are primarily 
1
H based and consequently, kex exceeds 
most differences in intrinsic 
1
H relaxation rates and rotating frame precession frequencies, 
thus ensuring that the fast exchange assumption is valid. A second motivation for assuming 
fast exchange is the resulting algebraic simplicity. Generally, the NMR parameters A become 
the simple averages: 
Eq 1.3 
A is the observed exchange-averaged parameter for the ligand (or receptor) in the presence of 
the receptor (or ligand). Observed differences between A and Afree provide a signature of 
receptor binding and indicate a hit in a NMR screening based on that parameter. In the case 
scenario described by equation 1.3, A is a simple population-weighted average and it applies 
to those parameters A for which chemical shift modulations are not relevant. These 
parameters include longitudinal relaxation and cross-relaxation rates, rotating-frame spin-
locking relaxation and cross-relaxation rates, and translational diffusion coefficients. The 
bound state contribution in Eq. 1.3 is pboundAbound. The ability to detect binding with adequate 
sensitivity depends critically on pboundAbound, being significant relative to pfreeAfree. However, 
typical screening conditions where LT>>RT make pbound<<pfree. For this reason, it is much 
preferred to measure NMR parameters A that become amplified in the bound state (i.e. Abound 
>> Afree). 
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From a structural perspective, the traditional way to solve macromolecular complexes by NMR 
spectroscopy requires the collection of proton–proton NOEs (Nuclear Overhauser Effects), 
which can be translated into distances. When the structures of the separate biomolecules are 
already known, the 3D structure of the complex can be derived by selectively analyzing the 
intermolecular NOEs. In addition to these intermolecular NOEs, also orientational restraints 
like residual dipolar couplings (RDCs), heteronuclear relaxation rates, or paramagnetic 
pseudo-contact shifts can be used, that may permit to define, more precisely, the orientation of 
the two macromolecules in the complex. 
[1-3]
 
Besides a wealth of structural information, NMR methods can supply a wide variety of 
transient and dynamic information of the complex. These NMR methods can be divided in 
those detecting the receptor signals (receptor-based experiments) and those detecting the 
ligand signals (ligand-based experiments). Both receptor- and ligand-based approaches have 
distinct advantages and disadvantages. Clearly, if receptor-based methods can be employed, 
then the potentially higher information that can be obtained makes these the methods of 
choice. Unlike ligand-based methods, receptor-based methods do not rely on fast exchange to 
retrieve bound state information and observation of receptor resonances permits the 
characterization of both higher and lower affinity hits. However, due to the scarcity of low-
molecular weight drug targets, ligand-based screening is, in general, of broader applicability 
and places less demands on other research disciplines and infrastructure.  
Next sections will explain, in detail, the fundamental of the methodologies applied on the 
course of this PhD Thesis. 
1.4.4 Receptor-based experiments 
The monitoring of molecular recognition processes using NMR receptor-based methods is 
based on the comparison of different NMR parameters of the receptor molecule resonances in 
the presence and absence of the ligand (or mixtures of putative ligands). Thus far, the 
receptor-based methods have focused mostly on proteins. Such methods incorporate site 
specific characterization, since they required previous assignment of the protein NMR 
resonances. This assignment should be ideally combined with the a priori knowledge of the 
receptor‟s 3D structure (either from X-ray or NMR) to drive lead generation.  
The NMR methods used for assignment of the protein resonances will be discussed in the 
chapter of Material and Methods. 
Chemical shift perturbation mapping 
One of the most frequently used receptor-based methods relies on the perturbation of the 
receptor chemical shifts upon binding of the ligand (CSP). The chemical shift is an extremely 
sensitive parameter to environmental changes (pH, temperature, and denaturalization) and, of 
course, interaction processes. CSP mapping obtained via NMR titration experiment is a 
straightforward NMR technique to define those protein residues which are involved in the 
binding to a partner molecule (as reviewed in 
[158]
). 
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A series of NMR experiments (generally 
15
N HSQC spectra) of the free protein and of the 
protein with increasing amounts of the ligand are recorded. The proximity of the ligand in the 
complex will modify the environment of the nuclei that are at the interface of the complex. As a 
result, nuclei involved in the binding will have a different chemical shift than in the unbound 
form. Due to the large size of most receptors, 2D NMR is often required and chemical shift 
mapping is usually obtained from 
1
H-
15
N HSQC and 
1
H-
13
C HSQC spectra. Of course, for 
these experiments, isotope labelling with 
15
N and/or 
13
C are often necessary, for sensitivity 
reasons.  
It is clear that the observed chemical shift changes upon binding can also result from indirect 
conformational changes in the protein due to the binding. Cases have been reported in which 
a protein will completely change its conformation upon complex formation; in that case, all 
chemical shifts will therefore be perturbed. In most cases, however, complex formation only 
induces few or minor structural rearrangements and chemical shift perturbation can then be 
used to define the interface residues. This technique, however, is generally applied only 
qualitatively and does not allow to unambiguously identify pairs of atoms that are in contact in 
the complex or to get precise intermolecular distance information. Furthermore, it does not 
provide any information about the orientation of the protein with respect to its counterpart. 
Because of that, chemical shift perturbation information results have rarely been used directly 
for structure calculations. 
[159]
 
The binding site is thus localized by identifying perturbations of the assigned protein 
resonances. This site specific characterization of binding can suggest strategies for fragment-
based lead generation, in which lower affinity molecular fragments binding to distinct subsites 
can be linked, or further elaborated, to yield higher affinity compounds. In addition, localization 
of binding sites also enables one to immediately distinguish specific from nonspecific binding.  
Intermolecular NOEs 
To solve the structure of a macromolecular complex by NMR, structural information is needed 
in addition to the intrinsic intramolecular NOEs to define the contacts between the two 
molecules. The most reliable information that can be obtained comes from proton-proton 
distances derived from the intermolecular NOEs. The analysis of these contacts may precisely 
identify the binding site and the distances between the protein and the bound ligand atoms.  
The NOE 
[160]
 originates from dipolar cross relaxation between protons and depends on the 
proton–proton distance and on the molecular motion of the interproton vector. An approximate 
relation for the NOE intensity is: 
NOE  < 1 / r6 >  f(c)       
where r is the proton-proton distance and f a function that depends, among others, on the 
correlation time (c) that describes the motion of the interproton vector. For rigid molecules, the 
values of all proton-proton correlation times are defined by the overall tumbling of the 
molecule, which in the simplest case can be described by a single isotropic overall rotational 
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correlation time. In that case, ratios of NOE intensities provide ratios of distances. These NOE 
intensities can be easily measured in 2D and 3D NOE spectra. 
Internal mobility attenuates the NOE effect in biomolecules and therefore the NOEs are 
generally translated into an upper limit to the distance rather than into a precise distance. In 
practice, the NOE becomes very weak at distances larger than 5-6 Å. Very often, these weak 
NOEs contain contributions from spin diffusion and should be used with care. Therefore, only 
an incomplete set of relatively imprecise distance restraints can be used in structure 
calculations, which then leads to a series of possible solutions. The more precise distance 
restraints and the larger number of distance restraints are obtained, the closer these solutions 
will be. NMR structures are therefore generally presented as an overlay of wireframes, where 
a close overlay represents the well determined regions. 
If the lifetime of the complex is long enough (i.e. for a complex with low dissociation rate), it is 
possible to observe clear NOEs between protons that belong to the different molecules. The 
simplest way to obtain these intermolecular NOEs is to record a homonuclear NOESY 
spectrum of a complex and to search for the additional NOEs, as compared to the NOESY 
spectra of the free biomolecules. Analysis of such spectra, however, is a lengthy process and 
it is often difficult to discriminate the inter- from the intramolecular NOEs. The use of isotope 
labeling and filtering can overcome this problem. 
Filtered experiments 
The introduction of 
13
C and 
15
N isotopes into one of the molecules of the complex allows the 
use of isotope-filtered experiments. These techniques permit to unambiguously assign 
intermolecular proton-proton NOEs (reviewed in 
[161]
). Isotope-filtered experiments were first 
introduced by Otting and Wüthrich, as two-dimensional X-double-half-filtered experiments, 
where X stand for the “NMR-active” heteroatom (
15
N and 
13
C for proteins). 
[162]
 
In addition, many hybrid schemes combining purge filters and 3D X-separated NOESY spectra 
have been developed to allow the recording of three-dimensional spectra to characterize 
binding processes, even protein-protein interactions in symmetric dimers. 
 [163-166]
 These 
isotope-filtering techniques rely on the presence of a scalar coupling between a proton and the 
attached “NMR-active” heteroatom (
13
C for example) and the absence of a scalar coupling 
between a proton and an “NMR-inactive” heteroatom (
12
C for example). The scalar coupling 
can be exploited to discriminate between these two different classes of protons. The classical 
scheme to measure intermolecular NOEs is to study complexes in which one protein is 
isotopically labeled and the other one is unlabeled. The experiment corresponds to a 
1
H-
1
H 
NOE experiment that is isotope-filtered in one proton dimension and isotope-edited in the 
other proton dimension. This results in a spectrum containing exclusively intermolecular NOEs 
providing that the scalar coupling is similar for all proton-heteronuclei pairs and that the 
labeled protein contains a high percentage of the “NMR-active” isotope (at least more than 
98%). Additionally, spectra showing only intramolecular NOEs for one of the species, 
removing all the signals of the other counterpart can also be obtained. 
[167]
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The study of macromolecular complexes by NMR has been facilitated enormously by these 
isotope-filtered NOE experiments. A limitation is that the additional delays in the isotope-
filtered experiments leads to lower sensitivity in the NOESY spectra and therefore only an 
incomplete set of NOEs can be obtained by these methods. In most cases, a conventional 
analysis of unfiltered NOESY spectra is also necessary. 
1.4.5 Ligand-based experiments   
These are probably the most frequently employed NMR experiments in the drug discovery 
process, both in academia and in industry. As the “ligand-observed detection” name suggests, 
detection takes place on the resonances of the free ligand, which has several advantages 
compared to the target protein. When the resonances of a small molecule are observed in a 
mixture, ligand recognition can be easily identified by using, for example, the inversion of the 
sign of the NOE signals of a ligand interacting with a larger target (Figure 1.10). In addition, 
there is no requirement of labelled protein, no limitations in size for the target molecule, or any 
requirement of knowledge about target structure.  
+
Large target Small ligands Complex
Slow Brownian motion
Fast relaxation
Slow diffusion
Negative NOE
Fast Brownian motion
Slow relaxation
Fast diffusion
Positive NOE
Motional properties of L
similar to R properties
koff
kon
KD = koff / kon = [R][L]/[RL] 
R
L
RL
 
Figure 1.10 Illustration of the different physical properties when a small ligand interacts with a large 
protein target. 
 
Due to the small size of the ligand molecules, the use of 1D NMR may be sufficient. Examples 
of these methods include line broadening effects (based on relaxation changes), diffusion 
editing, WaterLOGSY, and saturation transfer difference (STD) NMR spectroscopy. 
Transferred NOE is used to obtain the conformation of the ligand in the bound state. 
Preferably, methods from both categories should be used to obtain information about the 
ligand, the receptor, as well as their interactions. 
[1-3]
  
However, many of these techniques depend on size-dependent effects between ligand and 
target and can be difficult to resolve for weak binders and relatively small size differences 
between the ligand and the target. In addition, the information for structure-based ligand 
optimization obtainable through these techniques is more limited than for target observed 
techniques, as structural information regarding the binding site can only be obtained using the 
latter. 
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One of the more versatile and robust experiments in this area is known as the saturation 
transfer difference (STD) experiment. 
[168]
 STD can rapidly detect the presence of binding 
equilibria and also yields information on the ligand binding epitope. As a result of these 
features, STD has found widespread use as a fast and sensitive screening method for binding 
affinities in mixtures, useful for generating leads in the drug-discovery area.  
Saturation transfer difference (STD) 
Saturation Transfer Difference (STD) NMR Spectroscopy 
[168-169]
 is a ligand directed method 
for studying ligand-receptor interactions. The technique has no upper size limit for the receptor 
molecule and it can be applied to monitor any interaction, provided that there is the possibility 
to selectively irradiate the NMR signals of the receptor. Experimentally, for proteins, this 
selective irradiation is performed at the very high field aliphatic region (0 to -2 ppm), where 
there is a relatively high protein signal density and no ligand resonances. 
[170-171]
 The STD 
experiment is performed for a ligand:receptor sample, which contains a high excess of the 
ligand molecules (ca. 100:1 molar equivalents). 
First, a selective saturating pulse is applied within a narrow frequency region of receptor 
proton resonances, where ligand resonances are absent. Due to the typically large molecular 
weight, spin diffusion is able to “spread” this saturation throughout all the receptor proton 
resonances, including the key area of the binding pocket. If binding activity is present, the 
saturation is transferred to the signals of the bound ligand. Therefore, the signals of the actual 
ligand are also saturated and change their intensities. This information is taken back into 
solution for detection once the ligand dissociates. Since the ligands are typically small 
molecules with long relaxation times, the saturation information is able to persist for a time 
during which “new”, previously unsaturated ligand molecules can also bind with the saturated 
receptor, increasing the population of saturated ligands in solution. This process is illustrated 
in Figure 1.11. 
A difference spectrum is obtained by recording this spectrum with the irradiation frequency set 
on protein resonances (ON-resonance) and another spectrum with the saturation set at a 
frequency where there are no protein signals (ca. 100 ppm, dubbed OFF-resonance); 
subsequently the latter is subtracted from the first. Proton signals from non-binders or those 
within binding molecules but far removed from the binding pocket are cancelled in the 
difference spectrum (the ligands that are not bound to the protein will not obtain saturation 
transfer and their intensities will not be affected by the saturation pulse at the protein protons). 
Thus, the STD NMR spectrum will only contain signals from ligands in contact with the protein. 
The resonances of the protons in closest proximity to the receptor molecule will have the 
strongest enhancement in the STD spectrum; and thereby the method can be used to obtain 
detailed structural information on the binding epitope of the ligand. However, the relaxation 
time of the individual protons also influences the relative intensity of STD signals. 
[172]
 This 
highly versatile technique is frequently used in screening for drug candidates. 
[173]  
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Kon
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H
H
H
H
H
H
Koff
on resonance spectrum
STD spectrum  
Figure 1.11 Detection of binding using the standard saturation transfer difference (STD) experiment. 
[174]
 Frequency selective irradiation (large red arrow) causes selective 
1
H saturation (red coloring) of 
the target receptor. Irradiation is applied for a sustained interval during which saturation spreads 
throughout the entire receptor via 
1
H-
1
H cross-relaxation (spin diffusion). Saturation is transferred to 
binding compound during their residence time in the receptor binding site. The number of ligands 
having experienced saturation transfer increases as more ligand exchanges on and off the receptor 
during the sustained saturation period. Non binding compounds do not appear in the STD spectrum. 
Perhaps one on the most elegant aspects of this technique is that it can easily be used to identify the 
building blocks of ligands in direct contact to the receptor, because these regions (epitopes) receive 
the highest degree of saturation. 
 
Compared to other techniques, STD has several advantages. One is that the structure of the 
large receptors does not have to be determined to study eventual interaction or binding 
affinities. In addition, there is no upper limit on the size of the receptor. In fact, STD favors 
large receptor molecules at stronger magnetic fields (STD works better for large receptor 
molecules and small ligands). Rules of thumb are that the receptor have a molecular weight > 
20 kDa and the ligand < 8 kDa). It can be applied to a broad range of dissociation constants, 
ranging 10
-8
 < Kd < 10
-3
 M. Binding constants can also be obtained from STD NMR 
experiments. 
[169]
 The STD sequence can be used in combination with other pulse programs 
and has been added to 1D and 2D TOCSY, COSY, HMQC and HMBC, 
[169,175-176]
 or combined 
by editing/filtering 
13
C, 
15
N, 
19
F schemes. 
[177-178]
 This technique yields excellent sensitivity, in 
part due to the saturation amplification process alluded to and pictured above. As a result, only 
small amounts of receptor are needed (for instance, 0.3 nmol can be sufficient, depending on 
the size).  
STD has been shown to work on membrane bound protein with very complex ligand mixtures. 
[171,179]
 When the target molecule is small or has elongated structure, making the saturation by 
spin diffusion less efficient, extra care have to be taken to find appropriate settings for the 
experiments. 
[180-181]
  
It has been already shown that STD-NMR is an excellent technique for determining the 
binding epitope of the ligand, information that is of primarily importance for a rational drug 
design process. As consequence of the intermolecular saturation transfer process described 
above, the ligand saturation is higher for those protons that are in closer contact with the 
receptor. This kind of information can be accurately analyzed 
[182]
 and the STD effect can be 
quantitatively analyzed in a similar way to that mentioned above for quantitative estimation of 
trNOEs. 
[183-184]
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Transferred NOE 
It is well established that NOE effects (NOEs) are extremely useful for determining the 3D 
structure of molecules in solution. 
[185]
 When ligand molecules bind to receptor proteins, the 
NOEs undergo drastic changes leading to the observation of transferred NOEs (trNOEs). 
These changes are the basis for a variety of experimental schemes that are designed to 
detect and characterize binding activity. The observation of trNOEs relies on the existence of 
rather different tumbling times c for the free and bound molecules. Low- or medium-
molecular-weight molecules (MW < 1000 Da) have a short correlation time c (less than 1 ns) 
and, as a consequence, such molecules exhibit positive or almost negligible NOEs. Large 
molecules, with c above 2 ns, however, exhibit strongly negative NOEs. When a small 
molecule (ligand) is bound to a large-molecular weight protein (the receptor molecule), it 
behaves as a part of the large molecule and adopts the corresponding slow motion behavior. 
Therefore, it shows strong negative NOEs, so-called trNOEs. These trNOEs reflect the bound 
conformation of the ligand. Binding of a ligand to a receptor protein can thus easily be 
distinguished by looking at the sign and size of the observed NOEs (Figure 1.12).  
 
Figure 1.12. At the left: schematic representation of a NOESY spectrum for a free ligand. Cross peaks 
and diagonal peaks have different signs; at the right: Schematic representation of a TR-NOESY 
spectrum recorded for an exchanging ligand–protein system. Cross peaks and diagonal peaks have the 
same signs, as expected for a large molecule, thus indicating binding to the protein. The relative sizes 
of the peaks and the appearance of new ones may be used to detect conformational variations. 
[186]
 
 
Furthermore, the discrimination between trNOEs originating from the bound state and NOEs of 
the ligand in solution can also be achieved by the build-up rate, that is, the time required to 
achieve maximum intensity for trNOEs is in the range of 50 to 200 ms, whereas for small, non 
binding molecules, it is much longer, above 500 ms. Therefore, the maximum enhancement 
for trNOEs is observed at significantly shorter mixing times m than for isolated small 
molecules in solution. Various experimental implementations have been explored in the last 
two decades, ranging from 1D selective steady-state experiments to 1D and 2D transient NOE 
experiments. 
[185,187] 
 
However, one of the major drawbacks of this experiment is the possible existence of spin 
diffusion effects, which are typical for large molecules. In this case, apart from direct 
enhancements between protons close in space, other spins (including those of the receptor) 
may mediate the exchange of magnetization, thus producing negative cross peaks between 
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protons far apart in the macromolecule. Thus, protein-mediated, indirect trNOE effects may 
lead to interpretation errors in the analysis of the ligand bound conformation. However, using 
trNOEs in the rotating frame (TR-ROESY) experiments, 
[188-189]
 it is possible to distinguish 
which cross peaks are dominated by an indirect effect, usually mediated by a protein proton, 
and hence distinguishing direct from indirect enhancements. 
 
1.5 Computational approaches to modeling ligand-
receptor interactions 
Structural studies, using either X-ray crystallography or NMR, provide a tremendous amount of 
information on many three-dimensional structures of different complexes. Unfortunately, 
despite rapid progress in practical applications of these techniques, the structures of relatively 
few receptors and ligand–receptor complexes are still experimentally available and not all 
structures are possible to obtain via these methods, due to technical or time limitation reasons. 
In the absence of any experimental information on the 3D structure of the receptors under 
investigation, predictions from primary sequence remain the only means of generating the 
receptor structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. The roles of computational methods (purple) alongside experimental methods (blue) in 
structural biology (Figure adapted from 
[190]
). 
 
Obviously, the knowledge of the active site geometry significantly facilitates the design of new 
drugs by providing real spatial and chemical limitations on the structures of newly designed 
molecules. Thus, different theoretical methods have been also applied to predict the 3D 
structures and dynamic features of ligand–receptor complexes. Docking and MD simulations, 
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and variations thereof, provide another way to look at structures and interactions and 
complement nicely the aforementioned experimental techniques (Figure 1.13). The 
computational techniques used in this thesis are briefly commented next.  
1.5.1 Ligand-Receptor Docking   
In ligand–receptor docking protocols, the ligand is brought (manually or in some automated 
way) into the vicinity of the binding site and oriented so that electrostatic and van der Waals 
interactions (which correspond to Coulomb and dispersion terms, respectively, in molecular 
mechanics energy expressions) between ligand and receptor are optimized. The 
pharmacophoric conformation (if available) of ligands is frequently used in these studies. 
Earlier docking programs allowed the docking of only a rigid ligand into a rigid receptor, i.e., no 
conformational change of either receptor or ligand was permitted as the latter approached the 
former. Clearly, this is not the way the interaction occurs in nature, because both ligand and 
receptor are relatively flexible molecules that adjust their conformation to each other in the 
process of binding to maximize steric and chemical complementarities. Flexible docking 
calculations are very difficult and require an extremely fast computer. Nevertheless, the 
consideration of both ligand and receptor active site flexibility is becoming part of modern 
docking approaches. 
[191]
 
1.5.2 Molecular Dynamics 
Once the model of a ligand–receptor complex is built, its stability should be evaluated. Simple 
molecular mechanics optimization of the putative ligand–receptor complex leads only to the 
identification of the closest local minimum. However, molecular mechanics optimization of 
molecules lacks two crucial properties of real molecular systems: temperature and, 
consequently, motion. Molecular dynamics studies the time-dependent evolution of 
coordinates of complex multimolecular systems, as a function of inter- and intramolecular 
interactions. Because simulations are usually performed at normal temperature (300 K), 
relatively low energy barriers, on the order of kT (0.6 kcal), can be easily overcome. Thus if 
the starting configuration of the whole system (i.e., drug–receptor complex) resulting from 
docking is separated from the more stable configuration by such a low barrier, molecular 
dynamics will take the system over the barrier. Molecular simulations may identify more stable, 
therefore more realistic, conformational states of ligand–receptor complexes. Furthermore, 
they may provide unique information about conformational changes of the receptor due to 
ligand binding. They may shed light on the intimate mechanisms of receptor activation that 
currently cannot be studied by any other technique. Finally, molecular simulations frequently 
incorporate explicit solvent and thus allow the inclusion of solvent effects in the consideration. 
Unfortunately, due to the inherently very short elementary simulation step size, 2 fs, this 
technique is presently limited to relatively short total simulation times, on the order of hundreds 
of picoseconds to tens of nanoseconds. These limitations are mainly due to the fact that 
available computer power is still inadequate for significantly longer simulation times, unless 
supercomputer facilities are used for long time periods. Owing to the rapid increase in 
computational power due to advances in both hardware and software, NMR and molecular 
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modeling have become important integral parts of multidisciplinary efforts in the structural and 
dynamic characterization of protein-ligand complexes, a key step for understanding their 
biological and potential activities and developing structure-activity relationships. 
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2. Objectives 
Given the increasing interest raised by the actual and possible applications of NMR for 
studying molecular recognition processes at atomic level, the aim of this work has been 
focused on the development of an integrated NMR and computational approach for a better 
understanding of different phenomena of biological interest.  
The objectives for the present Thesis can be considered at different levels: 
As general objective, we have intended to implement, use, and get acquainted with different 
state-of-the-art NMR methodologies for the detection and structural characterization of binding 
events, including both receptor and ligand-based experiments. We have focused on two 
challenging cancer-related systems, intrinsically difficult to characterize by NMR: tubulin 
heterodimers and microtubules, and the FGF/FGFR/HS complex.  
In a parallel manner, we have attempted to combine the NMR experimental results with those 
obtained by specific computational methods. The final aim was to develop a clear, robust, and 
integrated approach for studying molecular recognition processes depending on the 
experimental NMR method employed, either ligand- or receptor-based. The combination of the 
NMR and modeling protocols should permit to obtain a clear 3D perspective of the recognition 
process. 
The specific objectives of the different chapters of this Thesis are detailed next: 
 
Chapter I: Insights into the molecular recognition of heparin by 
FGF and FGFR based on NMR and computational studies 
Heparin and heparin sulfate plays an active role in promoting the angiogenic activity of the 
growth factors (FGF) by means of stimulating receptor binding, dimerization, and activation. 
Biological activity requires assembly of a ternary complex that includes FGF, heparin and the 
FGF receptor (FGFR), being its interactions and the mechanism of such specificity still 
unclear. Based on the crystal structures published for the FGF-FGFR-heparin ternary 
complex, two competing models were proposed. Surprisingly, they display striking differences, 
even with different stoichiometries. Our hypothesis was that maybe only one of the crystal 
structures is biologically relevant. 
Therefore, in order to provide insights into the fine structural aspects of these physiologically 
relevant interactions, the aims of Chapter I were the following: 
1. To get a detailed conformational and dynamic characterization of heparin 
oligosaccharides and its precursors in solution using NMR spectroscopy in 
combination with Molecular dynamics simulations. 
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2. To study the interactions of different heparin-like oligosaccharides with FGF1 and 
FGFR2 and to characterize the corresponding protein-protein interactions, with the 
final aim of unravelling the topology of the ternary complex by NMR. For that, the 
specific objectives were: 
 The expression and purification of non labeled and isotopically labeled
 15
N-, 
and
 15
N,
 13
C proteins (FGF1 and FGFR-Ig2) for their further use in NMR 
studies. 
 The implementation of the standard 3D NMR experiments for backbone 
protein assignment and for structure calculation of FGFR-Ig2. 
 The conformational analysis of a heparin pentasaccharide when bound to 
FGFR-Ig2 as well as the study of the corresponding complex by NMR and 
modeling. 
 The characterization of the protein binding surfaces for the interactions of 
the ternary complex FGF-heparin-FGFR in solution by NMR, as compared 
to those previously described by X-ray.  
 The calculation of the 3D structure of the FGF1-heparin-FGFR2-Ig2 ternary 
complex in solution by NMR and modeling. 
 
Chapter II: Insights into the interaction of Microtubule-stabilizing 
agents with non-polymerized tubulin  heterodimers and 
microtubules by using an integrated NMR and computational 
approach 
Microtubules play a vital role in the life of all eukaryotic cells, being the assembly and 
disassembly of microtubules processes essential steps in the cell cycle.  These events are 
closely regulated, and interference with the regulatory mechanisms can lead to cell death.  
These properties have made tubulin a key target for developing new anti-cancer drugs. In fact, 
taxanes have obtained a prominent place in cancer chemotherapy with activity against a broad 
range of solid tumors. 
In an effort to overcome drug resistance, which limit, for instance, taxol application, other novel 
microtubule-stabilizing agents with a more favorable activity profile have been appeared in the 
last years. Due to the wide chemical diversity and different binding processes, the 
characterization of the mechanism of action of these compounds at atomic level is necessary. 
A rational approach to cancer therapy involves, as a first step, the structural characterization 
of these assemblies and their interactions with the different ligands. For this purpose, two key 
questions related to the mechanism of recognition and stabilization of tubulin by microtubule-
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stabilizing agents have been addressed in this Chapter: 
3. The NMR-based characterization of the binding of MSA-type drugs to assembled 
microtubules, including the number and location of the binding sites. 
4. The NMR-based characterization and understanding, at the molecular level, of the 
binding of these microtubule-stabilizing agents to tubulin  heterodimers, when 
tubulin is present in a non polymerized state.   
5. The elucidation of the geometry of the binary complex formed by different MSA and 
tubulin heterodimers by a combined NMR and modeling approach.  
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The work presented in the Thesis has been possible thanks to the effort of many scientific 
teams around the world. In particular, part of the work (FGF and FGFR expression and 
purification) presented herein was performed at the laboratory of Prof. Giménez-Gallego at 
CIB. Also, parts of the MD simulations have been performed in close collaboration with Dr. 
Francisco Corzana at Universidad de La Rioja. The work on tubulin interactions has been 
performed within the framework of a long-standing collaboration with Dr. Fernando Díaz at 
CIB. Labeled heparin samples and MSA molecules were also provided by different research 
groups. I deeply thank all of them for their continuous help. Particularly, I express my 
gratitude to Prof. Giménez-Gallego and his group for introducing me into the molecular 
biology techniques and to Dr. Corzana for embarking me in the molecular dynamics 
adventure.   
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3. Materials and Methods 
 
The materials and methods employed for studying the different topics display different intrinsic 
features. Therefore, we have differentiated the key aspects in the following separated 
sections, which correspond to the different chapters. Nevertheless, only the most relevant 
aspects, which are not given in the corresponding publications or explicited in the 
accompanying supporting informations will be given here. 
 
3.1 Chapter I. Insights into the molecular recognition of 
heparin by FGF and FGFR based on NMR and 
computational studies 
Materials 
13
C, 
15
N-labeled heparin and its precursors were prepared by a stepwise chemoenzymatic 
synthesis in milligram amounts from 
13
C, 
15
N N-acetylheparosan afforded by fermentation of E. 
coli in the laboratory of Prof. Robert Linhardt (Troy, NY, USA), as described in publication I. 
[1]
 
Non-labeled heparin oligosaccharides used for titration experiments in publications II and III 
were kindly provided from Prof. Manuel Martín Lomas, Dr. J. L. de Paz, and Dr. Pedro Nieto 
from CIC-Biomagune (San Sebastián) and Centro de Investigaciones Químicas de la Isla de la 
Cartuja, CSIC (Sevilla).  
The expression and purification of the proteins FGF1 and FGFR2-Ig2 were performed in 
collaboration with the lab of Prof. Guillermo Giménez-Gallego, at Centro de Investigaciones 
Biológicas (CSIC). 
 
3.1.1 Protein sample preparation 
Expression and purification of the proteins 
Uniformly labeled 
15
N FGF1 and non labeled FGF1 cloned in the pRAT-4 plasmid were 
expressed in E. coli BL21 and purified by heparin-Sepharose chromatography 
[2-3]
 as 
previously described. 
[4]
 In the case of FGFR2-Ig2 protein, a new expression protocol was set 
up for the expression of the soluble protein in native state, based on the method described by 
Fernandez-Tornero et al. 
[5]
 Secretion of the protein outside the bacteria is needed to preserve 
the disulfide bonds required for the proper protein folding. This was carried out by cloning 
FGFR2-Ig2 protein in pRHO expression vector, generated previously by Prof. Giménez-
Gallego´s group. Afterwards, pRHO-Ig2 vector was transformed in E. coli strain BL21 (DE3) 
SS for protein expression (Figure 2.1). 
[5]
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After a first screening of small expression cultures, performed using different culture media, 
volumes and temperatures, we selected the conditions that assured a better growth of E. coli 
and expression of the protein. In fact, in all used conditions, the proteins of interest were 
expressed soluble in native state. Cells were inoculated into 50 mL of LB medium, containing 
ampicillin as antibiotic, and were grown at 37ºC overnight. A small volume of the cultures 
(about 10 mL) were inoculated into 0.5L of M9 medium 
[6]
 supplemented with 100 μg/mL 
ampicillin. Cultures were grown at 37°C under shaking until they reached the mid-log phase 
(0.7 OD600). Then, protein expression was induced by adding isopropyl β-ᴅ-
thiogalactopyranoside (Boehringer Mannheim) to the culture (to a final concentration of 1mM) 
and grown overnight. The highly expressed protein was collected from the supernatant by 
centrifugation (6000 rpm, 10 min, 4°C) and stored at -80°C until further use.  
    
T7 1...20
LacI 2131...1050
ColE1 origin 3309...2627
pRHO_D2
4656 bp
FR_D2 158...490
AmpR 4066...3407
ompA 89...145
LacO 19...41
 
Figure 2.1 Structural organization of pRHO-Ig2 expression vector used for expression of FGFR2-Ig2. 
 
M9 composition used for growth media and the ones for the isotope-enriched proteins (see 
below) are shown in Tables 1-3. Reactives for the preparation of M9 media were bought from 
Merck, except vitamine B1, from Boehringer Mannheim. 
Expression of isotope-enriched proteins 
FGF1 and FGFR2-Ig2 have been expressed heterologously in E. coli to allow the uniform 
isotope enrichment of either nitrogen nuclei alone or nitrogen and carbon nuclei 
simultaneously with NMR active isotopes (
15
N and 
13
C).  
15
N,
13
C labeling give access to 3D NMR experiments that depend on the correlations of 
15
N 
and 
13
C nuclei that are very useful for the sequential assignment of the backbone resonances 
of the protein, while 
15
N-only labeled proteins have been used in the 
1
H-
15
N HSQC NMR 
titration experiments acquired in this work.  
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M9 medium 
M9 salt solution 10X 
 
100 mL 
 
100 mM MgSO4 
 
10 mL 
 
10 mM CaCl2 
 
10 mL 
 
100 mM thiamine-
HCl 
 
10 mL 
 
20% glucose 
 
10 mL 
 
sterile H2O 860 mL 
  
Total volume 1 L 
Table 1: M9 medium composition per L 
 
15N M9 medium 
M9 salt solution 10X 
(without NH4Cl) 
 
NH4Cl (
15
N) 
100 mL 
 
 
1g/L 
 
100 mM MgSO4 
 
10 mL 
 
10 mM CaCl2 
 
10 mL 
 
100 mM thiamine-
HCl 
 
10 mL 
 
20% glucose 
 
10 mL 
 
sterile H2O 860 mL 
  
Total volume 1 L 
Table 2: M9 medium composition for the 
15
N labeled proteins per L 
 
15N 13C M9 medium 
M9 salt solution 10X 
(without NH4Cl) 
 
NH4Cl (
15
N) 
 
100 mL 
 
 
1g/L 
 
100 mM MgSO4 
 
10 mL 
 
10 mM CaCl2 
 
10 mL 
 
100 mM thiamine-
HCl 
 
10 mL 
 
glucose (
13
C)  
 
4g/L 
 
sterile H2O 870 mL 
  
Total volume 1 L 
Table 3: M9 medium composition for the 
15
N,
13
C labeled proteins per L 
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The expression method followed for 
15
N,
13
C labeled proteins was the same aforementioned, 
except that uniform 
15
N and 
13
C isotope labeling was assured by providing 
15
N ammonium 
chloride and 
13
C6 D-glucose (both obtained from Cambridge Isotope Laboratories, Andover, 
MA, USA) in the growth medium as the sole source for nitrogen and carbon, respectively. M9 
medium 
[6]
 was used as a minimal medium for isotope enrichment during protein expression 
(Table 2-3). The cell supernatant was stored at -80°C until further processing. 
Protein purification 
Firstly, the cell supernatant was applied to a 25 mL column (2.5 cm x 5 cm) of DEAE-
Sepharose Fast Flow, equilibrated with buffer A (containing 10 mM sodium phosphate, pH 
6.0). The column was then eluted at a flow rate 4 mL/min. 
Secondly, a heparin-Sepharose column (Amersham Bioscience) was chosen for purification 
using a pH 6.0 buffered solution. Heparin-Sepharose beads were first added to the 
supernatant (0.5 L), and the mixture was incubated overnight at 15°C. The resin was then 
packed into a small column and washed extensively with wash buffer A (10 mM sodium 
phosphate, pH 6.0), after which the bound protein was eluted with elution buffer B (10 mM 
sodium phosphate, 1.5M NaCl, pH 6.0), at a flow of 4 mL/min, using firstly a linear salt 
gradient from buffer A to buffer B (from 0% B to 45% B). Thereafter it was eluted with 20 mL of 
the same buffer mixture and finally 40 mL of buffer B at 100%. Fractions of 10 mL were 
collected. 
The material was eluted as 2 peaks, with the second peak corresponding to pure FGFR2-Ig2, 
as checked on SDS-PAGE analysis. An averaged yield of 5 mg of protein, respectively, per L 
of culture was obtained.  
ÄKTA prime chromatographer (GE Healthcare Life Sciences) was used for protein purification. 
Biochemical analysis 
A 15 % SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
[7]
 was conducted for various 
samples during protein expression and protein purification to monitor these processes and 
check for protein purity. The gels were stained with Coomassie Brilliant Blue. 
3.1.2 NMR Methodology 
The NMR samples of FGF1 and FGFR2-Ig2 were prepared by concentrating the protein in 
buffer sodium phosphate 20mM NaCl 300 and 100mM respectively for a final mL volume, at 
pH 6.0 containing 10% D2O.  
Protein concentrations for NMR samples were adjusted to approx. 1mM for protein 
assignment, and to 0.2 - 0.3 mM for titration experiments. Norell 507-HP standard NMR tubes 
(Norell Inc., Landisville, NJ, USA) and Shigemi-type NMR tubes (Shigemi Inc., Allison Park, 
PA, USA) have been used. 
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NMR backbone assignments 
The assignment of the backbone resonances is the prerequisite for further characterization of 
structure, interactions and/or dynamics of any protein at atomic resolution by NMR 
spectroscopy. The assignment strategy involves the labeling of the protein with the NMR-
observable 
15
N and 
13
C isotopes. Therefore, FGF1 and FGFR2-Ig2, investigated in this Thesis, 
have been uniformly labeled with these isotopes as described in section 2.2.1. The labeling of 
nitrogen and carbon nuclei together with the abundant 
1
H nuclei allows for the intra- and inter-
residual correlation of 
1
H, 
15
N, 
13
C, 
1
H and 
13
C´ nuclei through scalar couplings in a series of 
three-dimensional NMR experiments 
[8]
, thus enabling the sequential mapping of resonances 
to the protein’s amino acid sequence. In addition, some of these assignment experiments can 
also provide correlations to the side chain 
1
H and 
13
C resonances. 
Acquisition of 2D- and 3D-spectra and sequential backbone assignment 
In a previous work in the lab, FGF1 assignment was performed. 
[4]
 Therefore, the assignment 
work of this Thesis was focused on FGFR-Ig2.  
A combination of three dimensional experiments was employed for FGFR2-Ig2 protein 
backbone assignment. The backbone carbonyl 
13
C resonances were assigned in a HNCO 
[9-11]
 
spectrum, which correlates the 
13
C’i-1 with the 
1
Hi and 
15
Ni nuclei, as well as the HN(CA)CO 
[12]
 
spectrum, which correlates the 
13
C’i-1 and 
13
C’i with the 
1
Hi and 
15
Ni nuclei. HNCACB and 
CBCA(CO)NH experiments were also recorded.  
Figures 2.2 and 2.3 summarize these experiments and illustrate the magnetization transfers 
along the nuclei. Among them, the core experiment in this case was the HNCACB experiment 
[13-14]
 , which correlates the 
1
Hi and 
15
Ni nuclei with the 
13
C,i, 
13
C,i, 
13
C,i-1 and 
13
C,i-1 nuclei. In 
principle, HNCACB spectra can yield complete sequential 
1
H, 
15
N, 
13
C and 
13
C assignments. 
However, additional experiments are usually required that not only provide the resonance 
frequencies of other nuclei, but also give important information to unambiguously assign the 
peaks to specific amino acid residues. For instance, the CBCA(CO)NH experiment 
[15-16]
 
correlates the 
1
Hi and 
15
Ni nuclei only with the 
13
C,i-1 and 
13
C,i-1 nuclei and thereby helps to 
distinguish i and i-1 signals from each other. A prerequisite of the sequential assignment using 
three-dimensional spectra is the picking of backbone amide 
1
Hi, 
15
Ni correlation peaks in highly 
resolved two-dimensional HSQC spectra. 
[17]
  
Previous assignment of similar states of FGFR-Ig2 has been available (BRMB code 5943, 
Hung 2005), which contributed to the initial assignments of the receptor, despite several 
residues are different at the N-terminal and C-terminal ends. 
All assignment experiments conducted were standard Bruker implementations of the published 
pulse sequences released with XWINNMR 3.5. All spectra have been processed using either 
XWIN-NMR 3.5 or TOPSPIN 2.0 software (Bruker Biospin, Karlsruhe, Germany). The 
acquisition and processing parameters are listed in table 4.1.2 of Chapter II.  
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Figure 2.2 Backbone resonance assignment experiments for FGFR2-Ig2. Resonance transfer by scalar 
coupling (coupling constants in Hz) is indicated by blue arrows. Detected nuclei are indicated by blue 
boxes. HNCACB 
[13-14]
, where magnetization is transferred from 
1
H
N
 to 
15
N and then via the N-Cα J-
coupling to the 
13
Cα and then from 
13
Cα and 
13
 Cβ and back again to
 15
N and 
1
H
N
 for detection. Transfer 
from Cαi-1 can occur both to 
15
Ni-1 and 
15
Ni, or viewed the other way, magnetization is transferred to 
15
Ni from both 
13
Cαi and 
13
Cαi-1. Thus for each NH group there are two Cα and Cβ peaks visible. 
However, the coupling to the directly bonded Cα and Cβ is stronger and thus these peaks will appear 
with greater intensity in the spectra. The chemical shift is evolved simultaneously on 
13
Cα and 
13
Cβ, so 
these appear in one dimension. The chemical shifts evolved in the other two dimensions are 
15
N and 
1
H
N
. CBCA(CO)NH 
[15-16]
, where magnetization is transferred from 
1
Hα and 
1
Hβ to 
13
Cα and 
13
Cβ, 
respectively, and then from 
13
Cβ to 
13
Cα. From here it is transferred first to
13
CO, then to 
15
N and then 
to 
1
H
N
 for detection. The chemical shift is evolved simultaneously on 
13
Cα and 
13
Cβ, so these appear in 
one dimension. The chemical shifts evolved in the other two dimensions are 
15
N and 
1
H
N
. The chemical 
shift is not evolved on 
13
CO. 
N
H
C
C
C ’
O
N
H
C
C
C ’
O
N
H
C
C
C’
O
R
i-1 i+1i
HNCACB
N
H
C
C
C ’
O
N
H
C
C
C ’
O
N
H
C
C
C’
O
R
R
R
i-1 i+1i
CBCA(CO)NH
H
HH
R R 
35 
R 94 35 
7 
11 
35 
130 130 
55 
140 
15 
94 
Material and methods 
 
 
61 
 
 
 
Figure 2.3 Backbone resonance assignment experiments for FGFR2-Ig2. Resonance transfer by scalar 
coupling (coupling constants in Hz) is indicated by blue arrows. Detected nuclei are indicated by blue 
boxes. HNCO 
[9-11]
, where magnetization is passed from 
1
H
N
 to 
15
N and then selectively to the carbonyl 
13
C via the 
15
N-
13
CO J-coupling. Magnetization is then passed back via 
15
N to 
1
H
N
 for detection. The 
chemical shift is evolved on all three nuclei resulting in a three-dimensional spectrum. HN(CA)CO 
[12]
, 
where magnetization is transferred from 
1
H
N
 to 
15
N and then via the N-Cα J-coupling to the 
13
Cα. From 
there it is transferred to the 
13
CO via the 
13
Cα-
13
CO J-coupling. For detection the magnetization is 
transferred back the same way: from 
13
CO to 
13
Cα, 
15
N and finally 
1
H
N
. The chemical shift is only 
evolved on 
1
H
N
, 
15
N and 
13
CO and not on the 
13
Cα. The result is a three-dimensional spectrum. Because 
the amide nitrogen is coupled both to the Cα of its own residue and that of the preceding residue, 
both these transfers occur and transfer to both 
13
CO nuclei occurs. Thus for each NH group, two 
carbonyl groups are observed in the spectrum. But because the coupling between Ni and Cαi is 
stronger than that between Ni and Cαi-1, the Hi-Ni-COi peak generally ends up being more intense than 
the Hi-Ni-COi-1 peak. 
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The sequential assignments of the protein have been carried out using CARA (version 1.8.4; 
Keller, 2004) software. The 
1
H chemical shifts have been referenced directly to the external 
standard sodium 3-(trimethylsilyl) propionate (TSP), while 
15
N and 
13
C chemical shifts have 
been referenced indirectly to the resulting 
1
H carrier frequency. 
[18-19] 
Structure calculations 
Structure calculations using experimental NMR constraints has traditionally relied on NOE 
measurements. These are often introduced into simulated annealing protocols as quantitative 
or semi-quantitative distance constraints, in the form of one extra potential energy term that 
has to be minimized along with the rest of the steric energy terms arising from the molecular 
geometry. 
[20]
 
Peak lists for the NOESY spectra of FGFR-Ig2 recorded with a 0.1 s mixing time were 
generated by interactive peak picking using the CARA (version 1.8.4; Keller, 2004) software. 
NOESY cross-peak volumes were determined by the automated peak integration routine 
implemented in CARA. The three-dimensional structure of the protein was determined using 
the standard protocol of combined automated NOE (nuclear Overhauser effect) assignment 
and the structure calculation of the CYANA program (version 2.1).  
Seven cycles of combined automated NOESY assignment and structure calculations were 
followed by a final structure calculation. The structure calculation started in each cycle from 
100 randomized conformers, and the standard simulated annealing schedule was used. The 
20 conformers with the lowest final CYANA target function values were retained for analysis 
and passed to the next cycle. Weak restraints on /ψ torsion-angle pairs and on side-chain 
torsion angles between tetrahedral carbon atoms were applied temporarily during the high-
temperature and cooling phases of the simulated annealing schedule in order to favor the 
permitted regions of the Ramachandran plot and staggered rotamer positions respectively. 
The list of upper-distance bonds for the final structural calculation consists of unambiguously 
assigned upper-distance bonds and does not require the possible swapping of diastereotopic 
pairs. The 20 conformers with the lowest final CYANA target function values were subjected to 
restrained energy-minimization in a water shell using the AMBER 9.0 program. The resulting 
20 energy-minimized CYANA conformers represent the solution structure ensemble of 
FGFR2-Ig2 shown on section 4.1.8 in Chapter I. 
MOLMOL program was used to visualize the three-dimensional structures. CYANA was used 
to obtain statistics on target function values, restraint violations and Ramachandran plots 
according to PROCHECK-NMR conventions. 
 Rmsd (root mean square deviation) values were calculated using MOLMOL for superpositions 
of the backbone N, Cα and C’atoms; the heavy atoms over the whole protein. To obtain the 
rmsd of a structure represented by a bundle of conformers, all conformers were superimposed 
onto the averaged one and the average of the rmsd values between the individual conformers 
and their average coordinates was calculated.  
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3.1.3 Ligand-protein interactions 
Chemical Shift Mapping 
Protein-ligand interactions were performed using either 
15
N FGFR-Ig2 or 
15
N FGF1 as 
receptors, alternatively, and the heparin oligosaccharides or non labeled protein as ligands, 
respectively. Titration experiments were monitored by identifying perturbations in the 2D 
1
H, 
15
N HSQC spectra of the labeled component. 2D 
1
H, 
15
N HSQC spectra were acquired with 32 
transients per t1 value. 2K complex points were acquired in t2, while 128 complex points were 
acquired in t1. 
To determine the per residue chemical shift perturbation upon binding and account for 
differences in spectral widths between 
15
N and 
1
H resonances, weighted average chemical 
shift differences, av, were calculated for the amide 
15
N and 
1
H resonances, using the 
equation: 
                                 av={[(HN)
2+(N/5)
2]}1/2                               Eq. 3.1 
 
where HN and N are the differences between free and bound chemical shifts.  
The weighted average chemical shift differences were mapped to the different available X-ray 
and NMR structures (PDB codes 1E0O, 1FQ9 and 1WVZ) using Discovery Studio Visualizer 
2.5.1.9167 (Accelrys Discovery Software Inc.) graphics program. 
3.1.4 Computational studies: parameters used for Docking and modeling 
AutoDock 4.0 
AutoDock is a suite of automated docking tools. This program is used to perform 
computational molecular docking of small molecules to proteins, DNA, RNA, and other 
important macromolecules, by treating the ligand and selected parts of the target as 
conformationally flexible.  
AutoDock actually consists of two main programs: AutoDock performs the docking of the 
ligand to a set of grids describing the target protein, while the AutoGrid module precalculates 
these grids. The AutoGrid program builds a grid in a three-dimensional space and a probe 
atom is placed at each grid point. The protein is situated inside the grid-box (either the entire 
protein or just a portion to enhance the speed of the calculation) and then, the interaction 
energy of this single atom with the protein is evaluated. In this manner, an affinity grid and a 
grid of electrostatic potential for each type of atom of the ligand (usually carbon, oxygen, 
nitrogen and hydrogen) is built up. 
It uses a scoring function based on the AMBER force field, and evaluates the binding process 
in two steps: in the first one, the ligand is in the free state and the intramolecular energy terms 
are calculated for the transition between the unbound to the bound state. The second step 
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consists in the evaluation of the intermolecular energy term, combining the ligand and protein 
in their bound conformations. Novel hybrid global-local evolutionary algorithms are used to 
search the phase space of the ligand-macromolecule system (Figure 2.4). 
Distinct methods can be appied in AutoDock to look for the best binding poses: 
1. Global Search Algorithm: 
− Simulated Annealing (Goodsell et al. 1990) 
− SA (Morris et al. 1996) 
− Genetic Algorithm (Morris et al. 1998) 
2. Local Search Algorithm: 
− Solis & Wets (Morris et al. 1998) 
3. Hybrid global-local search algorithm: 
– Lamarckian GA (Morris et al. 1998) 
Molecular
coordinates
AutoDock 4
• van der Waals
• electrostatic
• hydrogen bond
•torsional penalty
•desolvation
Scoring
function
Search
algorithm
Stochastic
local search
Genetic
algorithm
 
Figure 2.4 AutoDock 4.0 methodology. (Figure adapted from 
[21]
). 
At the end of the docking run, Autodock outputs a geometry result, which is the lowest energy 
conformation of the ligand found during that run. This conformation is characterized by its 
intermolecular, internal and torsional energy. The first two components give the ‘Docking 
energy’, while the first and third provide the ‘Binding energy’. Autodock 4.0 also breaks down 
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the total energy into the van der Waals (vdW) and the electrostatic energy components for 
each atom. We used the overall lowest binding energy output provided by Autodock 4.0 as 
well as the NMR-based experimental data, as the primary criterion for ranking the different 
solutions. 
Setup for Docking of heparin-protein complexes 
Docking simulations of heparin oligosaccharide ligands to protein model structures were 
performed with AutoDock, version 4.0. 
[22]
  
In the first step, we tested two structures of FGFR-Ig2, either from X-ray (PDB code 1E0O) 
and from NMR (PDB code 1WVZ) for docking calculations with the heparin oligosaccharides, 
without restricting the search to a certain protein region. The grid maps representing the 
protein in the actual docking process were calculated with the aid of AutoGrid. The set up of 
the grids were performed with 126 points in each dimension, with a spacing of 0.375 Å 
between the grid points. In all these cases, docking solutions obtained by using the protein 
coordinates from the crystal structure gave better results in agreement with the experimental 
data. 
The partial charges for the protein atoms were taken from the AutoDock version of the AMBER 
force field. 
[23]
 In order to accurately reproduce the effects of the highly negative charged 
substituents on the heparin oligosaccharides, partial atomic charges of the ligand required for 
the docking calculation were obtained by using the Gaussian 03 
[24]
 program as described 
below. 
The GA-LS (Lamarckian genetic algorithm) was chosen to search for the best conformers. 
During the docking process, the docking parameters were set to: Maximum Number of GA 
runs 100, Population size of 200, Maximum number of evaluation 300,000. 
AMBER software 
In the computational works presented in this Thesis, first AMBER6 and later AMBER9 and 
AMBER10 were used for all the MD simulations (over the course of time that this project was 
ongoing, AMBER was upgraded from version 9 to 10 and is currently at version 11). The 
AMBER package consists of a set of molecular mechanical force fields and a suit of programs 
to carry out and analyze molecular dynamics simulations, particularly for proteins, nucleic 
acids and carbohydrates (recently reviewed in 
[25]
). 
 
There are three main steps in MD simulations: system preparation, simulation and trajectory 
analysis. Different modules of the AMBER package carry out the different steps. During the 
preparation period, each atom in the molecule is assigned an atom or particle type. A 
coordinate file (prmcrd), which contains the Cartesian coordinates of all the atoms, and a 
parameter-topology file (prmtop), which contains all other information (atom names and 
masses, force field parameters, lists of bonds, angles, and dihedrals) are generated during this 
phase. The initial coordinate file can be a pdb (protein data bank) file, from an experimental 
Material and methods 
 
 
66 
 
NMR or X-ray structure. In absence of these data, several programs can be used to generate 
good initial coordinates. For instance, the Amber/Glycam builder tool 
(http://glycam.ccrc.uga.edu/Amber) program integrates well with Amber to construct initial 
models for carbohydrates. 
 
The main preparation programs in AMBER are ANTECHAMBER (which assembles force 
fields for residues or organic molecules that are not part of the standard libraries) and LEaP 
(which constructs biopolymers from the component residues, solvates the system, and 
prepares lists of force field terms and their associated parameters). They perform molecular 
conversions (for example, conversion of a pdb file to a prep file or a Gaussian input file), 
assign atom type and generate charges. The parmchk program is used to assign an addition 
force field (in a frcmod file) if parameters are missing in the so-called prep file. The 
Gaussian03 program 
[24]
 can be employed with the HF/6-31G* basis set for performing the 
quantum mechanical calculations on the ligands required for assignment of the RESP charges 
in antechamber. Sander and Ptraj are the AMBER modules prepared for simulation and 
trajectory analysis, respectively. 
 
The regular AMBER force field has limited parameters for organic molecules and, for that 
reason, has not been widely used for drug design and other studies of ligand-protein or ligand-
DNA interactions. However, another force field that covers most drugs, GAFF (General 
AMBER force field), can be safely employed for a variety of ligands. The force field for 
carbohydrates used in AMBER is Glycam. The Glycam force field has several versions 
[26]
 
(Glycam93, Glycam2000, the last version is Glycam06f), and follows the general approach of 
using dihedral angle terms for each molecular-class-specific linkage, in analogy to that used 
for the peptide backbone dihedral angle. 
[25]
 
 
System preparation and parameterization of the AMBER force field for GAGs 
Heparin-derived oligosaccharides were manually built using the initial coordinates from Mulloy 
for canonical heparin 
[27]
 (PDB code 1HPN) and modified accordingly. Partial atom charges 
were calculated with the RESP (Restrained ElectroStatic Potential Fit) procedure using either 
Gaussian98 
[28]
 or Gaussian03 
[24]
 with the 6-31G* basis set.  
The Parm94 and Parm99 force fields in AMBER were parameterized by introducing the 
Glycam06 parameter set for carbohydrates. This extension included the creation of new atom 
types such as the α,β-anomeric carbons, the definition of different parameters for the 
glycosidic linkages and for the carbohydrate specific bonds, angles, torsion angles and 
improper torsion angles. The parameterizations for the sulfate/sulfamate groups were also 
added to the force field, as previously described. 
[29]
 All of these modifications were written into 
a new file, which was used as a force field modified file, and loaded together with the original 
Parm force field into XLEaP sessions. The corresponding sodium ions were added randomly 
as counter ions until neutralization. The topology and coordinate files were used for 
subsequent simulations.  
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The same procedure was applied to build up the complexes with the proteins. We assumed 
that the doubly protonated state of histidine residues was the correct form at pH 6.0, and this 
protonation state was used for further MD simulations. As result of the residue recognition 
implemented in AMBER, the amino acid residue ‘His’ was interpreted as Nε and Nδ di-
protonated residue (residue: ‘Hip’). 
Protocol of MD simulations 
Heparin 
After the preparation of the input file, equilibration of the system, in this case in AMBER6, was 
carried out as follows. A series of energy minimizations were performed to refine the initial 
structure. As a first step, a short minimization with positional restraints on solute by a harmonic 
potential with a force constant of 500 kcal·mol
-1
·Å
-2
 was done. A 12.5 ps molecular dynamics 
calculation at 300 K maintaining positional restraints on the solute was then run to equilibrate 
the water box. For these two steps, a 9Å cut-off was used for the treatment of the electrostatic 
interactions. The system was equilibrated during an additional 12.5 ps period, using the mesh 
Ewald method. The system was then subjected to several minimization cycles during which 
the force constant for positional restraints on the solute were gradually reduced from 500 to 0 
kcal·mol
-1
·Å
-2
. Unrestrained MD trajectories at constant pressure (1 atm) and temperature 
(300 K) were collected and analyzed using the CARNAL module of AMBER. The simulation 
length was 7−9 ns. The simulation was performed using periodic boundary conditions and the 
particle-mesh Ewald approach 
[30]
 to introduce long-range electrostatic effects. The SHAKE 
[31]
 
algorithm for hydrogen atoms, which allows using a 2 fs time step, was also employed. Finally, 
a 9 Å cutoff was applied to Lennard-Jones interactions. For undersulfated heparin and 
heparin, different simulations were submitted starting from the skew boat or chair conformers 
for the IdoA ring. 
In the case of MD-tar simulations, NOE-derived distances were included as time-averaged 
distance constraints, using <r
-6
>
-1/6 
and
 
<r
-3
>
-1/3 
averages. Final trajectories were run using an 
exponential decay constant of 400 ps and a simulation length of 4 ns for the MD-tar 
simulations. 
Heparin-protein complexes 
The SHAKE algorithm was applied to all hydrogen-containing bonds,
[31]
 and 1fs integration 
step was used. The simulation used periodic boundary conditions and the electrostatic 
interactions were represented using the smooth particle mesh Ewald method,
[30]
 with a grid 
spacing of 1 Å. 
Each system was gently annealed from 100 to 300 K over a period of 25 ps. The systems 
were then maintained at a temperature of 300 K during 50 ps with a solute restraint and 
progressive energy minimizations, gradually releasing the restraints of the solute followed by a 
20 ps heating phase from 100 to 300 K, where restraints were removed. Finally, the production 
simulations for each system lasted 3ns and were also continued in the isothermal-isobaric 
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ensemble. Coordinate trajectories were recorded each 2 ps throughout all equilibration and 
production runs, which yielded an ensemble of 1500 structures of each complex for further 
analysis.  
The analysis of the trajectories, overlays, and RMDS calculations were performed using 
MOLMOL, VMD and PyMOL packages. 
 
3.2 Chapter II: Insights into the interaction of 
Microtubule-stabilizing agents with non-polymerized 
tubulin  heterodimers and microtubules by using an 
integrated NMR and computational approach 
Materials 
Tubulin heterodimers and microtubule samples were prepared in the laboratory of Dr. 
Fernando Díaz at CIB, as described in publication IV and V.  
NMR experiments 
The standard homo- and hetero-nuclear 2D NMR experiments were employed for the 
characterization of the NMR parameters of the ligands, including 2D COSY, TOCSY, NOESY, 
ROESY and HSQC experiments. COSY/TOCSY and NOESY/ROESY experiments were used 
to establish the connectivity of the molecular frames, through chemical bonds and distances in 
space, respectively. HSQC experiments complemented the homonuclear data by providing the 
corresponding one-bond heteronuclear chemical shift correlations. 
STD, tr-NOESY experiments and CORCEMA analysis were performed for each complex 
sample (see Experimental sections of publications IV and V for details). The theoretical basis 
of tr-NOESY and the CORCEMA protocol are detailed next. 
3.2.1 TR-NOESY experiments 
The conformation of the ligand in complex with a macromolecular target can be studied by 
NMR in solution for both tightly and weakly forming complexes. In the weak binding regime 
(koff > 10
4
 Hz), the structure of the bound ligand is accessible also for very large complexes 
(>100 kDa), which are not amenable to NMR studies in the tight binding regime. When a small 
molecule binds to a protein with low affinity (kD > 10
−6
 M), its NMR observable A equals the 
population-weighted average of Abound and Afree. (Eq. 3.2) 
𝐴 = 𝑝𝑏𝑜𝑢𝑛𝑑  𝐴𝑏𝑜𝑢𝑛𝑑 + 𝑝𝑓𝑟𝑒𝑒  𝐴𝑓𝑟𝑒𝑒                             Eq. 3.2                            
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Equation 3.2 is applicable if the exchange is fast on the relaxation and chemical shift (CS) 
timescales of the system, namely koff is larger than the CS difference between the free and the 
bound forms of the ligand (only one NMR line is observed) and larger than the relevant 
relaxation constants (T1
−1 
or T2
−1
) of the ligand-protein complex. Under these conditions, the 
NMR observable Abound, developed during the state Lbound by a ligand molecule, will be 
transferred to the state Lfree and vice versa; this transfer process is mediated by the rapid 
exchange between Lbound and Lfree  during the time t necessary to measure A. Thus, if the koff 
is larger than the transverse relaxation rate T2
−1
 of the complex, the transverse relaxation rate 
T2−1 of a ligand L in a mixture of ligand L and protein T is given by: 
 𝑇 2𝐿
−1 = 𝑝𝐿,𝑏𝑜𝑢𝑛𝑑  𝑇2𝐿,𝑏𝑜𝑢𝑛𝑑
−1 + 𝑝𝐿,𝑓𝑟𝑒𝑒  𝑇2𝐿,𝑓𝑟𝑒𝑒
−1                             Eq. 3.3                            
 
The individual populations pL,bound  and pL,free depend on the kD and on the concentrations of L 
and T. From Eq. 3.3 it is evident that the resonances of the ligand in a ligand-protein mixture 
for which the T2 of the protein is short can only be observed if pfree << pbound, namely if the 
ligand is in excess with respect to the protein ([L] >> [T]). Under these conditions, even if 
T2L,bound is too short to allow for the observation of the resonances of the complex, the NMR 
signals of the observed free ligand carry valuable information on the NMR properties of ligand 
in the complex. In the weakly binding regime and when the complex size too large to observe 
the NMR lines of the receptor, the structure of the ligand in the bound form can be obtained via 
transferred-NOEs measurements. Similarly to Eq. 3.3, the averaged NOE observed between 
two protons HA and HB of a ligand in the presence of its weakly binding receptor can be 
described as: 
   𝑁𝑂𝐸 𝐴𝐵 = 𝑝𝐿,𝑓𝑟𝑒𝑒  𝑁𝑂𝐸𝐴𝐵 ,𝑓𝑟𝑒𝑒 + 𝑝𝐿,𝑏𝑜𝑢𝑛𝑑  𝑁𝑂𝐸𝐴𝐵 ,𝑏𝑜𝑢𝑛𝑑                             Eq. 3.4  
 
If the correlation time of the complex is several orders of magnitudes larger than the 
correlation time of the free ligand, the NOEAB,bound  will be much larger than the NOEAB,free, thus 
dominating the NOEAB even in the presence of an excess of free ligand (pLfree > pLbound). In 
particular, if the NOE of the free ligand in solution is positive, a sign change of the NOE is 
observed upon addition of protein. This effect is called transferred-NOE. 
[32]
 
3.2.2 Complete relaxation and conformational exchange matrix 
(CORCEMA) analysis of STD effects 
Because the STD NMR method is one that relies on the transfer of cross relaxation, theoretical 
methods have been developed for the analysis of cross relaxation. It has been described a 
complete relaxation and conformational exchange matrix (CORCEMA)-based analysis that 
can be employed to obtain quantitative STD effects for a given model, by considering the 
relaxation processes and kinetic features of the system surveyed. 
[33]
 This procedure considers 
the influence of the complex and the ligand conformations on the relaxation rates of the ligand 
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protons and, therefore, on their corresponding STD effects. The CORCEMA method is also 
useful in determining the optimal experimental conditions for undertaking the STD-NMR 
measurements on a given complex by computer simulations. It also permits the structural 
refinement of ligands bound to receptors determined by computer modeling and X-ray 
crystallography. 
[34-35]
 For the construction of an accurate relaxation matrix, the CORCEMA-ST 
protocol requires a high resolution structure of the protein. 
 
The CORCEMA-ST protocol, as schematized in Figure 2.5, was employed in this Chapter for 
validating the 3D complex models obtained from Docking procedures. This protocol allowed 
the prediction of STD effects for an ensemble of 100 receptor-ligand complexes, once the 
binding constant and the free and bound correlation times were known (or estimated). Other 
parameters, such as the saturation time, protein and ligand concentrations, methyl protons in 
the ligand and in the protein and magnetic field were also given as an input data for the 
calculation. The theoretical STD intensities were quantitatively compared to those obtained 
experimentally by NMR, by the scoring function termed NOE R-factor, as implemented in the 
program. Then, we retained or rejected structures depending on the NOE R-factor, to get the 
best fit between experimental STD-NMR values and the predicted ones. 
 
 
Ensemble of structures
Docking calculations
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INPUT
Read PDB coordinates (< 8Å)
Saturation time
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Figure 2.5 CORCEMA-ST protocol followed herein for calculating theoretical STD intensities and 
comparing to experimental NMR intensities.  
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Introduction 
Heparin and heparin sulfate (HS) participate in many important biological processes, including 
blood anticoagulation, viral and bacterial infection and entry, angiogenesis, inflammation, 
cancer, and development. 
[1]
 Because of its wide range of biological functions, heparin has 
become an interesting molecule to biochemists, medicinal chemists and developmental 
biologists. 
Extensive structural studies of heparin have been carried out since its discovery, however, the 
chemical complexity and heterogeneity of heparin has made difficult the study of its primary 
structure. This can explain the fact that, despite its widespread clinical use as an anticoagulant 
drug, the structure-function relationship of defined heparin sequences is still poorly 
understood. Much of the interest in characterizing heparin structure is focused on the 
determination of sequences that interact specifically with proteins and peptides. Therefore, the 
chemical or enzymatic synthesis of defined heparin oligosaccharides is important in order to 
improve our understanding of heparin’s primary structure and to establish more detailed 
structure-activity relationships and to correlate specific sequences and sulfation patterns with 
protein binding and biological activity. 
[2-3]
  
In this sense, recent years have seen significant improvements in the preparation of highly 
homogeneous heparin derivatives, and the sequencing of heparin fragments. As example, the 
first chemoenzymatic synthesis of the stable isotope-enriched heparin from a uniformly labeled 
[
13
C,
15
N] N-acetylheparosan will be described in publication I. This and other novel strategies 
have allowed more detailed studies for the structural and conformational characterization of 
heparin derivatives, as will be shown in publication I, and a better understanding of the 
interactions of heparin with FGFs and FGF-FGFR complexes, as will be shown in manuscripts 
II and III. 
FGF signalling involves binding to specific cell-surface tyrosine kinase receptors (FGFRs) and 
is tightly regulated by heparin-like glycosaminoglycans that facilitate the formation of FGF-
FGFR complexes. 
[4-6]
 The various FGFs require heparin or heparin sulfate (HS) for biological 
activity, presumably to generate and stabilize ternary signaling complexes with FGFRs. High-
resolution X-ray crystal structures of FGF-FGFR-heparin complexes 
[7-9]
 and NMR solution 
structures of FGF-heparin complexes 
[10]
 have provided insights into structural aspects of 
these interactions and demonstrated the complexity of the molecular mechanism involved in 
heparin-mediated FGF signalling. 
Although two crystallographic models have been proposed for the FGF-FGFR-heparin 
signalling complex 
[8-9]
 and these two structures show similar arrangements for the complex of 
one molecule each of FGF, FGFR and heparin, the manner in which two FGF-FGFR 
complexes are brought together to form the ternary complex differs drastically between the two 
models (Figure 4.1.0). One model, dubbed as asymmetric model (Pellegrini model 
[8]
), shows 
the heparin as the fundamental organizing unit of the complex, dimerizing the two FGFs in the 
absence of any protein-protein contact (in a similar manner to a 2:1 FGF1-heparin complex 
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observed crystallographically by DiGabriele et al 
[7]
); the other model, dubbed as symmetric 
model (Schlessinger-Mohammadi model 
[9]
) shows additional interactions between the FGFR 
and both members of the other FGF-FGFR complex as the main determinant of dimerization, 
with the heparin contributing to the interaction and providing relief from electrostatic repulsion.  
The latter model also suggests that two molecules of heparin are required per ternary 
complex. These structures have served as a tremendous stimulus to further research into the 
nature of the interaction of HS and heparin with the FGFs and FGFRs. 
 
Figure 4.1.0 Proposed models for the ternary complex FGF-heparin-FGFR. A) Crystal structure of the 
complex FGF1-heparin-FGFR2 with stoichiometry 2:1:2. This model shows two FGFs dimerized by 
heparin, bringing two FGFR molecules together. B) Crystal structure of the complex FGF2-heparin-
FGFR1 with stoichiometry 2:2:2. This model shows two FGF–FGFR– heparin heterotrimers forming a 
complex via interactions of the FGFR in each complex with all three members of the other complex. 
FGFR is shown as cyan and green cartoons, FGF is shown as dark blue cartoon and heparin is shown 
as sticks, oxygen atoms colored red and sulfur atoms colored yellow. 
 
Our initial hypothesis was that maybe only one of the crystal structures is biologically relevant. 
Thus, as the main objective of this Thesis, we aimed at trying to answer a key question in the 
molecular recognition of heparin by FGFs and FGFRs: we try to unravel, the fine structural 
aspects of these physiologically relevant FGF-heparin-FGFR interactions, in solution, by using 
NMR. 
As first step to comprehend the molecular recognition process, in this Thesis, the complete 
three-dimensional study of labeled synthetic heparin oligosaccharides is presented, using 
NMR experiments, assisted by molecular modeling protocols. 
Results 
The work described herein focuses on the study of the conformational and dynamic solution 
features of synthetic heparin derivatives and characterization of their interactions with their 
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associated FGF1 and FGFR2-Ig2 proteins by using NMR spectroscopy and molecular 
modeling.  
4.1.1. Conformational analysis of uniformly 13C, 15N-labeled heparin and its 
precursors 
In a first approach, a collaboration with the group of Prof. Robert Linhardt (Troy, NY, USA), 
has permitted us to study the conformational analysis of uniformly 
13
C, 
15
N-labeled heparin 
and its precursors, using NMR spectroscopy in combination with Molecular Dynamics (MD) 
simulations, as described in publication I. 
[11]
 
13
C, 
15
N-labeled heparin polysaccharides and its 
precursors were prepared by a stepwise chemoenzymatic synthesis in milligram amounts from 
13
C, 
15
N N-acetylheparosan afforded by fermentation of E. coli in the laboratory of Prof. Robert 
Linhardt (Troy, NY, USA). Heteronuclear NMR experiments were also performed in their 
laboratory to unambiguously confirm the structures of these polysaccharides.  
Therefore, with the fully assigned NMR spectra at hand, I was directly involved in the 
characterization of the conformation of N-acetylheparosan, N-sulfoheparosan, undersulfated 
heparin, and heparin with MD simulations in explicit solvent performed with AMBER 
[12]
.  
The AMBER 
[12]
 molecular dynamics simulation suite of programs allowed us to explore the 
possible conformations for each molecule, by using different protocols: 
 1) MD simulations with NOE-derived distances included as time averaged distance restraints 
(tar). In this approach, two different trajectories using either <r
-6
>
-1/6
 or <r
-3
>
-1/3
 restraints have 
been calculated to cope with different internal motion timescales. In the case of relatively small 
molecules in which the time scale of internal fluctuations is longer than the overall tumbling 
time, NOE intensities average according to <r
-6
>
-1/6
, whereas if the internal fluctuations are 
significantly faster compared with the tumbling, they average according to <r
-3
>
-1/3
. 
[13]
 
2) MD simulations without time-averaged restraints, for comparison purposes.  
The experimental key proton-pair distances (Å) deduced from the NOE-based 3D NOESY-
HSQC experiments were implemented as tar-constraints in the tar-MD simulations.  
For all the MD simulations, with or without tar-restraints, a heptasaccharide molecule (with 
residues labeled 1-7. with 1 being the non-reducing end moiety), prepared from the repeating 
disaccharide of each GAG structure, as shown in Scheme 4.1.1, was employed. The starting 
geometry included a GlcNAc or a  GlcNS residue at the nonreducing end.  
Two independent simulations were performed for undersulfated heparin and heparin, one with 
the IdoA in the 
1
C4 conformation and other one with the IdoA in the 
2
SO skew boat geometry. 
The system preparation as well as the general MD protocol used in the computational part of 
the Thesis are detailed in section 3.1.4 of the Material and Methods section. 
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Scheme 4.1.1 Heptasaccharides prepared from the repeating disaccharide of each GAG structure for 
the MD simulations. From top to bottom: N-acetylheparosan (GlcAGlcNAc), N-sulfoheparosan 
(GlcAGlcNS), Undersulfated heparin (IdoA2SGlcNS), and Heparin (IdoA2SGlcNS6S).  
 
The trajectories were analyzed using the CARNAL module of AMBER6. The analysis of the 
output of the MD simulations, including the ring forms, the RMSD variations, and glycosidic 
linkage distribution maps, showed the goodness of the simulations, since largely stable values 
were always obtained, with absence of artifacts or strong changes in the system.  
As expected, the pyranose forms of the GlcA and GlcNS rings adopted the more stable 
4
C1 
conformation. In contrast, for the IdoA2S residues, interconversion between 
1
C4 and 
2
SO forms 
were always observed in both the restrained and unrestrained simulations. 
For the conformational analysis of the glycosidic linkages,  versus  (Ramachandran-type 
plots), distributions were plotted to establish the possible presence of more than one 
conformation, as shown for heparin in Figure 4.1.2. This analysis is detailed in the following 
article (Publication I). The averaged torsion angle values and averaged inter-proton distance 
values were computed and compared with experimental data. 
The results from the tar-MD simulations showed close agreement, in numerical terms, 
between the distances found in the refined models and the experimental data estimated by 
NMR (see table of Figure 4.1.2 for inter glycosidic distances). 
 The / distribution maps (/ defined as H1´-C1´-O-C4/ C1´-O-C4-H4) showed a well 
defined conformational space for each torsion, although a certain degree of flexibility was 
evidenced. In any case, in terms of the glycosidic angle , only exoanomeric orientations were 
observed. 
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Table Sx. The results of the tar-MD simulations (<r
-3
>
-1/3
 averaging) for the different glycosidic linkages 
of heparin. The experimental key proton-pair distances (Å) as deduced from the NOE-based 3D NOESY-
HSQC experiments were implemented as tar-contraints with a 10% margin. No stereospecific assignment 
was performed and the restraint was set to the corresponding C-6 carbon atom (adding 0.8 Å).  
 
H1 IdoA- H4 
GlcNS 
H1 IdoA- H3 
GlcNS 
H1 IdoA- 
H6a GlcNS 
H1 IdoA- 
H6b GlcNS 
H1 GlcNS- 
H4 IdoA 
H1 GlcNS- 
H3 IdoA 
12 -- -- -- -- 2.6 2.6 
23 2.6 4.5 2.2 3.7 -- -- 
34 -- -- -- -- 2.6 2.6 
45 2.6 4.5 2.2 3.7 -- -- 
56 -- -- -- -- 2.7 2.5 
67 2.6 4.4 2.3 3.8 -- -- 
MD-average 2.6 4.5 2.2 3.7 2.6 2.6 
experimental 2.4 4.5 2.6* 3.1* 2.8 2.8 
  
Figure 4.1.2 The / distributions for the glycosidic torsions of heparin (top), as estimated by MD 
simulations (4 ns of simulation time) in explicit water, and employing the NOE-derived distances 
(bottom) as experimental tar-restraints (<r
-3
>
-1/3
). 
As a result, the ring geometries and the / values of N-sulfoheparosan, in the generated 
structural models, were nearly identical to those of N-acetylheparosan, resulting in a similar 
local and global conformation. Thus, N-sulfonation does not modify the overall conformation of 
this GAG.  
In the case of the IdoA2S ring for undersulfated heparin, the NOE-based H2-H5 distance was 
found to be 3.8 Å (±10%). Since the idealized H2-H5 distances for the 
1
C4 and 
2
SO conformers 
are 4.0 and 2.4 Å, respectively, this value was consistent with a large (>85%) population of the 
1
C4 conformer of IdoA2S. In contrast, for heparin, the NOE-based H2-H5 distance was 2.8 Å 
(±10%), a value that, according to the idealized values given above, is consistent with >80% of 
the IdoA2S being in the 
2
SO form. These results indicated that the 6-O-sulfonation of the 
undersulfated heparin to heparin, markedly shifted the equilibrium of the adjacent IdoA2S 
residues, from the 
1
C4 to the 
2
SO conformer.  
More detailed information is presented in the following publication (Article I). 
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Abstract: We report the first chemoenzymatic synthesis of the stable isotope-enriched heparin from a
uniformly labeled [13C,15N]N-acetylheparosan (-GlcA(1,4)GlcNAc-) prepared from E. coli K5. Glycosami-
noglycan (GAG) precursors and heparin were formed from N-acetylheparosan by the following steps:
chemical N-deacetylation and N-sulfonation leading to N-sulfoheparosan (-GlcA(1,4)GlcNS-); enzyme-
catalyzed C5-epimerization and 2-O-sulfonation leading to undersulfated heparin (-IdoA2S(1,4)GlcNS-);
enzymatic 6-O-sulfonation leading to the heparin backbone (-IdoA2S(1,4)GlcNS6S-); and selective enzymatic
3-O-sulfonation leading to the anticoagulant heparin, containing the GlcNS6S3S residue. Heteronuclear,
multidimensional nuclear magnetic resonance spectroscopy was employed to analyze the chemical
composition and solution structure of [13C,15N]N-acetylheparosan, precursors, and heparin. Isotopic
enrichment was found to provide well-resolved 13C spectra with the high sensitivity required for
conformational studies of these biomolecules. Stable isotope-labeled heparin was indistinguishable from
heparin derived from animal tissues and is a novel reagent for studying the interaction of heparin with
proteins.
Introduction
Heparin and heparan sulfate (HS) participate in many
important biological processes, including blood anticoagulation,
viral and bacterial infection and entry, angiogenesis, inflam-
mation, cancer, and development.1-3 Heparin/HS carry out their
biological functions primarily by their interaction with proteins,
in which sulfo and carboxyl groups electrostatically interact or
hydrogen-bond with basic amino acids of the target protein.1
In a number of cases, heparin/HS has been demonstrated to bind
specifically and with high affinity to proteins, regulating their
biological functions.2,3 Structural analysis, relying on either
NMR or X-ray crystallography, has been reported for several
heparin/HS-protein complexes, revealing the relative impor-
tance of certain negatively charged groups in specific positions
of the uronic acid (UA) and/or glucosamine residues.4-6
Unfortunately, in most cases there is a lack of general ap-
proaches for the identification and positioning of the key groups
within heparin/HS required for protein-binding specificities.
Heparin and HS are acidic linear polysaccharides having
closely related structures. Both are isolated by extraction from
animal tissues and are members of the glycosaminoglycan
(GAG) family. These GAGs have an average molecular weight
of 10-15 kDa and a polydispersity of 1.05-1.6.7 Heparin and
HS are comprised of a repeating disaccharide structure of 1,4-
linked hexuronic acid and glucosamine residues. The most
common disaccharide unit of heparin is composed of a 2-O-
sulfo-R-L-iduronic acid 1,4-linked to 6-O-sulfo-N-sulfo-R-D-
glucosamine, -IdoA2S(1,4)GlcNS6S-. HS has a similar but less
sulfated structure containing primarily -D-glucuronic acid
(GlcA) and N-acetyl-R-D-glucosamine (GlcNAc).8 Heparin, a
clinical anticoagulant, binds to the serine protease inhibitor
antithrombin III (ATIII), causing it to undergo a conformational
change resulting in ATIII inhibition of thrombin and other
coagulation cascade proteases.2,8 ATIII binds to a specific
pentasaccharide sequence, contained within the heparin/HS,
† Departments of Chemistry and Chemical Biology and Chemical and
Biological Engineering, Rensselaer Polytechnic Institute.
‡ Department of Biology and Center for Biotechnology and Interdisci-
plinary Studies, Rensselaer Polytechnic Institute.
§ Centro de Investigaciones Biolo´gicas (CSIC).
⊥ Universidad de La Rioja UA-CSIC.
| Division of Medicinal Chemistry and Natural Products, University of
North Carolina.
(1) Capila, I.; Linhardt, R. J. Angew. Chem., Int. Ed. 2002, 41, 391–412.
(2) Munoz, E. M.; Linhardt, R. J. Arterioscler. Thromb. Vasc. Biol. 2004,
24, 1549–1557.
(3) Raman, R.; Sasisekharan, V.; Sasisekharan, R. Chem. Biol. 2005, 12,
267–277.
(4) Jin, L.; Abrahams, J. P.; Skinner, R.; Petitou, M.; Pike, R. N.; Carrell,
R. W. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14683–14688.
(5) Guerrini, M.; Guglieri, S.; Beccati, D.; Torri, G.; Viskov, C.; Mourier,
P. Biochem. J. 2006, 399, 191–198.
(6) Mulloy, B.; Linhardt, R. J. Curr. Opin. Struct. Biol. 2001, 11, 623–
628.
(7) Casu, B. AdV. Carbohydr. Chem. Biochem. 1985, 43, 51–134.
(8) Linhardt, R. J. J. Med. Chem. 2003, 46, 2551–2554.
Published on Web 09/04/2008
10.1021/ja8026345 CCC: $40.75  2008 American Chemical Society12998 9 J. AM. CHEM. SOC. 2008, 130, 12998–13007
having the structure GlcNAc/NS6S(1,4)GlcA(1,4)GlcNS3S-
6S(1,4)IdoA2S(1,4)GlcNS6S.9
Methods for analyzing heparin/HS sequence and conformation
are important for understanding biological activity and structure-
activity relationships.8 Nuclear magnetic resonance (NMR)
spectroscopy and mass spectrometry (MS) have become the
primary tools for establishing the chemical structure of heparin/
HS. NMR has also provided insight into the conformational and
dynamic solution properties of short-chain heparin/HS oligosac-
charides, prepared from animal sources or by chemical
synthesis.9-11 Mulloy and co-workers12 utilized a joint NMR
and molecular-modeling approach, in which models at atomic
resolution were generated for heparin and de-N-sulfonated, re-
N-acetylated heparin. While a number of high-quality crystal
structures have been reported for heparin/HS oligosaccharides
in complex with various proteins, no high-resolution crystal
structures have been reported for unbound heparin/HS polysac-
charides or oligosaccharides, due to difficulties in both purifica-
tion and crystallization. As a result, much of our understanding
of heparin/HS-derived oligosaccharide structure is derived from
crystallographic models of these carbohydrates in complex with
heparin-binding proteins.6 These structures often reveal carbo-
hydrates in distorted conformations and offer little information
on the flexibility of the carbohydrate and the number of
conformational forms. NMR is ideally suited to determine the
conformational and dynamic features of heparin/HS in solution.
Unfortunately, the extensive proton spectral overlap, the ex-
tended and flexible conformation, and the inherent microhet-
erogeneity (sequence variability and dispersity) of heparin/HS,
isolated from animal tissues, limit conformational analysis by
NMR to short oligosaccharides and make analysis in complex
with proteins nearly intractable.9-11
A principal way for reducing spectral overlap and resolving
proton resonances is the correlation of chemical shifts of
heteronuclei in additional spectral dimensions.13 Heteronuclear
NMR is highly effective in resolving heparin/HS spectra due
to the surprisingly high level of 13C dispersion. However, nearly
all heteronuclear NMR experiments that probe higher ordered
structures require isotopic enrichment for acceptable sensitivity.
While isotopic enrichment of animal-derived polysaccharides
is theoretically possible by feeding stable isotopic precursors,
the cost of such an approach is prohibitive. Chemoenzymatic
synthesis has recently been introduced as an alternative method
to prepare various heparin/HS derivatives for biological and
clinical evaluation.14,15 The biosynthesis of heparin/HS GAGs
has been extensively studied.16,17 A repeating 1,4-glycosidically
linked copolymer of -D-GlcA and R-D-GlcNAc, called N-
acetylheparosan, is synthesized through the stepwise addition
of uridine diphosphate-activated sugars. Bacteria, including
Escherichia coli and Pasteurella multocida, also biosynthesize
N-acetylheparosan.18,19 During heparin/HS biosynthesis in
animal cells, the N-acetylheparosan linear homocopolymer is
modified sequentially through the action of N-deacetylase/N-
sulfotransferase, C5-epimerase, and 2-, 6-, and 3-O-sulfotrans-
ferases (OSTs). Complete or nearly complete modification of a
chain results in heparin, while partial modification results in
HS.16,17 These biosynthetic enzymes have been cloned, ex-
pressed, and used for controlled synthesis of heparin/HS.15,20
N-Acetylheparosan and its derivatives have been the subject
of recent interest in an effort to prepare heparin-like therapeutics
from non-animal sources.14,21 Enzymatic sulfonation of these
derivatives offers products that closely resemble the heparins
isolated from animal tissues, suggesting a utility in the develop-
ment of new pharmaceuticals.15,20,22 Unfortunately, despite the
decreased heterogeneity of these heparin derivatives, structural
studies using NMR are still plagued by the low natural
abundance of heteronuclei. Heteronuclear NMR has been
extremely beneficial in solving the solution structures of proteins
and nucleic acids.23,24 Studies on 13C-labeled chondroitin sulfate
oligosaccharides25 and stable isotope-labeled hyaluronan and
hyaluronan oligosaccharides26 suggested to us that a similar
approach might be possible for heparin. As a demonstration,
the solution structures of N-acetylheparosan, heparin, and
intermediate GAGs have been analyzed here using heteronuclear
NMR and molecular dynamics (MD) with time-averaged
restraints (Tar-MD).
Experimental Section
Preparation of [13C,15N]N-Acetylheparosan. 13C,15N-isotopi-
cally labeled N-acetylated heparosan (-GlcA(1,4)GlcNAc-) was
prepared by fermentation of E. coli K5 strain in minimal media
containing 13C-D-glucose and 15NH4Cl.27
Expression of Recombinant HS Biosynthetic Enzymes and
Heparin Lyases. The catalytic domains of human C5-epimerase,
hamster 2-OST, hamster 6-OST-1, mouse 6-SOT-3, and mouse
3-OST-1 were recombinately expressed in E. coli and purified.20
Heparin lyases I, II, and III were cloned from the genomic DNA
of FlaVobacterium heparinum. The expression of the recombinant
heparin lyases was also carried out for E. coli.28
Preparation of Heparin and Its Precursors. 13C,15N-Labeled
N-acetylheparosan (5 mg) was N-deacetylated using NaOH, neutral-
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ized with HCl, and N-sulfonated with (CH3)3N ·SO3.29 Three
modification steps were used to convert 13C,15N-labeled N-
sulfoheparosan to anticoagulant heparin: C5-epimerization/2-O-
sulfonation, 6-O-sulfonation, and 3-O-sulfonation. Each step was
performed in buffer in the presence of a PAPs regeneration
system.15
NMR. 1H and 13C NMR, 2D 1H-13C HMQC, and constant-
time HSQC and 3D HCCH-COSY, HCCH-TOCSY, and (H)CCH-
TOCSY spectra were recorded on 13C,15N-labeled N-acetylhepa-
rosan, N-sulfoheparosan, undersulfated heparin, and heparin samples
in D2O. The proton and carbon chemical shifts were calibrated
against 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS). A series
of 3D 13C-separated NOE spectra were also acquired for each
sample at mixing times of 20, 40, and 100 ms.
Disaccharide Composition Analysis of Anticoagulant Hep-
arin. Heparin and anticoagulant heparin (20 µg, respectively) were
incubated in 50 mM sodium phosphate buffer, pH 7.0, with heparin
lyase I, II, and III mixture (100 m-units) at 37 °C for 10 h.
Completely digested products were heated in a boiling water bath
for 10 min to halt the reaction. The denatured protein was removed
by centrifugation at 12000g for 10 min, and disaccharides were
analyzed by HPLC-ESI-MS.30
APTT Activity and ATIII-Binding. 13C,15N-Labeled heparin
and anticoagulant heparin (100-1500 ng) were subjected to APTT
assay, and anticoagulant activity was calculated from a standard
curve prepared using the same concentrations of pharmaceutical
heparin.31 The 3-O-[35S] sulfated, anticoagulant heparin was
incubated with ATIII and captured using ConA-Sepharose. Binding
of 35S-labeled anticoagulant heparin to ATIII was determined by
scintillation counting.
Molecular Dynamics Simulations. For all the MD simulations,
with or without time-averaged restraints (tar), a heptasaccharide
(residues labeled 1-7 with 1 being a nonreducing end residue),
prepared from the repeating disaccharide of each GAG structure,
was employed, starting with a GlcNAc residue at the nonreducing
end. Two independent simulations were performed for undersulfated
heparin and heparin, one with the IdoA in the 1C4 conformation
and one with the IdoA in the 2SO skew boat geometry.
Tar-MD Simulations in Explicit Water with NOE-Based
Restraints. Tar-MD simulations were performed with AMBER32
to 6.0 (parm94),33 implemented with GLYCAM 06 parameters34
and with parameters computed for the sulfo and sulfamo groups,35
to accurately simulate the conformational behavior of the sugar
moiety and the sulfo and sulfamo groups, respectively. The tar-
MD used 1805, 1977, 1993, and 2135 water molecules for
N-acetylheparosan, N-sulfoheparosan, undersulfated heparin, and
heparin, respectively. In all cases, the starting geometries were
generated from the available data12 deposited in the Protein Data
Bank (pdb code 1hpn) and modified accordingly. Final trajectories
were run using an exponential decay constant of 400 ps and a
simulation length of 4 ns. Experimental cross-relaxation rates were
derived from the NOESY-HSQC experiments acquired with 20,
40, and 100 ms mixing times. The experimental distances and
experimental NOEs were compared to those computed for the tar-
derived ensembles and for single conformers of the model hep-
tasaccharides using the isolated spin-pair approximation and a full-
matrix relaxation approach with software developed in-house. An
isotropic reorientation model was inadequate and unable to
simultaneously accommodate the experimental intra- and inter-
residue NOEs for the different residues. Thus, a symmetric top
model with correlation time values τ⊥ ) 8 ns and τ| ) 0.16 ns was
employed for heparin and the related molecules, as described by
Mulloy and co-workers.12
Molecular Modeling without Restraints in Explicit Water.
The solute molecule was first immersed in a TIP3P36 bath of water
molecules with the LEAP module. The simulation was performed
using periodic boundary conditions and the particle-mesh Ewald
approach37 to introduce long-range electrostatic effects. The
SHAKE algorithm for hydrogen atoms, which allows using a 2 fs
time step, was also employed. Finally, a 9 Å cutoff was applied to
Lennard-Jones interactions (see Supporting Information for details).
Results and Discussion
Preparation of Uniformly Labeled [13C,15N]N-Acetylhepa-
rosan. [13C,15N]N-Acetylheparosan was afforded by fermenta-
tion of E. coli K5 strain on medium containing uniformly labeled
13C-D-glucose and 15NH4Cl (Figure 1A). The average molecular
weight of the [13C,15N]N-acetylheparosan was ∼75 kDa,15 and
its isotopic purity was 94% based on disaccharide analysis using
high-performance liquid chromatography (HPLC) and detection
with electrospray ionization mass spectrometry (ESI-MS) (see
Supporting Information).
Preparation of Uniformly Labeled Heparin and Its Pre-
cursors. 13C,15N-Labeled heparin and its precursors were
prepared by a stepwise chemoenzymatic synthesis in milligram
amounts from [13C,15N]N-acetylheparosan. The initial chemical
N-deacetylation/N-sulfonation steps result in a partial depolym-
erization N-acetylheparosan, reducing the average chain length
of all of the precursors to∼20 disaccharide units,15 and ultimately
giving a heparin molecular weight of ∼12 kDa. The percent
conversion of each step (Figure 1A) was calculated on the basis
of disaccharide analysis (see Supporting Information).15,20
Treatment with 2-OST and C5-Epi afforded an undersulfated
heparin that was treated with 6-OST to afford heparin. Finally,
treatment with 3-OST-1 results in an anticoagulant heparin. The
presence of 13C,15N-label permitted the unambiguous assignment
of all proton and carbon resonances. It is notable that, while
excess enzyme and PAPS cofactor were used in each step, none
of the enzymatic modifications were complete. The final
products, both heparin and anticoagulant heparin, however,
resemble the pharmaceutical heparin products extracted from
animal tissues38 in disaccharide composition (see Supporting
Information), with 86-89% of their structure consisting of the
trisulfated, IdoA2S(1,4)GlcNS6S, disaccharide repeating unit.
Chemical Structure Analysis of Uniformly Labeled Hep-
arin and Its Precursors. 1D, 2D, and 3D NMR were applied to
confirm the structures of N-acetylheparosan, N-sulfoheparosan,
undersulfated heparin, and heparin with significant improvement
in resolution. 1H-13C HMQC, 1H-13C constant-time (CT)-
HSQC, 3D HCCH-COSY, HCCH-TOCSY, (H)CCH-TOCSY,
and 13C-separated NOESY spectra were applied to unambigu-
ously assign the spectra (Table 1, the GlcN signals are
designated N1-N6 and the GlcA/IdoA signals are designated
(29) Nadkarni, V. D.; Toida, T.; Van Gorp, C. L.; Schubert, R. L.; Weiler,
J. M.; Hansen, K. P.; Caldwell, E. E. O.; Linhardt, R. J. Carbohydr.
Res. 1996, 290, 87–96.
(30) Warda, M.; Zhang, F.; Radwan, M.; Zhang, Z.; Kim, N.; Kim, Y. N.;
Linhardt, R. J.; Han, J. Glycoconjugate J. 2008, 25, 441–450.
(31) Pearlman, D. A.; Case, D. A.; Caldwell, J. W.; Ross, W. R.; Cheatham,
T. E., III; DeBolt, S.; Ferguson, D.; Seibel, G.; Kollman, P. Comput.
Phys. Commun. 1995, 91, 1–41.
(32) Kollman, P. A., University of California, San Francisco, 1999.
(33) Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.;
Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman,
P. A. J. Am. Chem. Soc. 1995, 117, 5179–5197.
(34) Woods, R. J.; Dwek, R. A.; Edge, C. J.; Fraser-Reid, B. J. Phys. Chem.
B 1995, 99, 3832–3846.
(35) Lan, J. Ph.D. Thesis, University of Edinburgh, 2007.
(36) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.;
Klein, M. L. J. Chem. Phys. 1983, 79, 926–935.
(37) Darden, T.; York, D.; Pedersen, L. J. Chem. Phys. 1993, 98, 10089–
10092.
(38) Linhardt, R. J.; Gunay, N. S. Semin. Thrombos. Hemostas. 1999, 25,
5–16.
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G/I1-G/I6). NMR assignments for N-acetylheparosan and
heparin, found in the literature,12,39 were comparable to those
presented in Table 1. Examples of 1H-13C HMQC spectra of
N-acetylheparosan, N-sulfoheparosan, undersulfated heparin, and
heparin are shown in Figure 1B-E (see Supporting Informa-
tion). The HMQC spectra show both highly degenerate proton
and well-dispersed carbon resonances. A high degree of
chemical homogeneity is evident and the differences in the
chemical structures of these GAGs are clearly reflected in these
spectra. Chemical differences at the chain termini were not
observable since they comprise low relative concentrations
(<5%) as a result of the high chain length. The 3D-HCCH-
COSY (Figure 2) spectra were instrumental in the assignment
of severely overlapped proton signals that could not be resolved
in homonuclear spectra. Even in cases where overlap in both
the 1H and 13C dimensions was observed, such as for N3, N4,
and N5 of N-acetylheparosan and N-sulfoheparosan, constant-
time encoding of 13C chemical shifts was effective at resolving
and aiding in the assignment of cross-peaks. The chemical shifts
of 15N and corresponding 1H were assigned on the basis of
(39) Guerrini, M.; Naggi, A.; Guglieri, S.; Santarsiero, R.; Torri, G. Anal.
Biochem. 2005, 337, 35–47.
Figure 1. (A) Scheme of stepwise chemoenzymatic synthesis of 13C,15N-labeled anticoagulant heparin. The major saccharide units are shown (with the
exception of anticoagulant heparin which shows a minor fully modified sequence). The GlcN residues are labeled N and the GlcA/IdoA residues are labeled
G/I. HMQC spectra of (B) 13C,15N-labeled N-aceylheparosan (blue), (C) 13C,15N-labeled N-sulfoheparosan (red), (D) 13C,15N-labeled undersulfated heparin
(green), and (E) 13C,15N-labeled heparin (purple).
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1H-15N HSQC (Supporting Information). The 1H and the
corresponding 15N signals were observed at 8.26 and 123.25
ppm, and they shifted upfield to 5.92 and 92.5 ppm, respectively,
after N-deacetylation and N-sulfonation.
The percent conversions of 97% (99%) for N-deacetylation
and N-sulfonation, 87% (93%) for C5-epimerization and 2-O-
sulfonation, and 90% (95%) for 6-O-sulfonation, obtained from
NMR and (disaccharide analysis, Figure 1A), were comparable
to those calculated from these spectra. The chemoenzymatic
process used in GAG synthesis results in a polydisperse product
containing minor structural heterogeneity as a result of incom-
plete modification. Thus, the assignments obtained (Table 1)
correspond to the major disaccharide-repeating unit present in
each GAG. While saccharide residues at the reducing and
nonreducing ends of the GAG chains can also contribute to
heterogeneity, NMR did not readily observe these end groups,
as they corresponded to <5% of the saccharidic units. The
percent conversion of heparin to anticoagulant heparin, resulting
from 3-O-sulfonation, was too low to be unambiguously
confirmed and/or quantified by NMR or by disaccharide
analysis.
Heparin structure varies between species and organs; for
example, porcine intestinal and bovine lung heparins (both
pharmaceutical heparins) have distinctly different structures.1,38
On treatment with heparin lyases, individual chains can afford
as many as many as eight different disaccharides and several
resistant oligosaccharides to as few as one repeating disaccha-
ride, -IdoA2S(1,4)GlcNS6S-. This microheterogeneity of animal-
derived heparin results from variability of the activity, speci-
ficity, and accessibility of enzymes in the Golgi at the time of
biosynthesis. Heparan sulfate, a closely related polysaccharide,
has an even more complex structure than heparin, and it is often
an impurity in pharmaceutical heparin isolated from animal
tissues. Chemoenzymatically synthesized heparin contains no
heparan sulfate impurity and no residual linkage region impurity,
and since it is lacking N-acetyl-substituted glucosamine residues
it shows a simpler disaccharide composition than pharmaceutical
heparin.
Uniform 13C/15N isotopic labeling facilitated the NMR-based
structural analysis of the GAGs. The well-dispersed 13C-spectra
enabled sensitive application of a wide array of multidimensional
heteronuclear experiments by overcoming limitations resulting
from severe overlap of proton resonances that have historically
hindered the interpretation of GAG NMR data. One-bond
1H-15N couplings in N-acetylheparosan were sensitively de-
tected, but rapid solvent exchange in N-sulfoheparosan decreased
their value in the structural assignment of N-sulfonated GAGS.
In the future we anticipate that 15N labeling will be important
in the NMR studies of these GAGs due to the sensitivity of
15N chemical shift to the local environment. 15N dispersion can
Table 1. Chemical shifts (δ, ppm) for the Major N and G/I
Residues Present in N-Acetylheparosan, N-Sulfoheparosan,
Undersulfated Heparin, and Heparin (see Figure 1A for Structures)
δ (ppm)
N-acetylheparosan N-sulfoheparosan
undersulfated
heparin heparin
1H NMR
UA (G/I) H1 4.43 4.47 5.19 5.16
H2 3.31 3.35 4.29 4.28
H3 3.63 3.73 4.19 4.14
H4 3.68 3.80 3.97 4.05
H5 3.74 3.77 4.80 4.76
GlcN (N) H1 5.31 5.56 5.25 5.35
H2 3.78 3.22 3.19 3.22
H3 3.78 3.63 3.63 3.60
H4 3.62 3.63 3.63 3.72
H5 3.78 3.78 3.80 3.96
H6 3.81 3.81 3.81 4.35
H6′ 3.78 3.76 3.80 4.20
CH3 1.97 - - -
13C NMR
UA (G/I) C1 105.5 105.3 102.1 102.3
C2 76.6 75.7 77.4 78.8
C3 79.2 79.5 70.6 71.2
C4 79.1 78.9 78.7 79.0
C5 76.5 79.3 71.2 72.2
C6 178.2 178.3 179.2 179.1
GlcN (N) C1 99.8 100.1 100.3 99.6
C2 56.3 60.6 61.2 60.7
C3 72.2 72.6 71.7 72.5
C4 81.4 80.8 80.4 78.6
C5 73.7 73.5 73.9 72.1
C6 61.4 62.4 62.7 69.2
CH3 23.9 - - -
CO 176.6 - - -
Figure 2. Strip plots from the 3D-HCCH-COSY spectrum of 13C,15N-
labeled heparin. Panels A-E illustrate a sequential walk from C2 of GlcN
to C6 of GlcN; panels F-I under C2 of IdoA to C5 of IdoA.
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be instrumental in overcoming spectral degeneracies by com-
bining 15N- and 13C-separated dimensions within an NMR
experiment. This dual heteronuclear labeling strategy should
facilitate sequence-specific assignment and provide structural
data at atomic resolution for heparin oligosaccharides in the
future, particularly when used for heparin-protein complexes.
Characterization of Anticoagulant Heparin. In the transfor-
mation of heparin to anticoagulant heparin, the small number
of sites undergoing 3-O-sulfonation afforded no detectable
change by NMR. To determine percent conversion,13C,15N
heparin was treated with 3-OST-1 and [35S]PAPS, affording
3-O-[35S]sulfo-13C,15N anticoagulant heparin. Measurement of
[35S] showed that 1 µg (83 pmol) of heparin incorporated 115
pmol of [35S]sulfo group, representing ∼1.5 3-O-[35S] sulfo
groups/chain. This corresponds to the sulfonation of ∼7.5% of
heparin’s GlcN-3-hydroxyl groups.
The ATIII binding activity of this anticoagulant heparin was
also determined.20 After 3-OST-1 modification, scintillation
counting demonstrated that only 35.2% of the 35S-labeled
anticoagulant heparin chains bound to ATIII, confirming that
the 3-OST-1 modified heparin binds to ATIII.
Anticoagulant activity was next assessed using activated
thromboplastin time (APTT).40 The activity of chemoenzymati-
cally synthesized heparin was 20 ( 6 U/mg, while chemoen-
zymatically anticoagulant heparin was 180 ( 15 U/mg, com-
parable to the 170 U/mg displayed by a standard pharmaceutical
heparin. Previously, we had reported anti-Xa and anti-IIa
activities comparable to those of pharmaceutical heparin for
heparin chemoenzymatically synthesized without isotopic label-
ing.15
While chemoenzymatically synthesized heparin showed only
four disaccharide peaks in HPLC-ESI-MS (see Supporting
Information), anticoagulant heparin showed additional (4%)
heparin lyase-resistant peaks as a result of the incorporation of
3-O-sulfo groups. 35S incorporation studies confirmed that
∼7.5% of the GlcN residues were 3-O-sulfonated and that
approximately one-third of these chains bind with high affinity
to ATIII, closely resembling the percentage of chains in
pharmaceutical heparin with high affinity for ATIII.38 APTT
assay showed the activity of anticoagulant heparin to be
comparable to that of standard pharmaceutical heparin.
Conformational Analysis of Heparin and Its Precursors.
From the fully assigned spectra (Table 1) and quantitative NOEs
(Table 2), the conformation of the starting N-acetylheparosan,
N-sulfoheparosan, undersulfated heparin, and heparin were
examined with experimentally restrained MD simulations using
a protocol41 similar to that recently applied by our group on a
dermatan sulfate oligosaccharide.42 Existing models of GAGs
and related glycans were used to evaluate NOE cross-peak
assignments and degeneracy.43 Once the assignment process was
completed, the intensities of the NOE cross-peaks at the various
mixing times were normalized to the corresponding diagonal
peaks. The interproton distances were deduced from a full-matrix
relaxation approach on model chair and skew-boat geometries.44
Spin-diffusion was essentially absent at 20 ms NOE mixing time
and gave a very minor contribution at 40 ms NOE mixing time.
A maximum error of 10%, estimated from spectral signal-to-
noise, resulted from noncorrected spin-diffusion contributions
and resonance overlap, problems largely eliminated by our 3D
13C-separated approach. The observed data correspond to an
average for all the glycosidic linkages of the GAG and should
show identical ensemble-averaged behavior on the long time
scale required for measuring NOE values.
Tar-MD simulations were employed to generate 3D models
of the different GAGs. For comparison purposes, the same
simulations were also performed without time-averaged re-
straints (7-9 ns of simulation time), providing similar results.
Tar-MD45-48 simulations were performed for heparin and its
precursors to obtain a conformer ensemble having distances
comparable to those estimated by NMR. The NOE-derived
distances were included as time averaged distance constraints
in two different trajectories using either 〈r-6〉-1/6 or 〈r-3〉-1/3
restraints to cope with different internal motion timescales. In
all cases, tar-MD trajectories were collected in the presence of
explicit water, and unrestrained MD simulations were also
computed for comparison purposes.
Results from the tar-MD simulations for N-acetylheparosan
(Table 3 and Figure 3A) show close agreement, in numerical
terms, between the distances found in the refined models and
experimental data using a 4 ns tar-MD simulation with explicit
water. The φ/ψ distribution maps indicate that the glycosidic
(40) Murugesan, S.; Park, T. J.; Yang, H.; Mousa, S.; Linhardt, R. J.
Langmuir 2006, 22, 3461–3463.
(41) Corzana, F.; Busto, J. H.; Jime´nez-Ose´s, G.; Garcı´a de Luis, M.;
Asensio, J. L.; Jime´nez-Barbero, J.; Peregrina, J. M.; Avenoza, A.
J. Am. Chem. Soc. 2007, 129, 9458–9467.
(42) Silipo, A.; Zhang, Z.; Can˜ada, F. J.; Molinaro, A.; Linhardt, R. J.;
Jime´nez-Barbero, J. ChemBioChem 2007, 9, 240–252.
(43) Hricovı´ni, M.; Nieto, P. M.; Torri, G. In NMR spectroscopy of
glycoconjugates; Jimenez-Barbero, J., Peters, T., Eds.; Wiley-VCH:
Weinheim: 2002; pp 189-230..
(44) Neuhaus, D., Williamson, M. P., Eds. The nuclear OVerhauser effect
in structural and conformational analysis; Wiley: New York, 1989.
(45) Pearlman, D. A. J. Biomol. NMR 1994, 4, 1–16.
(46) Torda, A. E.; Scheek, R. M.; van Gunsteren, W. F. J. Mol. Biol. 1990,
214, 223–235.
(47) Torda, A. E.; Scheek, R. M.; van Gunsteren, W. F. Chem. Phys. Lett.
1989, 157, 289–294.
(48) Forster, M.; Jones, C.; Mulloy, B. J. Mol. Graphics 1989, 7, 196–
201.
Table 2. Experimental Key Proton-Pair Distances (Å) As Deduced from the NOE-Based 3D NOESY-HSQC Experiments Employing the
Isolated Spin-Pair Approximation (As Described in the Experimental Section) from Three Different NOESY Experiments, at 20, 40 and 100
ms Mixing Times (Estimated Experimental Error is 10%)
H1 GlcA- H4 GlcNAc H1 GlcA- H3 GlcNAc H1 GlcA- H6 GlcNAc H1 GlcA- H6 GlcNAc H1 GlcNAc- H3 GlcA H1 GlcNAc- H4 GlcA
N-acetylheparosan 2.5 4.5 2.7a 2.7a 2.7 3.6
N-sulfoheparosan 2.7 4.5 2.5a 2.5a 2.7 3.8
H1 IdoA- H4 GlcNS H1 IdoA- H3 GlcNS H1 IdoA- H6 GlcNS H1 IdoA- H6 GlcNS H1 GlcNS- H3 IdoA H1 GlcNS- H4 IdoA
undersulfated heparin 2.5 4.5 2.7a 2.7a 2.5 2.7
heparin 2.4 4.5 2.6a 3.1a 2.8 2.8
a No stereospecific assignment was performed, and the restraint was included in the tar-MD simulations to the corresponding C-6 carbon atom
(adding 0.8 Å).
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linkages cover a similar area of the allowable conformational
space, independent of their position in the sequence (Figure 3A).
In terms of the glycosidic angle φ, only exoanomeric orientations
were adopted, demonstrating the goodness of the employed force
field. Only a very minor proportion (<2%) of non-exoanomeric
conformers were predicted for the linkage between residues 2
and 3 of the heptasaccharide sequence undergoing MD simula-
tion. Both GlcNAc(1,4)GlcA and GlcA(1,4)GlcNAc linkages
show conformers with a negative-ψ angle highly populated with
only minor incursions for the anti-ψ and positive-ψ values.
Analogous φ/ψ plots are also provided heparin (Table 4 and
Figure 3B) and for N-sulfoheparosan, and undersulfated heparin
(see Supporting Information). The ensemble shows that the
conformational space accessible for each glycosidic linkage
covers a well-defined area of the total available φ/Ψ energy
surface. Flexibility is apparent in N-acetylheparosan, which
cannot be defined by a single, rigid chain model, with a behavior
indeed similar to that reported for hyaluronic acid (HA), a
similar structure having a -4)GlcA(1,3)GlcNAc(1- repeating
disaccharide unit, with almost four sugar rings per helix turn.49
The reported standard deviations of the glycosidic linkages in
this polymer are ∼13°, while in our tar-MD approach for
N-acetylheparosan, the estimated maximum deviations for φ and
Ψ angles from the major value are ∼35°.
MD simulations were similarly performed on all GAG
precursors and heparin. A superimposition of 20 conformers,
randomly collected from the tar-MD simulations, is shown in
Figure 4. After discarding data from the first nanosecond, the
root-mean-square deviation (rmsd) of the skeleton atoms of all
(49) Almond, A.; Deangelis, P. L.; Blundell, C. D. J. Mol. Biol. 2006,
358, 1256–1269.
Table 3. Results of the Tar-MD Simulations (〈r-6〉-1/6/〈r-3〉-1/3 Averaging) for the Different Glycosidic Linkages of N-Acetylheparosana
H1 GlcA- H4 GlcNAc H1 GlcA- H3 GlcNAc H1 GlcA- H6aGlcNAc H1 GlcA- H6b GlcNAc H1 GlcNAc- H4 GlcA H1 GlcNAc- H3 GlcA
1f2 - - - - 2.5/2.5 3.3/3.4
2f3 2.5/2.6 3.6/4.4 2.6/2.9 2.6/2.9 - -
3f4 - - - - 2.5/2.5 3.4/3.4
4f5 2.4/2.6 4.4/4.4 2.7/3.0 2.6/2.9 - -
5f6 - - - - 2.5/2.5 3.3/3.3
6f7 2.6/2.5 3.0/4.2 2.7/2.7 2.7/2.6 - -
MD-average 2.5/2.6 3.5/4.3 2.6/2.9 2.6/2.8 2.5/2.5 3.3/3.4
experimental 2.5 4.5 2.7b 2.7b 2.7 3.6
a The experimental key proton-pair distances (Å) as deduced from the NOE-based 3D NOESY-HSQC experiments were implemented as structural
restraints with a 10% margin, using a flat well potential. b No stereospecific assignment was performed and the restraint was set to the corresponding
C-6 carbon atom (adding 0.8 Å).
Figure 3. φ/ψ distribution for (A) N-acetylheparosan and (B) heparin. In the tar-MD simulation a heptasaccharide (saccharide residues 1-7) is used. Each
panel shows the φ/ψ plot between adjacent saccharide residues.
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the sampled structures was 2.1 Å, compared to the averaged
structure. The unrestrained simulations showed a very similar
behavior. The simulation began with all seven saccharide
residues 1-7 of the heptasaccharide in the 4C1 form. While the
NMR data were acquired on a polysaccharide of approximately
20 disaccharide units, our simulations were performed on
heptasaccharide models of the polysaccharides. Therefore,
special attention was paid to the motion of the central residues,
as a paradigm for the motion of the disaccharide entities within
the intact polysaccharide. At the end of the simulation no
interconversion into other ring forms was observed for either
GlcNAc or GlcA residues. In contrast, in the case of the IdoA
residues, interconversion between 1C4 and 2SO forms was
observed in both the restrained and unrestrained simulations.
These results are consistent with observations that GlcNAc and
GlcNS residues were solely in the 4C1 conformation based on
3JH-H values.5 Additionally, the pyranose form of GlcA also
has been shown to prefer the more stable 4C1 form.50 Tar-MD
simulations were also used here to examine the conformation
of N-sulfoheparosan. The ring geometries and the φ/ψ values
of N-sulfoheparosan in the generated structural models were
nearly identical to those of N-acetylheparosan resulting, in a
similar local and global conformation (Figure 4B, also see
Supporting Information). The length (N-N distance between
the GlcN residues at positions 1 and 13) and shape of the two
chains were similar when oligosaccharides having 13 residues
were modeled from the more populated values of the tar-MD
Φ/Ψ distributions of the central residues for each structure
(Figure 5). The lengths of heparosan and N-sulfoheparosan were
57.4 and 58.4 Å, differing by only 1.0 Å. The pairwise rmsd
between the 13-mer N-acetylheparosan and N-sulfoheparosan
chains was 4.9 Å, and the pairwise rmsd for the central
trisaccharide was 1.0 Å. Thus, it appears that N-sulfonation does
not modify the conformation of this GAG (Figure 5A). Neither
anti-conformer nor non-exo conformer was found in the final
ensemble of N-sulfoheparosan, and the models showed even
less conformational variation (rmsd 1.9 Å) than that of N-
acetylheparosan. The observed increase in the ensemble-
averaged H1GlcA-H4GlcNS distance results from an increase
in positive ψ-conformers for this linkage, as can be observed
in the corresponding curves in Figure 3A for heparosan (5 (
65°) and those in Figure 3B for N-sulfoheparosan (25 ( 60°).
Epimerization of the GlcA C5 position and 2-O-sulfonation
affords undersulfated heparin. The structural impact of these
modifications was explored through the tar-MD simulations on
undersulfated heparin (Figure 4C, also see Supporting Informa-
tion). In solution, IdoA2S pyranose exhibits both the 2SO and
1C4 forms in equilibrium.50,51 As a means of evaluating bias in
the resulting structures, dual sets of simulations were initiated
with IdoA2S in the 2SO and half in the 1C4 conformer. Both
sets of simulations converged within 4 ns, with an rmsd value
of 2.4 Å. The estimated NOE-based H2IdoA2S-H5IdoA2S
distanceis3.8Å((10%).SincetheidealizedH2IdoA2S-H5IdoA2S
distances for the 1C4 and 2SO conformers are 4.0 and 2.4 Å,
respectively, this value is consistent with a large, >85%
population of the 1C4 conformer of IdoA2S. There was a
decrease in the length of the corresponding 13-mer chains, from
58.4 Å for N-sulfoheparosan to 51 Å for undersulfated heparin
with all of the IdoA2S residues in the 1C4 conformation (Figure
5). Nevertheless, deviations from an idealized helical geometry
are found throughout the resulting ensemble members.
Heparin’s repeating unit was next afforded by 6-O-sulfonation
of the undersulfated heparin. In contrast to its undersulfated
precursor, when the force field matched the H1GlcNS6S-
H4IdoA2S and H1GlcNS6S-H3IdoA2S distances, the NOE-
based H2IdoA2S-H5IdoA2S distance was calculated at 2.8 Å
((10%), a value that, according to the idealized values given
above, is consistent with >80% of the IdoA2S being in the 2SO
form, with an rmsd value of 2.2 Å. These results clearly
demonstrate that the addition of a 6-O-sulfo group onto GlcNS
residues markedly shifts the equilibrium of adjacent IdoA2S
residues from the 1C4 to the 2SO conformer. The balance of the
1C4 to 2SO equilibrium in an IdoA residue within a GAG chain
had been previously shown to depend on both its own
substitution with a 2-O-sulfo group and the substitution of the
adjacent GlcN residues.12,52 Mulloy and co-workers50 showed
that the overall conformation of the chain (i.e., the optimal
angles around the inter-residue glycosidic linkages) is not greatly
affected by the position of the 1C4 to 2SO equilibrium. Our
observations are similar with only a very minor 0.7 Å difference
between the lengths of the 13-mer chains built using 1C4 and
2SO geometries for the IdoA2S. The helical structure of the chain
only becomes apparent in the fully modified heparin (Figures
4D and 5B and see Supporting Information). While the global
structures of the members of the tar-MD heparin ensemble
deviate from the idealized geometry in models proposed by
Mulloy and co-workers,12 there is good agreement at a local
structural level. The ring geometries and glycosidic linkages in
the tar-refined heparin ensemble are consistent with previous
structuralstudiesperformedonshortheparinoligosaccaharides.10,11
Medium-range to long-range structural ordering is also consis-
tent with the previous studies and, in the current study, heparin
(50) Mulloy, B.; Forster, M. J. Glycobiology 2000, 10, 1147–1156.
(51) Sanderson, P. N.; Huckerby, T. N.; Nieduszynski, I. A. Biochem. J.
1987, 243, 175–181.
(52) van Boeckel, C. A.; van Aelst, S. F.; Wagenaars, G. N.; Mellema,
J.-R.; Paulsen, H.; Peters, T.; Pollex, A.; Sinnwell, V. Recl. TraV. Chim.
Pays-Bas 1987, 106, 19–29.
Table 4. Results of the Tar-MD Simulations (〈r-6〉-1/6/〈r-3〉-1/3 Averaging) for the Different Glycosidic Linkages of Heparina
H1 IdoA- H4 GlcNS H1 IdoA- H3 GlcNS H1 IdoA- H6 GlcNS H1 IdoA- H6 GlcNS H1 GlcNS- H4 IdoA H1 GlcNS- H3 IdoA
1f2 - - - - 2.6/2.6 2.6/2.6
2f3 2.6/2.6 4.5/4.5 2.3/2.2 3.7/3.7 - -
3f4 - - - - 2.6/2.6 2.5/2.6
4f5 2.6/2.6 4.5/4.5 2.3/2.2 2.9/3.7 - -
5f6 - - - - 2.6/2.7 2.5/2.5
6f7 2.4/2.6 4.4/4.4 2.3/2.3 3.7/3.8 - -
MD-average 2.5/2.6 4.4/4.5 2.3/2.2 3.2/3.7 2.6/2.6 2.5/2.6
experimental 2.4 4.5 2.6b 3.2b 2.8 2.8
a The experimental key proton-pair distances (Å) as deduced from the NOE-based 3D NOESY-HSQC experiments were implemented as
tar-constraints with a 10% margin. b No stereospecific assignment was performed and the restraint was set to the corresponding C-6 carbon atom (adding
0.8 Å).
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forms a left-handed helix with rotational and translational
parameters similar to those of short heparin oligosaccharides.
Therefore, the key helical parameters in heparin, including
helical width, groove depth, and axial rise, are not significantly
influenced by overall chain length. Local conformational flex-
ibility is evident in the tar-refined ensemble, consistent with
previous reported observations. However, this flexibility does
not appear to result in accordion-like stretching along the
helical axis (Figure 5). Some rotational freedom about the
glycosidic linkages was observed in the heparin ensemble,
and this fact results in small inter-residue deviations that
would be expected to propagate along the extended heparin
structure, resulting in long-range disorder or bending of the
helical axis. These global distortions are representative of
the conformational space explored in solution by the dynamic
heparin polysaccharide.
Figure 4. Superimposition of 20 conformers randomly taken from the tar-MD simulations for each GAG. The three central residues have been chosen for
the superimposition to show the propagation of the flexibility around the GAG chain: (A) N-acetylheparosan, (B) N-sulfoheparosan, (C) undersulfated
heparin, and (D) heparin. Carbon is shown in green, oxygen in red, nitrogen in blue, and sulfur in yellow.
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The structure of heparin has been extensively studied since
its discovery.7,8 The advent of NMR was instrumental in
defining heparin’s major uronic acid residue as IdoA and has
greatly improved our understanding of heparin’s primary
structure.53 NMR-based conformational analyses of heparin and
heparin oligosaccharides have resulted in an improved under-
standing of its ring conformations and their flexibility.9-11,54
Molecular modeling coupled with NMR12 has led to structures
widely used for analyzing heparin binding to proteins.4-6
However, NMR has had limited success in high-resolution
structure determination of the heparin molecule portions within
these complexes. X-ray crystallography has offered an inde-
pendent method to look at heparin’s structure. Despite the
publication of a number of crystal structures of heparin
oligosaccharides complexed with heparin-binding proteins,6
unbound heparin has only been studied at low resolution in fiber
structures.55
Future studies will be required to map the fine structural
features of heparin and compare these to various pharmaceutical
heparins prepared from animal tissues. Additional studies will
focus on the use of uniformly stable isotope-labeled GAGs as
binding partners for various heparin-binding proteins. In such
studies, it should be possible to study conformational changes
in the bound and unbound GAG using NMR. Moreover, it
should be possible to prepare structurally homogeneous oli-
gosaccharide binding partners56 uniformly labeled with NMR-
sensitive isotopes that enable high-resolution structural deter-
mination of these complexes. This should afford the improved
understanding of heparin structure-activity relationships re-
quired for the design of a novel and specific class of heparin-
based therapeutic agents.
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rosan and undersulfated heparin; stereoview of heparin helix;
disaccharide composition of heparin and anticoagulant heparin;
key proton-pair distances by tar-MD for N-sulfoheparosan and
undersulfated heparin. This information is available free of
charge via the Internet at http://pubs.acs.org.
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Figure 5. Superimposition of simulated 13-mers. (A) N-Acetylheparosan
(gray and red) is shown superimposed with N-sulfoheparosan (blue). (B)
Undersulfated heparin (gray and red) is shown superimposed with heparin
(green).
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4.1.2 Characterization of heparin-like oligosaccharides interactions with FGF1 
and FGFR2-Ig2 proteins by using NMR spectroscopy and molecular modeling 
 
The objective of the major part in this Thesis was to study the interactions of different heparin-
like oligosaccharides with FGF1 and FGFR2, and to characterize the corresponding protein-
protein interactions, with the final aim of unraveling the topology of the ternary complex in 
solution by NMR. The main results of this work are presented in publications II and III. 
 
Non-labeled heparin oligosaccharides used for titration experiments in publications II and III 
were kindly provided from Prof. Manuel Martín Lomas, Dr. J. L. de Paz, and Dr. Pedro Nieto 
from CIC-Biomagune (San Sebastián) and Centro de Investigaciones Químicas de la Isla de la 
Cartuja, CSIC (Sevilla). 
In the case of FGF1 and FGFR2-Ig2 proteins, I performed the expression and purification in 
close collaboration with the laboratory of Prof. Guillermo Giménez-Gallego, at the Centro de 
Investigaciones Biológicas (CSIC). A novel protocol for the expression of soluble FGFR-Ig2, in 
its native and fully active state, was developed, as described on section 3.1.1 of Material and 
Methods. In addition, I over-expressed and purified FGF1, as previously reported by our 
group. 
[10]
  
I was also able to efficiently incorporate 
15
N and 
15
N, 
13
C in the target proteins by means of 
uniform labeling strategies to suit our experimental needs. 
 
Expression of 15N and 15N, 13C labeled FGFR-Ig2 
As first step, the isotope labeling of FGFR was required in order to study their properties with 
NMR spectroscopy at atomic resolution.  
Herein, I report, for the first time, the expression of a soluble FGFR-Ig2 in E. coli using an 
isotope enriched medium, in its native and fully active form, different to the expression and 
purification from inclusion bodies and refolding that have been traditionally used for the 
expression of similar states of this protein. 
[14]
 
 The expression of the protein in E. coli, as described on Section 3.1.1 of Material and 
Methods, typically yielded about 6 mg of 
15
N singly or 
13
C,
15
N doubly labeled protein per liter of 
M9 minimal medium.  
After purification with heparin-Sepharose ion exchange chromatography, the protein was 
already more than 95 % pure as judged from SDS-PAGE analysis (see figure 4.1.3). The 
supernatant of the previous steps did not contain any significant amounts of the desired 
protein. 
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FGFR2-Ig2
 
Figure 4.1.3 Coomassie-stained 15 % SDS polyacrylamide gel of various fractions containing FGFR-Ig2 
during heparin-Sepharose ion exchange chromatography. The molecular weights of the marker 
proteins (Bio-Rad, Hercules, CA) are indicated on the left. 
 
Later, I implemented and recorded the standard 3D NMR experiments for backbone protein 
assignment, obtaining the protein assignment almost to completion, as shown in the next 
pages. Efficient calculation of the three-dimensional structure of FGFR-Ig2 from distance and 
torsion angle constraints was performed by torsion angle dynamics-driven simulated 
annealing, as implemented in CYANA software.  
NMR backbone assignment 
The assignment of the backbone resonances of FGFR2-Ig2 was the prerequisite to investigate 
its interactions with NMR spectroscopy at atomic resolution. As detailed in section 3.1.2 of 
Material and Methods, I employed a combination of three dimensional experiments for 
FGFR2-Ig2 free protein backbone assignment, the obtained 
1
H, 
13
C and 
15
N chemical shifts 
are given in Table 4.1.7. These included the standard 3D NMR HNCACB and CBCA(CO)NH, 
HNCO and HN(CA)CO experiments.  
NMR acquisition and processing parameters of the experiments employed for the assignment 
of FGFR-Ig2 are shown in Table 4.1.4.  
It is worth noting that initially our idea was to record the three dimensional experiments with a 
1:1 FGFR2-Ig2/pentasaccharide complex sample, but it turned out that the protein, at higher 
concentrations and in the presence of the heparin oligosaccharide, was able to form 
aggregates of higher molecular weight. Then, we proceeded to assign the free protein instead. 
In general, the HNCACB experiment proved to be the most important spectra for the 
assignment of the backbone residues of the protein. Combinations of alanine, glycine, serine 
or glycine residues in the amino acid sequences in most cases have been the most valuable 
starting points for the sequential correlation of the resonances because of their very 
characteristic peak patterns, especially in the HNCACB spectra.  
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Table 4.1.4 NMR acquisition and processing parameters for the assignment of FGFR-Ig2. 
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An example for the sequential assignment using strip representations from the HNCACB and 
CBCA(CO)NH spectra of FGFR2-Ig2 are shown in Figure 4.1.5 for the residues N2 to A8.  
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Figure 4.1.5 Sequential backbone resonance assignments using CBCA(CO)NH (left) and HNCACB (right) 
experiments (as exemplified for residues N2 to A8 of FGFR-Ig2). The walk between adjacent Cα peaks 
(blue) is indicated by black lines, while the walk between adjacent Cβ peaks (red) is indicated by 
dashed gray lines. 
 
 
 
An important advantage of the HNCACB experiment is the presence of cross-peaks for both i-
1 and i+1 residues, which allows for an unambiguous assignment in most cases. In addition to 
the 
1
H
N
, 
15
N, 
13
C and 
13
C, which have been assigned from the HNCACB and CBCA(CO)NH 
spectra, 
13
C’ resonances have been picked and assigned from the HNCO and HN(CA)CO 
experiments. 
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Figure 4.1.6 shows the 2D 
1
H-
1
H NOESY spectrum of FGFR-Ig2. The complexity of this 
spectrum illustrates the difficulties for the unambiguous assignment of resonances by using 2D 
spectra. That is why multidimensional 3D NMR experiments were employed for the 
assignment of the protein. 
 
 
Figure 4.1.6 2D 
1
H-
1
H NOESY spectrum of 0.4mM FGFR-Ig2 in PBS 20 mM, NaCl 100 mM, in 90% 
H2O:10% D2O, at pH 6.0 and 298 K. 
 
 
 
Nevertheless, with the aid of 3D experiments, it was possible to completely assign FGFR2-Ig2 
1
H
N
, 
15
N, 
13
C, 
13
C and 
13
C’ backbone resonances for 101 of the 103 residues (i.e. 98% of all 
residues without the seven prolines and the N-terminal glutamic acid), in aqueous solution at 
pH 6.0 and 298 K. This assignment rate is comparable to the rate for a similar FGFR2-Ig2 
protein that has been published before, where several residues are different at the N-terminal 
and C-terminal ends. 
[15]
  
 
Table 4.1.7 shows the chemical shifts of the 
1
H, 
15
N, 
13
Cand 
13
C signals assigned for the 
FGFR2-Ig2 at pH 6.0 and 298 K.  
  
Once the assignment of the protein was completed, the Figure 4.1.8 shows the result for the 
assignment of FGFR2-Ig2 annotated in a 
1
H-
15
N-HSQC spectrum. All of the major peaks were 
assigned. Interestingly, cis/trans isomerization of one of the prolines at the C-terminus of the 
protein, P108, caused peak doubling of a number of residues on either side of the proline, 
including R106, S107, H109 and R110 residues.  
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Table 4.1.7 Backbone resonance assignments for FGFR-Ig2 at pH 6.0 and 298 K. 
 
Residue Chemical shift (p.p.m.) 
H N C C C’ 
a
Glu
0
 
Phe
1 
 
8.536 
 
121.370 
 
54.880 
 
36.545 
170.468 
171.290 
Asn
2 8.367 121.240 50.319 36.156 171.544 
Ser
 3 8.337 116.792 56.241 60.581 172.142 
Asn
4 8.464 119.936 50.798 35.638 171.709 
Asn
5 8.124 118.190 50.669 35.638 171.470 
Lys
6 8.048 121.855 53.196 28.965 170.693 
Arg
7 9.106 121.568 53.131 30.261 171.006 
Ala
8 8.568 127.487 48.466   
a
Pro
9     172.770 
Tyr
10 7.412 115.662 51.317 37.323 173.816 
Trp
11 7.961 118.587 51.511 28.382 168.063 
Thr
12 8.194 112.585 59.350 65.894 172.037 
Asn
13 8.132 119.889 50.798 36.286 171.455 
Thr
14 8.712 114.466 61.942 65.376 174.324 
Glu
15 8.957 124.294 56.435 25.661  
Lys
16 7.847 117.323 54.038 29.354 169.975 
Met
17 7.521 117.734 52.807 30.196  
Glu
18 7.400 118.444 55.139 27.216 169.482 
Lys
19 8.180 120.691 53.584 29.224 171.440 
Arg
20 8.420 125.555 54.686 28.641 172.516 
Leu
21 8.216 122.255 52.548 39.590 173.188 
His
22 9.148 124.681 52.742 29.872 173.412 
Ala
23 8.805 128.687 48.272 16.072 170.259 
Val
24 8.561 123.235 55.722 32.269  
a
Pro
25     170.887 
Ala
26 8.064 123.224 50.734 15.788 169.333 
Ala
27 9.580 118.110 52.289 15.295 169.153 
Asn
28 7.757 120.539 50.475 36.740 172.799 
Thr
29 8.656 116.187 59.545 67.708 173.053 
Val
30 8.605 126.490 57.277 32.010  
Lys
 31 7.665 124.996 50.928 32.010  
Phe
32 8.765 123.256 50.993 40.044  
Arg
33 8.689 117.781 51.879 30.779 174.518 
Lys
34 9.398 122.099 51.965 44.125  
a
Pro
35      
a
Ala
36     171.559 
Gly
37 7.638 104.992 39.979  175.982 
Gly
38 7.760 103.203 41.793  176.147 
Asn
39 8.430 117.036 48.013 38.100  
a
Pro
40     170.797 
Met
41 8.835 122.696 50.863 28.771  
a
Pro
42     171.634 
Thr
43 8.837 109.597 58.055 68.162 173.143 
Met
44 8.780 120.443 51.446 33.954 172.247 
Arg
45 8.919 125.154 51.835 30.585 173.322 
Trp
46 8.871 119.083 53.649 28.836 171.141 
Leu
47 9.724 121.549 50.215 41.016 170.438 
Lys
48 8.894 121.113 51.210 31.945 170.125 
Asn
49 9.739 127.950 51.122 33.889 170.976 
Gly
50 8.163 101.588 42.830  173.457 
Lys
51 7.686 120.519 51.122 32.528 171.275 
Glu
52 8.921 123.289 56.046 26.762 170.991 
Phe
53 8.738 127.924    
a
Lys
54     169.841 
Gln
55 8.736 120.770 56.501 25.144  
Glu
56 8.691 111.904   169.557 
a
Backbone unassigned 
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Table 4.1.7 (continued) 
 
Residue Chemical shift (p.p.m.) 
H N C C C’ 
 
His
57 
 
8.073 
 
119.550 
 
54.167 
 
29.224 
 
171.664 
Arg
58 7.785 115.879 52.380  171.544 
Ile
 59 8.833 126.555 60.257 33.306 169.004 
Gly
60 8.943 116.092 41.599  171.664 
Gly
61 8.100 108.508 42.765  171.081 
Tyr
62 7.683 120.446 51.122 32.528 176.595 
Lys
63 8.662 120.349 53.649 27.540  
Val
64 8.653 121.664 59.231  170.633 
Arg
65 8.502 124.918 53.605 27.428  
a
Gly
66     169.841 
Gln
67 8.735 120.572 56.500 27.734  
a
His
68      
Trp
69 9.313 126.462    
Ser
70 7.901 110.650 54.167 64.793 171.156 
Leu
71  124.885 8.714  170.887 
Ile
72 9.097 125.356 57.536  171.051 
Met
73 8.616 125.537 52.094 33.047  
Glu
74 8.694 121.951 52.714 27.762 170.289 
Ser
75 8.266 116.088 54.998 58.379 172.530 
Val
76 8.444 115.930 60.128 29.807 170.349 
Val
77 9.187 117.146 55.852 30.196  
a
Pro
78     168.571 
Ser
79 8.130 109.123 57.083 59.415 171.320 
Asp
80 8.922 120.200 52.742 38.230 170.035 
Lys
81 7.838 121.543 54.686 29.937 171.694 
Gly
82 8.475 108.090 41.599  175.952 
Asn
83 8.089 117.041 48.531 37.064 172.082 
Tyr
84 9.685 125.646 54.621 37.647 172.082 
Thr
85 9.217 121.700 57.407 69.133 173.218 
Cys
86 9.108 124.038 50.021 39.072 174.279 
Val
 87 8.929 124.278 58.832 29.807 171.514 
Val
88 9.008 129.613 58.638 30.261 171.589 
Glu
89 8.483 123.051 52.418 31.881 171.470 
Asn
90 8.926 119.751 48.984 37.841 170.782 
Glu
91 9.188 115.698 55.852 26.438 170.633 
Tyr
92 7.939 116.495 55.074 35.897 171.111 
Gly
93 7.784 107.257 43.283  176.953 
Ser
94 8.122 111.381 53.325 62.525 173.352 
Ile
95 8.906 119.847 57.601 38.100 173.233 
Asn
96 8.801 114.705 49.891 40.368 173.442 
His
97 8.282 119.386 53.520 31.427 174.055 
Thr
98 7.343 120.873 59.350 67.967 174.368 
Tyr
99 9.347 125.286 53.779 39.072 172.022 
His
100 9.326 120.653 52.742 27.928 174.189 
Leu
101 9.037 128.649 50.863 42.376 172.291 
Asp
102 9.140 126.467 50.798 41.016 172.217 
Val
103 7.821 122.295 58.314 30.779 171.156 
Val
104 8.379 125.489 58.055 30.650 171.141 
Glu
105 8.711 124.849 53.779 27.864 170.528 
Arg
106 8.625 122.196 53.455 28.058 170.603 
Ser
107 8.520 118.827 53.455 60.322  
a
Pro
 108     170.184 
His
109 8.446 119.044 52.677 26.568 172.814 
Arg
110 8.178 128.109 54.621 28.382  
a
Backbone unassigned 
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As can be seen below 
1
H-
15
N-HSQC spectrum quality is excellent and the observed signal 
dispersion seems to indicate that the domain is well folded. 
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Figure 4.1.8 Annotated 
1
H,
15
N-HSQC spectrum of 0.2mM FGFR-Ig2 in PBS 20 mM, NaCl 100 mM, at pH 
6.0 and 298 K. 
 
Structure Determination 
Once I obtained the resonance assignment I carried out the structure determination of the free 
protein. Distance constraints were obtained from two-dimensional 
1
H-
1
H NOESY (τmix = 100 
ms) (Figure 4.1.6). Backbone  and  dihedral angle constraints were generated from 
1
Hα, 
13
Cα, 
13
Cβ, 
13
C′, and 
15
N shifts using TALOS (Cornilescu G., 1999) (Figure 4.1.9). The  and 
 dihedral angles were restrained to TALOS-predicted values ± 30
o
. The structure was solved 
using CYANA (Herrmann T., 2002) followed by final refinement by AMBER (Case et al., 2008) 
in explicit water solvent, as described in Material and Methods, Section 3.1.2. The final 
structures were generated using 1088 NOE-derived distance restraints (comprising 834 short-
range, 68 medium-range and 186 long-range NOEs, where ‘long range’ means they are five or 
more amino acids apart in the sequence), φ and ψ dihedral angle restraints and two disulfide 
bond constraints. The ensemble of 20 final simulated annealing structures, and the average 
structure are shown in Figure 4.1.10. Also NOE and RMSD statistics produced by the 
simulated annealing protocol and Ramachandran plot for the ensemble of 20 structures are 
shown in Figure 4.1.10. The three-dimensional structure obtained herein is very similar to that 
previously published of a similar FGFR Ig2 domain construct. 
[15]
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Figure 4.1.9. Backbone φ and ψ dihedral angle constraints generated from 
1
Hα, 
13
Cα, 
13
Cβ, 
13
C′, and 
15
N 
shifts using TALOS (Cornilescu G., 1999), which predicts protein backbone angles by secondary shift 
homology using a database of 20 high-resolution protein structures and their corresponding chemical 
shifts.  
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Parameter  
NOE cross-peaks   
                   Assigned (%) 
 
94.6 
 
NOE upper distance limits   
                  Short-range, |i–j|≤1  
 
834 
 
                  Medium-range, 1<|i–j|<5 
 
68 
 
                  Long-range, |i–j|≥5 
 
186 
 
CYANA target function (Å2) 
 
1.34 
 
Rmsd to mean coordinates (Å)a 
 
 
                   Backbone (22-47,70-89,97-103) 
 
0.51 
                   All heavy atoms (22-47,70-89,97-103) 
 
1.17 
Ramachandran plot statistics (%) 
 
 
                     Residues in most favoured regions 
 
79.2 
 
                    Residues in additionally regions 
 
20.6 
 
                    Residues in generously regions 
 
0.2 
 
                    Residues in disallowed regions 0.0 
a
The numbers in parentheses indicate the residues for which the rsmd was  
calculated. 
Parameter  
NOE cross-peaks   
                   Assigned (%) 
 
94.6 
 
NOE upper distance limits   
                 Short-range, |i–j|≤1  834 
                  Medium-range, 1<|i–j|<5 
 
68 
 
                  Long-range, |i–j|≥5 
 
186 
 
CYANA target function (Å2) 
 
1.34 
 
Rmsd to mean coordinates (Å)a 
 
 
                  Backbone (22-47,70-89,97-103) 
 
0.51 
                   All heavy atoms (22-47,70-89,97-103) 
 
1.17 
Ramachandran plot statistics (%) 
 
 
                     Residues in most favoured regions 
 
79.2 
 
                    Residues in additionally regions 
 
20.6 
 
                    Residues in generously regions 
 
0.2 
 
       Residues in disallowed regions 
C -terminus
N -terminus
Figure 4.1.10 Ensemble of the 20 best structures of FGFR2-Ig2. NOE and RMSD statistics produced by 
the simulated annealing protocol and Ramachandran plot for the ensemble of structures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ramachandran plot 
NOE and RMSD statistics 
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Heparin-FGFR interactions 
Once the assignment and characterization of the FGFR-Ig2 protein was completed, our aim 
was the conformational analysis of a heparin pentasaccharide when bound to FGFR-Ig2, as 
well as the study of the corresponding binary complex by NMR and modeling, as referred in 
Publication II.  
With this purpose, double 
13
C isotope-filtered NMR experiments of a heparin-FGFR complex 
were acquired, 
[16]
 by using a double-labeled [
15
N, 
13
C] FGFR-Ig2 sample (spectra are shown 
in Figure 4.1.11), in a similar manner to that reported previously by our group. 
[17]
 This 
experiment allows to separate and selectively observe either inter- or intramolecular cross-
peaks of the 
1
H-
12
C pairs of the bound heparin oligosaccharide, without interferences of 
1
H-
13
C 
protons of the protein (reviewed in 
[18]
). 
 
 
 
 
 
 
 
 
 
I H2-H5  I H2-H5 
free 
50 ms 100 ms 
200 ms 600 ms 
I H2-H5  
 
Figure 4.1.11 600 MHz 
1
H-
1
H NOESY spectra (D2O, 298 K) of the free pentasaccharide (top) and after 
the addition of an equimolecular amount of FGFR-Ig2 (lower part) at 50, 100, 200 and 600 ms mixing 
times. The key distance H2-H5 of the IdoA2S ring is highlighted with a circle. 
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As a result of the analysis of the key distance H2-H5 of the IdoA2S ring, (as highlighted with a 
circle in Figure 4.1.11), the protein showed to selectively recognize the 
2
SO twisted-boat 
conformation for the iduronate ring of the GAG.  
Although, I could not measure unambiguous intermolecular NOEs in the corresponding filtered 
experiments, a series of the 
15
N-
1
H HSQC-based titrations experiments permitted to have 
additional experimental evidence regarding the protein binding to the pentasaccharide (see 
Figure 3 of publication II).  
From an integrated general perspective and to provide a detailed 3D perspective of the 
molecular complex, the NMR experimental data was complemented with Docking procedures 
and molecular dynamic (MD) simulations. This combined approach let us to propose a model 
for the mutual recognition of these molecules. 
 
For the heparin pentasaccharide, the best cluster obtained with Autodock (Figure 4.1.12 A) 
was in close agreement with the experimental data based on the 
15
N-
1
H HSQC titrations 
experiments mentioned above, represented in Figure 4.1.12 C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.12 A) Docking results for heparin pentasaccharide complexed with FGFR2-Ig2. B) The 
conformer representing the highest populated, lowest energy cluster is tridimensionally represented 
according to the electrostatic potential. C) Residues significantly perturbed upon binding of the ligand 
are highlighted in CPK on FGFR structure (PDB code 1E0O), as obtained from the titration experiments. 
 
Thus, the corresponding coordinates were employed as starting structures for MD simulations, 
with explicit solvent. The preparation of the input files are described in Section 3.1.4 of 
Material and Methods and the employed protocol is detailed in the experimental section of 
Publication II.  
 
The behavior of the ligand and its interactions with the receptor were scrutinized. From the 
ligand’s perspective, its conformational behavior, when bound to FGFR-Ig2, was firstly 
analyzed. The pyranose ring of GlcA and GlcNS of the pentasaccharide were shown to prefer 
A 
B C 
Best Docking              
cluster 
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the more stable 
4
C1 chair conformation during the whole simulation, in agreement with the 
results obtained for the MD simulation of the free heparin derivatives in Publication I.  
 
In contrast to the observed conformational interconversion for IdoA2S residues between 
1
C4 
and 
2
SO forms in both restrained and unrestrained simulations for the free heparin 
oligosaccharides of Publication I, interestingly, within the complex, the IdoA2S residue 
adopted a 
2
SO skew-boat conformation during the whole simulation, as can be deduced from 
inspection of Figure 4.1.13 A, where the key H2-H5 distance corresponds to a 
2
SO skew-boat 
(2.4 Å) ring conformation, instead of a 
1
C4 chair (4.0 Å) conformation. 
 
A) 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 4.1.13 Plots that show A) the key distance H2-H5 of IdoA2S B) the interglycosidic distances 
throughout the 3ns MD simulation, for the pentasaccharide when bound to the FGFR-Ig2. It clearly 
shows the stability of the 
2
SO skew-boat form for the IdoA2S residue along the simulation.  
 
The conformational behavior around the glycosidic linkages was very stable, as can be seen in 
Figure 4.1.13 B. More detailed information, such as the conformational analysis of the / 
distributions for the glycosidic torsions (Ramachandran-type plot), and the analysis of the 
intermolecular hydrogen bonds, are shown in the following article (Publication II).  
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Abstract: The interaction of the 
synthetic pentasaccharide AGA*IAM 
(GlcNS,6S-GlcA-GlcNS,3S,6S-IdoA2S 
-GlcNS,6S-Me) with the extracellular 
Ig2 domain of the fibroblast growth 
factor receptor (FGFR2) has been 
studied by NMR and computational 
methods. Analysis of the heparin 
pentasaccharide in the free state and in 
the complex indicated the existence of a 
conformational selection process. 
While an equilibrium exists between 
1
C4 and 
2
SO conformers (ratio 60:40) 
for the 2-O-sulfo-α-ʟ-iduronate ring 
(IdoA2S) in the free state, FGFR2 
selects only the unique twisted-boat 
2
SO 
conformation of this IdoA2S residue. 
Additionally, the protein residues 
involved in the binding with AGA*IAM 
have also been characterized. The 
obtained NMR results, both from the 
ligand and protein’s perspective, were 
employed to model the bound 
conformation of the pentasaccharide, 
by a combined docking and molecular 
dynamic simulation approach. 
 
Keywords: Heparin • molecular 
recognition • NMR • protein-
carbohydrate interaction • 
fibroblast growth factor 
 
Introduction 
Sulfated glycosaminoglycans (GAGs) bind and regulate the activity 
of a wide variety of receptor proteins. Over the past decades, 
extensive studies to characterize the binding features of these GAGs, 
with different degrees of complexity, have led to an improved 
understanding of GAG-protein interactions at the molecular level. 
[1]
 
To a large extent, these studies have focused on protein interactions 
with heparin, due to its key role in a plethora of relevant 
physiological processes. [2] 
Heparin, a complex linear polysaccharide, is basically 
constituted of disaccharide repeating units of ʟ-iduronic acid (IdoA) 
and ᴅ-glucosamine linked by α-14-glycosidic linkages. They 
typically contain sulfate groups at positions 2 of the ʟ-iduronic acid 
units (IdoA2S), and 2 and 6 of the ᴅ-glucosamine units. Importantly, 
the ʟ-iduronic acid residue is a flexible entity with more than one 
low-energy conformation accessible. [3] It has been proposed that the 
conformational flexibility of the iduronate pyranose ring may be 
crucial for certain specific protein interactions exhibited by this 
family of glycosaminoglycans (GAGs), thus attracting considerable 
attention. (i.e. [4]) Heparin-derived oligosaccharides in their free and 
bound states to different proteins have been studied by NMR 
spectroscopy, X-ray crystallography, and molecular modelling 
methods.[5] It is now well established that whereas glucosamine and 
GlcA derivatives are stable in the 4C1 chair form,
[6] the iduronate 
residue in heparin can adopt three low-energy conformations 4C1, 
1C4 and 
2SO.
[7] In internal 2-O-sulphated iduronate residues in 
heparin, the ratio of the 1C4 and 
2SO conformers is about 60:40, 
although the balance of this chair to skew-boat equilibrium depends 
both upon its own substitution with 2-O-sulphate, and on the degree 
of substitution of the adjacent glucosamine residues.[8] Moreover, 
protein binding may also influence this chair to skew-boat 
equilibrium, favouring one specific form upon binding. 
One of the best studied model systems for heparin-protein 
interactions has been the specific binding of heparin to the plasma 
protein antithrombin III (AT),[4, 9] therapeutically used for 
preventing blood coagulation.[10] The unique pentasaccharide 
[a] L. Nieto, Dr. A. Canales, Prof. G. Giménez-Gallego, Prof. J. Jiménez-
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sequence AGA*IA, GlcNAc,6S-GlcA-GlcNS,3S,6S-IdoA2S-
GlcNS,6S, found in only about one-third of the heparin 
polysaccharide chains, is known to be responsible for the high 
specificity of the heparin-AT interaction and activation. [11] That is 
why many efforts have been put to structurally characterize the 
synthetic pentasaccharide AGA*IAM 
[11] (Figure 1) or its synthetic 
variants [12] in their free [13] and bound states with AT. [12b, 14] In the 
case of this specific AGA*IAM pentasaccharide, whereas the ratio of 
the 1C4 and 
2SO conformers of the IdoA2S residue is about 40:60 in 
solution [3], when complexed with antithrombin III the equilibrium is 
shifted. Indeed, in the AT-bound state, the IdoA2S residue adopts a 
unique twisted-boat 2SO conformation. 
[13, 14b] From a general 
perspective, this selective recognition process makes this system a 
paradigm of conformational selection processes in the field of 
sulphated carbohydrates. 
However, to the best of our knowledge, there is a lack of 
information regarding the specific binding of this key 
pentasaccharide AGA*IAM entity to other carbohydrate binding 
proteins. Fittingly, the interactions of heparin with fibroblast growth 
factors (FGFs) and their receptors (FGFRs) have been the subject of 
many studies. [15] In particular, most of the work has focused on a 
more thorough understanding of the nature of the FGF-heparin 
complexes, suggesting that different growth factors may bind to 
heparin in a specific way. [16] Regarding the conformational 
flexibility of the iduronate ring, the X-ray co-crystal structure of the 
complex of a heparin hexasaccharide with FGF-2 interestingly 
shows that a tightly interacting IdoA2S residue adopts the less 
populated 2SO skew boat conformation, whereas the other weakly 
interacting residue adopts the standard 1C4 conformation. 
[17] In 
agreement with these results, later findings by our group pointed out 
the conformational flexibility of a synthetic heparin-like 
hexasaccharide when bound to FGF-1, where both 1C4 chair and 
2SO 
skew-boat conformations of the IdoA2S ring were recognized by the 
protein. [18]  
Nevertheless, whereas the interactions of heparin involved in 
FGF binding have been studied in detail, little information has been 
available on its interactions with FGFRs. [19] In fact, reported studies 
with the Ig2 domain of FGFR2, protein domain responsible for 
ligand specificity, did not include a heparin-like oligosaccharide 
component, but a simple sugar disaccharide, sucrose octasulfate. [20]  
Thus, the study of the molecular recognition process of 
AGA*IAM by other carbohydrate binding proteins may be relevant 
from the therapeutic as well from the basic biochemical and 
biomedical perspectives. In particular, the understanding, at the 
molecular level, of the specificity and affinity of heparin-like 
interactions for FGFR may be crucial for designing heparin-inspired 
drugs. 
As reported in the NMR studies mentioned above, the analysis 
of different NMR spectroscopy parameters such as chemical shifts, 
NOEs (nuclear Overhauser effects) and coupling constants for 
GAGs, when bound to a protein, can enable the detailed 
characterization of the ligand bound conformation. In this particular 
case, it can provide information about the conformational 
preferences of the iduronate unit in the bound state.  
In this context, we have decided to investigate the binding and 
conformational properties of the AGA*IAM pentasaccharide in the 
presence of the Ig2 domain of FGFR2 in solution, by NMR 
spectroscopy. The analysis has been performed by analyzing double 
13C isotope-filtered NMR experiments,[18] with a double-labeled 
[15N, 13C] FGFR-Ig2 sample. This experiment allows to separate and 
selectively observe either inter- or intramolecular cross-peaks of the 
1H-12C pairs of the bound GAG, without interferences of 1H-13C 
protons of the protein. From an integrated general perspective and to 
provide a detailed 3D perspective of the molecular complex, the 
NMR experimental data have been complemented with the aid of 
molecular dynamic (MD) simulations. 
Figure 1. Chemical structure of the synthetic pentasaccharide AGA*IAM, 
[11] 
(GlcNS,6S- GlcA- GlcNS,3S,6S-IdoA2S -GlcNS,6S- Me) 
Results and Discussion 
The conformational analysis of the pentasaccharide bound to FGFR-
Ig2 has been performed by using a combined NMR spectroscopy 
and molecular modeling approach. Analysis of 1H chemical shifts 
(Table 1) and three-bond proton-proton (3JH-H) were monitored for 
the free ligand and for a 10:1 ratio pentasaccharide:FGFR2-Ig2 
complex at 25ºC both in the same buffer in D2O (NaPi 20 mM, 
NaCl 100 mM, pH 6.0). The largest chemical shift changes were 
found for proton resonances G5, that shifted downfield (0.03 p.p.m.), 
and for A*2, A*3 that shifted upfield (both -0.03 p.p.m.), indicating 
that these residues are probably involved in the binding process. 
Also, the 3JH-H values were measured in the free state and within the 
complex with FGFR2-Ig2 at 25ºC. As expected for the glucosamine 
residues, 3JH1-H2 values (3.2-3.7 Hz) and 
3JH2-H3 values (10-11 Hz) 
showed that these glucosamine rings remain in the 4C1 chair 
conformation in both the free and bound state. In the case of the 
iduronate residue, the splitting of I1 (3.7 Hz) and I2 (7.4 Hz) 
indicates a 2SO:
1C4 65:35 ratio in free state, what agrees well with 
the data previously described for the same pentasaccharide.[3, 14b] 
The expected J values for IdoA in the canonical structures (PDB 
code 1HPN[21]) were calculated for each set of conformations (IdoA 
in 1C4 and 
2SO) with the Mspin software (
3JH1-H2=2.1 Hz for 
1C4 and 
4.6 Hz for 2SO, and 
3JH2-H3=3.2 Hz for 
1C4 and 9.4 Hz for 
2SO). The 
experimental values of 3JH1-H2 and 
3JH2-H3 for the IdoA when free 
increased (3.9 and 7.8 Hz, respectively) in the presence of just a 
10% of FGFR2-Ig2, strongly suggesting that the 2SO conformer is 
further favoured for the IdoA2S residue (more than 95%) upon 
binding to FGFR2-Ig2. 
Table 1. Chemical shifts (δ, ppm) of the protons of AGA*IAM, free and bound to 
FGFR2-Ig2 in D2O at 298 K. 
 A G A* I AM 
Nucleus Free Bound   Free Bound  Free Bound Free Bound Free Bound 
H-1 5.63  5.62 4.63  4.63 5.52  5.52 5.18  5.17 5.02  5.02 
H-2 3.26  3.27 3.43  3.41 3.46  3.43 4.31  4.31 3.29  3.28 
H-3 3.61  3.60 3.84  3.84 4.35  4.32 4.16  4.16 3.66  3.67 
H-4 3.59  3.59 3.85  3.84 4.00  3.99 4.16  4.15 3.79  3.78 
H-5 3.90  3.90 3.78  3.81 4.17  4.16 4.75  4.75 3.97  3.96 
H-6 
4.17  4.17 
4.38  4.37 
 
4.50  4.49 
4.27  4.27 
 
4.41  4.42 
4.16  4.16 
   
 3 
A H1-G H4
I H1-AM H4
A*H1-I H3/4
G H1-A*H4 I H2-H5I H2-H5
 
 
 
        
       
       
       
      
                                                                                                                                                                                                                        
[a] Calculated from NOEs build-up curve from filtered experiments. 
A H1-H2=2.4 Å was used as internal reference. [b] The apparent 
experimental distance 2.4 Ǻ corresponds to the contribution of both 
H1 A*-H4 I and H1 A*-H3 I NOEs due to the partial overlapping 
of H3 and H4 of the IdoA2S residue in AGA*IAM. 
Figure 2. 600 MHz 1H-1NOESY spectra (D2O, 298K) of the free pentasaccharide (left) and after the addition of an equimolar amount of FGFR-Ig2 (right). Key distance I H2-H5 is 
highlighted with a circle. Right panel: Table with deduced key distances (Å) for AGA*IAM in the free and FGFR-Ig2 bound state
[a]. 
Additional quantitative data were obtained from the analysis of 
the two-dimensional NOESY experiments recorded for the free 
ligand, and in presence of the protein. In case of the complex, 13C-
filtered NOESY experiments of a 15N,13C FGFR2-Ig2: 
pentasaccharide sample (1:1 ratio) at different mixing times (50, 100, 
200 and 600 ms) were performed and interpreted using a full 
relaxation and conformational exchange matrix analysis. 
In the free and bound state, weak and strong negative NOEs 
were observed for the pentasaccharide, respectively, at 25ºC at 600 
MHz. The bound conformation of this GAG to FGFR-Ig2 was 
deduced from the analysis of the filtered-NOESY cross peaks, as 
shown in Figure 2. Key distances for both the free and bound GAG 
conformations, calculated from NOE build up curves of protons 
cross-relaxing across the glycosidic bonds and for H2-H5 for the 
IdoA2S, are also shown.  
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of the key distance H2-H5 showed that the IdoA2S 
unit within the complex adopts a 2SO skew boat ring conformation 
(2.4Å) instead of a 1C4 chair (4Å) conformation, as encoded by the 
more intense H2-H5 cross-peak in Figure 2.  
To complete the panorama of the interaction process, additional 
experimental data were obtained from HSQC-based titrations of 15N-
labelled FGFR2-Ig2, in the presence of increasing amounts of the 
pentasaccharide. On this basis, the most affected protein residues 
were deduced (see Figure 3). 
Then, the data obtained from the NMR experiments, both from 
the ligand and receptor’s perspective, were employed to model the 
bound conformation of the pentasaccharide, by using a combined 
docking and MD simulation approach.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3. Upper panel: A) Overlaid 1H-15N HSQC spectra of FGFR-Ig2 after addition of 0, 0.25, 0.5, 1.0 and 2.0 molar equivalents of AGA*IAM. B) Spectral expansion with the 
most significant “peak walking” chemical shift perturbation. Bottom: Characterization of the heparin binding site of FGFR-Ig2 domain. C) Plots of the 
1H- and 15N- weighted average 
chemical shift difference for backbone NH groups in the AGA*IAM-free and AGA*IAM-FGFR-Ig2 bound state (2:1 molar ratio). Right panel: Residues significantly perturbed are 
highlighted on FGFR structure (PDB code 1EO0). Magenta codes for large (>0.15 ppm), and yellow for smaller (0.07   0.15 ppm) chemical shift changes. 
       Proton pair Free (Å) Bound[a](Å) 
A H1 – G H4 2.9 2.6 
G H1 – A*H4 2.5 2.6 
A* H1 – I H4 
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2.6 
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2.4[b] 
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7.508.008.50
115.0
120.0
T98
E18
M17K16
K81
A26
Y10
S75
N83
Y92
N5 W11
H57
K19
L21
K6
V103
R58
N28 Y62
N13
K51
H97
S3
S94
T12
T29
V76
N39R33
S107
E89
R106
V24
E74
H109
N4
F1 N2
7.007.508.008.509.009.5010.00
105.0
110.0
115.0
120.0
125.0
130.0
A B 
K19 
A B 
a
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
1 10 19 28 37 46 55 64 73 82 91 100 109
a
a
a
0
0,02
0,04
0,06
0,08
0,1
0,12
1 10 19 28 37 46 55 64 73 82 91 100 109
a
a
Residue Number
C
he
m
ic
al
sh
ift
ch
an
ge
(p
pm
)
Residue Number
pentasaccharide octasaccharide
E15
N13
K16
M17
E18
K19
R20
V30
N28S75
S70
L71 F32
E15
K16
M17
E18
N28S75
S70
L71 F32
K19
H22
R33
I72
a
0
0,05
0,1
0,15
0,2
0,25
0,3
0,35
0,4
1 10 19 28 37 46 55 64 73 82 91 100 109
a
a
a
0
0,02
0,04
0,06
0,08
0,1
0,12
1 10 19 28 37 46 55 64 73 82 91 100 109
a
a
Residue Number
C
he
m
ic
al
sh
ift
ch
an
ge
(p
pm
)
Residue Number
pentasaccharide octasaccharide
E15
N13
K16
M17
E18
K19
R20
V30
N28S75
S70
L71 F32
E15
K16
M17
E18
N28S75
S70
L71 F32
K19
H22
R33
I72
S75
a a
C
he
m
ic
al
sh
ift
ch
an
ge
(p
pm
)
 
C 
         10        20         30         40        50         60        70         80        90               110 
si e Number 
 4 
First, docking of the GAG to the protein resulted in several 
solutions. The structure of the complexes that better fitted with the 
protein chemical shift perturbations observed during NMR titration 
experiments was considered for unrestrained molecular dynamics in 
explicit solvent. Along the MD simulation, the overall binding 
orientation of the complex was maintained and the electrostatic and 
hydrogen bonding interactions with the protein were optimized. 
Moreover, the / distributions for the glycosidic torsions of 
the heparin pentasaccharide showed that the conformational space 
for each torsion angle was well defined, with small fluctuations 
(Figure 4). Interestingly, the distance I H2-H5 remained stable along 
the simulation, as can be seen in Figure 1A of Supplementary data. 
This fact supports the experimental findings that evidenced the 
conformational preference for the skew-boat form in the complex. 
Interestingly, a similar MD run, only with the isolated 
pentasaccharide, without the protein, showed transitions between the 
chair and the skew-boat geometries. Therefore, this observation 
provides further evidence on the role of the FGFR-Ig2 domain to 
stabilize the 2SO form. 
Although no unambiguous intermolecular NOEs could be 
measured in the corresponding filtered experiments, the HSQC-
based titrations permitted to have additional experimental evidence 
regarding protein binding to the pentasaccharide (Figure 3). A 
binding model that accounts for all the experimental data is shown 
in Figure 5.  
The possibility of intermolecular hydrogen bonds (also 
including bridging water molecules) during the 3 ns of MD 
simulation was also monitored (cut off = 4Å). No persistent water-
mediated sugar-protein contacts were detected. The analysis of the 
possible intermolecular hydrogen bonds between the FGFR and the 
pentasaccharide showed several hydrogen bonds conserved 
throughout the simulation time. One of them, between the 
carboxylate group of residue G and the side chain of R33, was 
especially persistent, with occupancy of 86% during the simulation 
time (see Figure 2 of Supplementary data). In the proposed 3D 
model of the complex shown in Figure 5, nine charge-charge 
interactions between protein residues and negatively charged groups 
of the GAG stabilize the complex. These include the charged 
residues K16, K19, H22, K31, R33 and H68. Fittingly, residues K16 
and K19, which showed important variations in the HSQC 
experiments (see the spectral expansion of Figure 3B) showed 
interactions with the 3-O-sulphate of A* and the 6-O-sulphate of AM, 
respectively, for a large percentage of the simulation time. The other 
residues which showed noticeable variations in the HSQC spectra 
are also either interacting with the saccharide rings or in the vicinity 
of the interacting residues (E15, M17, R20, V30, F32, S70 and L71). 
These key charge-charge interactions also permit to explain the 
major chemical shift variations of the corresponding protons 
attached to the G H-5 and A* H-3 of the pentasaccharide, which 
were experimentally observed upon binding (Figures 3 and 5). 
Figure 4. The / distributions for the glycosidic torsions of the heparin 
pentasaccharide, as estimated by MD simulations (3 ns of simulation time) in explicit 
water. As can be seen the conformational space for each torsion is well defined. 
The comparison of the averaged values of /dihedral angles 
along the complete MD simulation indicated a fairly stable 
distribution of /dihedral angles, similar to that described for the 
pentasaccharide in its free state and when bound to AT (Table 2). 
Table 2. Comparison of the averaged value for the / dihedral angles along the 3ns 
MD simulation with those previously reported for the same pentasaccharide in free and 
bound state to AT in solution by Hricovini et al.[13]  
 1  /  1 2 /  2 3  /  3  4  /  4 
AGA*IAM free
[a] -34/ -27 47   6 -35   -42 43   6 
AGA*IAM bound AT
[a] -56   -60 40   12 -32   -43 45   16 
AGA*IAM bound FGFR-Ig2 -41   -28 53   22 -52   -44 43   13 
[a] Data previously reported by Hricovini et al. [Ref. 13] 
 
 
 
 
 
Figure 5. Conformation of the pentasaccharide AGA*IAM in its complex with FGFR-Ig2, as deduced from NMR data and MD calculations. The IdoA2S is in skew-boat 
2SO 
conformation, whereas the rest of the residues are in the 4C1 chair conformation. 
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Conclusions 
Binding of flexible ligands by protein receptors is a subtle process, 
which involve variations in enthalpy and entropy, as well as 
presentation issues. Herein, the enthalpy gain is probably provided 
by the stabilizing charge-charge interactions between the ligand and 
the protein domain. In any case, no quantitative analysis of the 
different enthalpy and entropy contributions has been performed. 
Our results indicate that within the complex FGFR-Ig2-AGA*IAM, 
the protein induces a conformational selection process which 
favours the 2SO geometry of the flexible iduronate ring, similar to 
that observed for antithrombin III. This fact contrasts with the 
observations found for the interaction with FGF-1, also a partner of 
FGFR in the same biological event. These facts point out the 
importance of conformational mobility, entropy issues, and binding 
site topology when considering the interaction of flexible ligands 
with key proteins. Indeed, different receptors may take different 
geometries of the same ligand. 
Experimental Section 
Protein expression and purification 
A recombinant FGFR2-Ig2 construct was expressed in native conditions following 
previously described methods for disulfide bond containing proteins [22]. The gene 
coding for the human FGFR2-Ig2 (residues 147-255) was amplified via PCR and 
subcloned into pRHO vector using the EcoR I and Hind III clone sites. Transformed E. 
coli BL21(DE3)-SS cells were grown in minimal media at 37ºC to an A600 of 0.7, and 
then the cultures were induced with 1 mM isopropyl-ᴅ-thiogalactopyranoside and 
further cultivated at 37ºC for 16h. The harvested cell suspension was centrifuged for 10 
min at 30,000  g(6000-7000rpm), obtaining the protein in the supernatant. 15N- and 
13C/15N-labelled proteins were purified from cells grown in M9 medium containing 
either 15NH4Cl as the sole nitrogen source or (
13C6)-ᴅ-glucose and 
15NH4Cl as the sole 
carbon and nitrogen sources, respectively. These highly expressed proteins were 
purified first purified by DEAE Sepharose and secondly, heparin affinity 
chromatography (GE Healthcare) under native conditions and eluted with buffer 
containing 1.5M NaCl. It was concentrated by ultracentrifugation with Vivaspin 
(Amicon Co., USA) and stored at -80ºC until use.  
 
NMR Spectroscopy 
All NMR experiments were acquired at 298 K on a Bruker Avance 600 MHz 
spectrometer equipped with cryogenically cooled HCN-probes with z-axis gradients. 
NMR samples were prepared in the same buffer (20 mM sodium phosphate, 100 mM 
NaCl, at pH 6.0). In the case of two dimensional NOESY spectra of the GAG and the 
complex were acquired in D2O at 25ºC, to avoid the resonance overlap of the H
2HO 
signal with I5. Chemical shifts were referenced relative to 3-trimethylsilyl-propionate. 
Double-filtered 13C NOESY (50-600 ms mixing time) were recorded with a 15N,13C 
FGFR2-Ig2 sample, and a FGFR2:pentasaccharide 1:1 ratio. Cross-relaxation rates were 
obtained from the build up curves of NOEs versus mixing time. Build up curves showed 
good linearity for these mixing times.  
For oligosaccharide titration experiments, NMR samples were prepared in the same 
buffer (20 mM sodium phosphate, 100 mM NaCl, 90% H2O/10% D2O at pH 6.0). 1H-
15N HSQC spectra were acquired at 600 MHz with 2048 points in the 1H dimension (t2) 
and 128 points in the 15N dimension (t1). All spectra were processed and analyzed using 
TOPSPIN2.0 (Bruker Corp, Karlsruhe, Germany) and CARA version1.8.4 (Keller and 
Wüthrich 2004) softwares, respectively.  
 
Titration experiments 
Titration was performed by stepwise addition of AGA*IAM (using a stock solution at 
high concentration) into 15N-labeled FGFR-Ig2, typically at a concentration of 0.1-0.3 
mM to a final 1- to 2-fold excess of the ligand, and 1H-15N HSQC spectra were acquired 
for each titration point. The molar ratio of FGFR Ig2 to oligosaccharide was 1:0, 1:0.25, 
1:0.5, 1:1, 1:1.5, 1:2. Titration was continued until no further chemical shift changes 
were observed. Minimal changes in pH were ensured throughout the sample 
preparations. 
 
AutoDock and Molecular Dynamic simulations 
Initial input protein coordinates for the docking protocol were retrieved from the 
corresponding structure of Ig2 domain of FGFR2 (PDB code 1E0O). [15a] The 
pentasaccharide model was built from PDB code 1HPN[21], and a structure in agreement 
with the experimental data was extracted from a MD trajectory of the pentasaccharide 
alone in explicit solvent with AMBER software (only the 2SO conformation of ʟ-
iduronate ring was taken into account, as deduced from experimental data). Partial 
charges were calculated with Gaussian 03 (Frisch et al 2004). The corresponding binary 
FGFR-Ig2/pentasaccharide was first docked with AUTODOCK program. 
AutoDockTools package was used to generate all the necessary input files and the 
docking grids, employing the Lamarckian genetic algorithm search and maintaining the 
ligand rigid. [23] Furthermore, the best docked solution was submitted to molecular 
dynamic simulations. The protein was defined by the ff99 and gaff parameter sets in 
AMBER force field, whereas the sugar ligand was defined with Glycam06 parameters 
and with parameters computed for the sulfo and sulfamo groups [24], to accurately 
simulate the conformational behaviour of the sugar moieties, respectively. A TIP3P 
cubic box with at least 8 Å distance around the complex was used under periodic 
boundary conditions (PBC). The full complex was solvated by 22325 TIP3P water 
molecules and neutralized with 3 Cl- counter ions for the complex.  
The AMBER 10 molecular dynamics simulation program (Case et al., 2008) allowed us 
to performed a 3 ns MD simulation. The Shake algorithm [25] was applied to all 
hydrogen-containing bonds, and 1fs integration step was used. The electrostatic 
interactions were represented using the smooth particle mesh Ewald method,[26] with a 
grid spacing of 1Å. Each system was gently annealed from 100 to 300 K over a period 
of 25 ps. The systems were then maintained at a temperature of 300 K during 50 ps with 
a solute restraint and progressive energy minimizations, gradually releasing the 
restraints of the solute followed by a 20 ps heating phase from 100 to 300 K, where 
restraints were removed. The coordinate trajectory was recorded each 2 ps throughout 
all equilibration and production runs, which yielded an ensemble of 1500 structures of 
the complex for further analysis. MD trajectories were analyzed using a combination of 
AMBER and VMD packages. 
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 FGF-Heparin-FGFR interactions 
As the final objective in this Chapter, condensed in manuscript III, we aimed at the 
characterization of the protein binding surfaces for the interactions of the ternary complex 
FGF-heparin-FGFR, in solution, by NMR.  
Two different GAGs were chosen to study the role of heparin in FGFR-Ig2 activation, a 
pentasaccharide that corresponds to the segment responsible of the interaction of heparin with 
antithrombin (AT)-III, and an octasaccharide with the main sulfation pattern of the regular 
region of heparin (Figure 1 of Publication III).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.14 
15
N-
1
H HSQC experiments of FGFR-Ig2 in the presence of the pentasaccaride (spectra at 
the top) and octasaccharide (spectra at the bottom): blue free FGFR-Ig2, red 2 equivalents of 
oligosaccharide. 
15
N FGFR-Ig2  
+ octasaccharide 
15
N FGFR-Ig2  
+ pentasaccharide 
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Interestingly, both ligands were bound to the protein, as can be deduced from the inspection of 
the 
15
N-
1
H HSQC-based titration experiments shown in Figure 4.1.14. 
Two sets of titration experiments were then performed: (i) HSQC spectra of labelled 
15
N-
FGFR-Ig2 were recorded in the absence or in the presence of increasing amounts of a heparin 
oligosaccharide and unlabeled FGF1; and (ii) the 
1
H and 
15
N chemical shifts of 
15
N FGF1 were 
monitored upon gradual addition of a heparin oligosaccharide and unlabeled FGFR2-Ig2. The 
results obtained from these experiments are highly detailed in the following manuscript 
(publication III), and are not commented here again.  
In summary, mapping the perturbed residues affected in the titration experiments onto the 
aforementioned available crystallographic structures of the ternary complexes, the key 
conclusions were deduced: the perturbed residues could be clustered in two different sites of 
the proteins, the so-called primary and secondary binding sites. This secondary interaction 
surface site provided a much better fit with the spatial arrangement shown in the symmetric 
model. The alternative model could not explain the experimentally observed perturbations. 
Therefore, our data permit to conclude that the symmetric model does indeed exist in solution. 
Additionally, a 3D model of the FGF1-heparin-FGFR2-Ig2 ternary complex was proposed, on 
the basis of the NMR experimental data, assisted by computational methods (docking 
procedures and MD simulations). The relative orientation of the three molecules was optimized 
by using AutoDock and MD simulations, maximizing the interaction surfaces and the contacts 
between the oppositely charged residues. It was observed that the overall orientation was 
maintained throughout the simulations. Moreover, for the different MD trajectories, the analysis 
of the protein backbone rmsd showed that the protein complexes were stable along the 
simulation time (Figure 4.1.15).  
 
 
 
 
 
 
 
Figure 4.1.15 The rmsd simulation trajectories of the different complexes show that the binary FGFR-
FGF complex is the least stable as compared to the full ternary complexes and that both ternary 
complexes (with the penta and octasaccharide) follow similar rmsd deviation paths. 
In the derived structure of the ternary complexes, the heparin oligosaccharides interact with 
both FGFR-Ig2 and FGF1. Interestingly, the analysis of the key H2-H5 distance for the IdoA2S 
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Trajectory data points along the simulation (3 ns)
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residues again showed a preferred 
2
SO skew-boat conformation for both penta and 
octasaccharide molecules within the ternary complex, as can be deduced from Figure 4.1.16. 
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Figure 4.1.16 Plots that show the key IdoA distance H2-H5 throughout the MD simulations, for the 
penta (internal IdoA unit) and octasaccharide (4 units of IdoA numbered as 2-4-6-8 for each 
octasaccharide molecule). The 2SO skew-boat conformation (2.4 Å) is preferred instead of the 
1
C4 chair 
conformation (4 Å)  during the MD simulations. 
More detailed information will be given in the following publication (Manuscript III). 
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Manuscript III: 
Unravelling the molecular basis of the ternary complex 
heparin-FGF-FGFR in the FGF signalling process. 
A 3D view by using NMR 
Abstract 
Heparin and heparan sulfate (HS) are essential molecules for Fibroblast Growth Factor (FGF) 
signaling. They act at the cell surface, together with FGF receptors (FGFRs), as co-receptors 
for the FGF family. It is known that heparin/HS interact with both FGFs and FGFRs to form the 
active ternary complexes, which initiate the signaling process by activating phosphorylation. In 
the present study, and in order to gain insights into the role of heparin in the architecture of the 
ternary complex formed, we have employed two short length, synthetic heparin fragments to 
characterize their binding interactions with its associated FGF1 and FGFR2 Ig2 proteins, by 
using NMR spectroscopy in solution. Biological assays have also shown that both penta and 
octasaccharide molecules are active in promoting FGF1-mediated FGFR signaling, with 
comparable activity to that of low-molecular-weight heparin. In particular, we used 
15
N-
1
H-
HSQC (heteronuclear single quantum coherence) NMR experiments, by using alternatively 
15
N-FGFR2-Ig2 or 
15
N-FGF1 samples and heparin together with the alternative non labelled 
proteins as ligands, to analyze the corresponding chemical shift perturbations and thus, to 
identify the heparin binding region of the corresponding binary and ternary complexes. Our 
first observation showed that the isolated FGFR2 Ig2 domain is capable of binding to both 
heparin oligosaccharides in the absence of FGF1. In the case of the ternary complexes, our 
findings confirm the existence of both a primary and a secondary FGF-FGFR interaction 
binding site, thus supporting the formation of a symmetric complex, in agreement with one of 
the postulated models for FGF-FGFR dimerization. Finally, we have also proposed a 3D 
model of the FGF1-FGFR2 Ig2-pentasaccharide ternary complex, based on our NMR 
experimental data, assisted by docking protocols and Molecular Dynamics simulations. 
Introduction 
Fibroblast growth factors (FGFs) are involved in a variety of key biological processes, 
including cell replication, angiogenesis, differentiation, cell adhesion, migration and wound 
healing. The human and mouse fibroblast growth factor family consist of 22 members that 
significantly differ in both size and sequence. With some exceptions (those members from 
FGF-11 to FGF-14), FGFs exert their diverse biological actions by binding to a series of 
membrane tyrosine kinase receptors (FGFRs) that are encoded by four genes. 
[1-3]
 For this 
reason, the FGF family is currently admitted to be constituted by only 18 members. FGFRs are 
transmembrane proteins with a common extracellular architecture, consisting of three 
immunoglobulin (Ig)-like domains. All FGFs, except those of the FGF-19 subfamily
 [4]
 also 
strongly bind to glycosaminoglycans (GAGs) of the heparin and heparan sulphate (HS) type.  
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The first models for understanding the role of heparin/heparan sulphate in FGF signalling 
assumed that these GAGs only interacted with FGF. In this sense, HS was initially conceived 
as a FGF trap, protecting it from thermal, proteolytic, or pH-dependent degradation. However, 
it was later shown that HS also directly participated in FGF signalling. 
[5-6]
 Yayon et al., using 
genetically engineered cells lacking endogenous HS, demonstrated that heparin is required for 
the high affinity binding of FGF2 to FGFR1. 
[6] 
Rapraeger et al. independently demonstrated 
that heparin/HS was required for FGF2 signalling and proposed that heparin promoted FGF 
signalling by concomitantly interacting with both FGF and FGFR. 
[5]
 These proposals were 
then supported by different data, which suggested that the high-affinity FGF region actually 
consisted of both FGFR and heparin/HS binding sites. 
[7]
 Therefore, heparin/HS seemed also 
to be essential for the appropriate assemblage of an effective signalling complex. 
Several efforts have been made in order to characterize FGF-heparin interactions. 
[8-9]
 
However, less information is available about the FGFR-heparin recognition process, what 
could be explained by the difficulty in obtaining soluble FGFR domains in bacteria. 
[10-12]
 In 
fact, some investigations of the kinetics of the ternary complex interactions by SPR have 
proposed that FGFR and HS are unbound in the absence of FGF. 
[13] 
Although previous NMR 
analysis of FGFR-heparin interactions by other groups employed a GAG mimic (sucrose 
octasulfate, SOS) as ligand. 
[14] 
Of course, this molecule is rather small (only a disaccharide), it 
is not a GAG, and does not show any sequence similarity with HS or heparin. However, it is 
worth noting that FGF1/FGF2 Ig2 FGFR interactions could be recently characterized in the 
absence 
[15]
 and in the presence 
[16]
 of heparin like oligosaccharides.  
FGFR dimerization is the key event required for signal transduction in this context. 
[17-18]
 One 
of the most controversial issues in FGF signalling has been the mechanism by which FGF and 
heparin/HS cooperate to promote FGFR dimerization. X-ray crystallography-based structural 
analysis of these processes have permitted to explore two distinct FGF1-heparin-FGFR2 
[11]
 
and FGF2-heparin-FGFR1 
[19]
 ternary complexes. Interestingly, there are striking 
discrepancies in the proposed topologies and stoichiometries of the two ternary complexes. 
There is a 2:1:2 FGF1:heparin:FGFR2 structure, which shows a FGF1 trans-oriented dimeric 
structure, sandwiching a HS chain, for which there are basically no ―symmetric‖ protein-protein 
interactions, neither between FGF-FGF nor between FGFR-FGFR molecules. FGF interacts 
with FGFR only via the so-called primary site (in Ig2-Ig3), while heparin only interacts with one 
of the FGFR molecules. For this reason, this model has been dubbed as ―asymmetric‖. In 
contrast, there is also a ―symmetric‖ model, for a 2:2:2 FGF2:heparin:FGFR1 complex, which 
shows FGF-FGFR interactions, not only via the primary site present in the asymmetric model, 
but also via the so-called secondary site (in Ig2). The HS moiety adopts a cis-type orientation 
when interacting with the FGF and, in addition, there are contacts between the two Ig2 
modules of the two FGFR moieties. Moreover, a difference is found in the orientation of the 
linking Ig2-Ig3 proline (Pro253), which adopts a cis conformation in the asymmetric model, 
thus reorientating Ig3 in a complete different way to that in the symmetric two-end model. In 
this symmetric model, the conformation of Pro253 is trans. The importance of the Pro 
conformation was later supported by a subsequent crystal structure of S252W FGFR2c-FGF2 
complex. 
[20] 
Another crystal structure of FGF2-FGFR1-SOS complex has also been published, 
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suggesting that a GAG mimic, sucrose octasulfate (SOS), induces FGF-FGFR dimerization in 
vitro, in a reminiscent manner to that of the symmetric model. 
[21] 
 
In this context, and in order to clarify the importance and biological role of these complexes, 
we are engaged in the analysis of this FGF1-heparin-FGFR2 molecular recognition process 
from the NMR view point to try to assess or discriminate the existence of both or just one of 
the two ternary complexes in solution. In principle, it should not be unexpected that only one of 
these ―symmetric‖ or ―asymmetric‖ models is present in solution and is biologically relevant. 
In a previous work, we have studied the 3D structure of the complex formed by FGF1 and a 
synthetic heparin hexasaccharide, which displays sulfate groups only on one side of its helical 
structure in solution. 
[22]
 This hexasaccharide can substitute natural heparins in FGF1 
mitogenesis assays in spite of not inducing any dimerization of the growth factor. These 
results confirmed that initial GAG-induced FGF1 dimerization was not an absolute requirement 
for biological activity. These data seems to fit better with the symmetric model since the FGF-
trans dimer required for the asymmetric model cannot be formed in these conditions.  
Recent results by Ibrahimi et al. have also supported the existence of the symmetric model, 
since mutations in the secondary site (present only in the symmetric model) reduced FGF10 
signalling. 
[23]
 In addition, the interaction of FGF1 with the Ig2 domain of FGFR in the absence 
of GAGs has been studied in solution by Kochoyan et al. by using NMR spectroscopy. 
[15] 
It 
was found that FGFR Ig2 could bind to FGF1 not only via the primary site (present in both 
models), but also via the secondary site (only present in the symmetric one).  On the other 
hand, mass spectroscopy and gel filtration analysis of the ternary complexes have indicated 
that both types of complexes could be formed in solution. 
[24]
 In addition, in a recent work 
published by Saxena et al, several synthetic heparin mimetics (hexa-, octa- and 
decasaccharides), were shown to support FGF1 and FGF2 signaling through FGFR4, 
confirming the existence of both a secondary FGF1-FGFR4 interaction site and a direct 
FGFR4-FGFR4 interaction site, thus supporting the formation of the symmetric model. 
[16]
 
It has been largely demonstrated that the interaction between FGF and FGFR and GAGs is 
dependent on the GAG length and sulfation pattern for optimal binding, even between pairs 
with a common FGF or FGFR. 
[25]
 In this context, numerous studies have been attempted to 
find the minimal oligosaccharide length capable of promoting FGF signalling. This is an issue 
that still remains controversial. Some data analysis have supported that the octasaccharide is 
the shortest biologically active GAG needed, 
[26-27]
 while in other cases, tetra- and hexa-
saccharides seemed to be sufficient to promote FGF signaling, although less potent. 
[16,28]
 
Herein, we present our results on the role of heparin for the activation of the FGFR receptor by 
using two biologically active and well-characterized synthetic heparin fragments by NMR 
spectroscopy. We have employed an octa- and a pentasaccharide, with different size, distinct 
degree of sulfation and diverse presentation properties of the sulphate groups, to gain insights 
into the role of heparin oligosaccharides on the architecture of the FGFR2-FGF1-heparin 
ternary complex in solution. Since for both X-ray structures, the FGF and heparin binding sites 
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are primary located at the FGFR Ig2 domain, we have used this domain to characterize the 
corresponding FGFR2-heparin interactions and FGFR2-heparin-FGF1 interactions in solution.  
Results 
Protein backbone assignment 
The NMR analysis of FGF1 and its interactions with heparin oligosaccharides have been 
previously reported. 
[17]
 For FGFR, the FGFR-Ig2 domain construct used in the present study 
was 109 amino acids long and spanned residues 147-255 of the full length human FGFR2.  
NMR resonance assignments for FGFR-Ig2 were performed by combination of the 3D triple-
resonance HNCO, HN(CA)CO, HNCACB and CBCA(CO)NH experiments. The obtained 
assignments for the first 103 amino acids  segment, 
1
H, 
15
N and 
13
C resonances, were 
consistent with those established by Hung et al. 
[14]
 The six additional residues (106-111) 
present in our FGFR-Ig2 domain were also assigned. For the sake of clarity we have 
numbered the residues as Hung et al. 
[14] 
 
Chemical shift mapping of the interaction surface 
Molecular interactions between FGFR2, heparin and FGF1 were characterized by NMR 
titration experiments using 
1
H-
15
N HSQC spectra. 
Two sets of titrations were performed: (i) HSQC spectra of labelled 
15
N-FGFR-Ig2 were 
recorded in the absence or in the presence of increasing amounts of a heparin oligosaccharide 
and unlabeled FGF1; and (ii) the 
1
H and 
15
N chemical shifts of 
15
N FGF1 were monitored upon 
gradual addition of a heparin oligosaccharide and unlabeled FGFR2-Ig2. 
(i) FGFR-Ig2 titrations 
 FGFR-Ig2-heparin interactions 
Two different GAGs have been chosen to study the role of heparin in FGFR-Ig2 activation 
(Figure 1). Pentasaccharide (1) corresponds to the segment responsible of the interaction of 
heparin with antithrombin (AT)-III. Additionally, octasaccharide (2) shows the main sulfation 
pattern of what is known as the regular region of heparin. 
 
Figure 1. Synthetic oligosaccharides used in this study: the pentasaccharide corresponding to the binding 
site of heparin for AT-III and the octasaccharide corresponding to the regular region of heparin. 
(1) 
(2) 
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Chemical shift perturbation analysis of FGFR-Ig2 upon addition of the GAGs was first 
performed. It is well established that chemical shifts are sensitive to local changes in protein 
structure and provide a qualitative analysis of the structural effects of protein-ligand 
interactions, being 
1
H-
15
N HSQC NMR titration experiments a standard tool in the 
characterization of molecular recognition processes. 
[29-31]
 
When the 
15
N-labelled FGFR2-Ig2 was titrated with oligosaccharides 1 and 2, in the absence 
of FGF1, chemical shift perturbations for several residues were revealed, pointing out that a 
molecular recognition process is occurring in solution. The backbone resonances (
1
H, 
15
N) of 
the bound form of FGFR2-Ig2 obtained upon the addition of the oligosaccharide were 
assigned in a straightforward manner, by comparison with the unbound form. Also, the sugar 
resonances were assigned for both free and bound forms. The superimposition of the FGFR-
Ig2 HSQC spectra in the presence and in the absence of the carbohydrate clearly indicated 
that a number of backbone resonances underwent considerable shifting upon addition of 
ligand 1 (pentasaccharide), as can be seen in Figure 2. Inspection of the changes in chemical 
shifts during the titration permitted to guess that the Ig2-pentasaccharide interaction took place 
in the fast exchange regime in the chemical shift NMR timescale. HSQC experiments were 
collected with five protein ligand ratios 1:0.25, 1:0.5; 1:1; 1:5; 1:2. No further chemical shift 
changes in the HSQC spectra were observed beyond the titration point FGFR-Ig2/ligand 1:1.5, 
indicating saturation of the heparin binding site at this molar ratio. 
For ligand 1, at a ratio 1:2, the largest chemical shift perturbations (higher than 0.15 ppm) 
were detected for residues N13, E15, K16, M17, and E18. These residues are clustered on a 
well-defined surface of the protein structure of the FGFR-Ig2 domain (Figure 3), indicating that 
there is a specific interaction between the protein and the oligosaccharide at this particular 
region. 
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Figure 2. A) The 
1
H-
15
N HSQC spectra of Ig2 (0.2 mM) for the titration with ligand . The superimposed 
spectra are shown after additions of 0, 0.25, 0.5, 1.0, 1.5 and 2.0 molar equivalents of ligand 1. B) 
Spectral expansion with significant ―peak walking‖ chemical shift perturbation. 
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In addition, by mapping these chemical shift perturbation sites onto the crystallographic 
structures of both ternary complexes (PDB codes 1E0O and 1FQ9), a good correlation with 
the FGFR Ig2-heparin binding site in both structures was found. Nevertheless, no possible 
discrimination between the ―symmetric‖ or ―asymmetric‖ structures was possible at this stage. 
Apart of these residues, the chemical shifts of other backbone signals were modified. K19, 
N20, N28, V30, F32, S70, L71 and S75 showed a clear perturbation above 0.07 ppm (0.07 
  0.15 ppm). As can be seen in Figure 3B, these residues coloured in yellow, are rather 
scattered along the protein structure. Out of these ones, S75 is not involved in direct 
interactions with heparin, neither in the asymmetric model nor in the symmetric one. 
Furthermore, residues S75, N28 and V30 are located at the interface of the Ig2-Ig2 
interactions, which only take place in the symmetric model architecture. Therefore, the 
observed perturbation could be related to the presence of dimers of this type in solution.  
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Figure 3. Characterization of the heparin binding site of FGFR Ig2 domain. A) Plots of the 
1
H- and 
15
N-
weighted average chemical shift difference for backbone NH groups in heparin-free and heparin-bound Ig2 
FGFR (at molar ratio of heparin to Ig2 1:2) are shown, with the heparin penta and octasaccharide, 
respectively. Note the different scales of chemical shift changes for both panels. The inset shows 
backbone amide chemical shifts along the titration in the case of the pentasaccharide for some FGFR 
residues exhibing measurable changes. B) Residues significantly perturbed are highlighted on FGFR 
structure (PDB 1EO0). Magenta codes for large (>0.15 ppm), and yellow for smaller (0.07   0.15 
ppm) chemical shift changes. 
A 
B 
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Strikingly, a clear loss in the intensity of a number of Ig2 HSQC crosspeaks was also 
evidenced during the titration course. This decrease of the intensity of the amide resonances 
could be related to the existence of an additional recognition process, which does not take 
place in the fast exchange regime, and which probably is related to the presence of species of 
large molecule weight.   
The comparison of the crystallographic structures of the FGFR Ig2 domain in the complexes 
FGF2-FGFR1 
[12]
 and FGF2:heparin:FGFR1 
[19]
 reveals a similar fold of the protein in both 
cases (the average RMSD of the -sheets regions is 0.15 Å). However, there are significant 
variations in certain regions. It is worth noting that the major changes are located at the Q67-
S70 loop (RMSD 0.27 Å). Interestingly, this is the region where the residues with the higher 
decrease in intensity titration with 1 are located. In this context, Hung et al. detected a highly 
degree of flexibility for free Ig2-domain in the same loop by using 
1
H-
15
N heteronuclear NOEs. 
[14]
 In our construct, we also obtained similar results.  
As can be deduced from inspection of Figure 2, the free and bound forms of the protein are in 
fast exchange on the NMR time scale, suggesting that the affinity between the 
pentasaccharide and FGFR2-Ig2 is likely in the micromolar range. An approximate equilibrium 
dissociation constant (Kd) of the pentasaccharide/FGFR-Ig2 complex was determined by least 
square fitting of the chemical shift changes accompanying ligand binding, as a function of the 
ligand:FGFR Ig2 ratio, as described in the experimental procedures.  
Using the chemical shift changes of K16, M17, E18 and K19, upon the addition of the 
pentasaccharide, a first approximation, a Kd value 10 µM was estimated for a 1:1 complex 
(Figure 4). This result is in agreement with values previously reported that cover a very wide 
range from 10 nM to 104 M using different techniques. 
[32]
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Figure 4. 
15
N-labeled Ig2-pentasaccharide 
1
H-
15
N HSQC titration curves for residues K16, M17, E18, and 
K19. Representative fitting of the chemical shift changes to Eq. 2 for peaks corresponding to the given 
residues as a function of pentasaccharide/FGFR-Ig2 ratio.  
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As mentioned above, a clear loss in intensity was observed along the titrations, which were not 
due to dilution effects. Since the most affected residues coincided with the Ig2-Ig2 contact site 
seen in the symmetric model structure, we hypothesized that the protein could be dimerizing in 
the presence of the pentasaccharide. Therefore, we acquired NMR Diffusion-Ordered 
Spectroscopy (DOSY) experiments for the isolated FGFR Ig2 domain at a 0.2mM 
concentration, and for a 1:2 FGFR-Ig2:pentasaccharide sample. A significant change in the 
average translational diffusion coefficients was observed, resulting in an average molecular 
weight close to the double of the isolated Ig2 domain, thus supporting the presence of Ig2 
dimers in solution in the presence of the pentasaccharide, and without the requirement of the 
presence of FGF1.  
In a second set of experiments, the titration of FGFR-Ig2 with ligand 2 (octasaccharide) was 
also carried out. The largest shifts (> 0.08 ppm) were observed for M17, E18 and K19. 
Significant changes (> 0.03 ppm) were also detected for residues E15, K16, H22, N28, F32, 
R33, S70, L71, I72 and S75 (Figure 3). Thus, the perturbations observed in the FGFR-Ig2 
cross peaks were fairly similar to those detected for the pentasaccharide, with some additional 
signals, such as H22, R33 and I72, also affected by the octasaccharide. As in the previous 
titration with the pentasaccharide, most of the shifted resonances belonged to residues within 
about 5Ǻ of the bound heparin in the crystal structures previously mentioned. However, other 
variations, such as that observed for S75 can only be explained due to Ig2- Ig2 interactions.  
FGFR-Ig2-heparin-FGF1 ternary complex 
Further experiments were performed by preparing samples of FGFR Ig2 in the presence of 
both heparin oligosaccharides and FGF1. Thus, a 
15
N labelled FGFR-Ig2/pentasaccharide 
sample (molar ratio 1:2) was titrated with increasing amounts of unlabelled FGF1. The FGFR-
Ig2 perturbations were monitored by examining the chemical shift changes, as well as the 
decrease in peak intensities. Upon the addition of FGF1, for a 1:2:1 FGFR Ig2: 
pentasaccharide: FGF1 ratio, several signals showed additional chemical shift perturbations. 
The ones with higher shifts were L21, H22, A23, and F53. Residues N28, D102, V104 and 
E105 also displayed significant shifts. In addition, a significant decrease in resonance intensity 
was observed for several residues, such as K19, R20, L21, H22, A23, V24 and N28.  
Moreover, the intensity of the cross peak of residue E56 became so weak that could not be no 
longer detected. Figure 5A shows the comparison of the intensities of FGFR-Ig2-
pentasaccharide complex in the absence and presence of FGF1 (as intensity ratio per 
residue). Again, it is not unfair to guess that the differential decay in crosspeak intensities is 
related to the existence of specific protein-protein interactions. Therefore, the observation of 
particular chemical shift perturbations and decreased peak intensities support the interaction 
of FGF1 with FGFR2-Ig2 in the presence of heparin. 
Mapping those FGFR Ig2 residues affected by the addition of FGF1 onto the two 
crystallographic structures of the ternary complexes revealed that these residues could be 
clustered in two sites, located in opposite faces of the protein. One set of residues with L21, 
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H22, A23, V24, N28, D102, V104 and E105 belong to the primary FGF-FGFR Ig2 domain 
binding site, which is common for both X-ray structures. In contrast, F53 and E56 are not 
located in this region and are located in the secondary binding site, which is only present in the 
symmetric model (Figure 7). Fittingly, the observed changes could not be explained from the 
FGF-FGFR Ig2 interactions present in the asymmetric model.  
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Figure 5. Plot that shows the fractional changes in resonance intensities observed in the HSQC titrations 
when the ternary FGFR-Ig2-FGF1-pentasaccharide complex is formed.  (A) observing 
15
N-FGFR, (B) 
observing 
15
N-FGF1. Note that the maximum value in the graph corresponding to a value of 4 indicate that 
the resonance associated is not longer apparent. A value of zero indicates not change or not measurable 
change due to overlapping. 
 
Following a similar procedure, a 
15
N labelled FGFR-Ig2 /octasaccharide sample (molar ratio 
1:2) was titrated with increasing amounts of unlabelled FGF1. When a 1:2:1 FGFR 
Ig2:octasaccharide:FGF1 molar ratio was reached, residues A27, N28, S75 and E105 
experienced considerable chemical shift perturbations. In addition, some signals significantly 
broadened (L21, A23 and A27), while others completely disappeared (E56 and H22). As 
mentioned above for ligand 1, when these effects were mapped into the ternary complex 
crystal structures, residues L21, H22, A23, N28 and E105 were found at the primary FGF-
FGFR Ig2 domain binding site, as described above. In contrast, changes at E56 and S75 can 
only be explained by considering FGF-FGFR Ig2 and FGFR Ig2-FGFR Ig2 interactions, 
respectively, which only take place in the symmetric structure of the ternary complex models. 
FGF1-heparin-FGFR-Ig2 ternary complex 
In order to obtain a complete picture of the intermolecular interactions present for the ternary 
complex in solution, 
15
N labelled FGF1 was then titrated with the heparin oligosaccharides and 
with FGFR. The interaction of FGF1 with heparin oligosaccharides has already been described 
by us. 
[22]
 As expected, all affected residues are in the vicinity of FGF1 heparin binding site 
(Figure 6).  
Chapter I  
 
124 
 
 
-1
-0,5
0
0,5
1
0 0,5 1 1,5 2
34
35
87
124
126
132
137
138
140
144
15
N
 

(p
pm
)
a
0
0,02
0,04
0,06
0,08
0,1
0,12
0,14
0,16
0,18
0,2
22 31 40 49 58 67 76 85 94 103 112 121 130 139 148
a
a
Residue Number
C
he
m
ic
al
sh
ift
ch
an
ge
(p
pm
)
pentasaccharide
G34H35
V45
L87
K126
K132
G134
R136
T137
H138 Y139
G140
Q141
A143
L145
L147
15
N
 

(p
pm
)
aa
C
he
m
ic
al
sh
ift
ch
an
ge
(p
pm
)
 
Figure 6 Characterization of the heparin pentasaccharide binding site of FGF1. Plot of the 
1
H- and 
15
N-
weighted average chemical shift difference for backbone NH groups in heparin-free and heparin-bound 
FGF1 (at molar ratio of heparin to FGF1 1:2). Residues significantly perturbed are highlighted on FGF1 
structure (PDB 1EO0). Magenta codes for large (>0.08 ppm), and yellow for smaller (0.08   0.04 
ppm) chemical shift changes.  
 
When the 
15
N FGF1/pentasaccharide sample (at a 1:2 molar ratio) was titrated with unlabelled 
FGFR-Ig2 and a 1:2:1 ratio was reached, the detailed analysis of the HSQC titration resulted 
in the identification of many perturbed peaks that either disappeared (L28, C30, N32, E104, 
Y108, K126, H138, G140, A143, F146, L147, L149), showed a significant change in intensity 
(R49, D50) (Figure 5B), or underwent considerable chemical shifts (F36, Q59, L87, H107, 
L145).. Residues L28, C30, F36, R49, D50, H107, Y108, F146, L147 and L149 are located at 
the primary FGF1-FGFR Ig2 binding site, whereas E104, H138, G140, A143 and L145 are 
located at the secondary binding site, which is present only in the symmetric model. While N32 
and K126 are at the heparin and Ig2 interaction interface (Figure 8). The variations observed 
for Q59 and L87 could not be explained at a first approximation.  
Finally, titration NMR experiments were also carried out in the absence of heparin, with a 
15
N 
labelled FGF1 sample and addition of increasing amounts of FGFR2 Ig2. At a 1:1 molar ratio, 
the cross peaks of several residues disappeared: L28, C30, E104, Y108, N109, T137, G140, 
F146, L147, L149. Clearly, again it is demonstrated that in absence of heparin, FGF1 binds to 
FGFR2 through a primary binding site (L28, C30, Y108, N109, F146, L147 and L149), and a 
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secondary binding site (containing residues E104, T137, G140), again suggesting the 
presence of a symmetric two end model as that occurring in solution. 
Biological assays 
Effect of the penta and the octasaccharide on the mitogenic activity of FGF-1 was tested in a 
heparin-less lymphoid cell line stably transfected with the full three-Ig domain murine FGF 
receptor 1 (splice variant IIIc). 
[26,33]
 This specific cell line was used to evaluate the penta- and 
octasaccharide activity as enhancers of FGF-1 driven mitogenesis, since being a lymphoid-
derived line is heparan sulfate deficient. 
[34]
 This strategy is an absolute requirement for 
overcoming the interferences that the plasmalemmal heparan sulfate, present in the rest of cell 
lines of the organism, may introduce in the evaluation of the FGF-1-mitogenesis enhancer 
activity of the penta and octasaccharide, respectively.  
Figure 7 illustrates the induction of the FGF-1 
mitogenic activity by heparin (upper panel), the 
octa- (middle panel) and the pentasaccaride 
(lower panel). Although less efficiently than 
heparin, both compounds show an appreciable 
inducing activity with the advantage of being 
chemically homogeneous, an indispensable 
requisite for high-resolution structural studies. 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of increasing concentrations of heparin 
(upper panel), octasaccharide (middle panel), and 
pentasaccharide (lower panel) on the mitogenic activity 
of FGF-1. Half-maximal activities of heparin, 
octasaccaride and pentasaccaride are 0.38, 3.14, and 
13.06 μg/mL, respectively. 
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Material and methods 
Synthetic heparin-like oligosaccharides were prepared following established protocols. 
[35]
 
Protein expression and purification 
Non labelled and
 15
N-labeled FGF1 were expressed and purified as previously reported. 
[17]
 A 
recombinant FGFR2-Ig2 construct was expressed in native conditions following previously 
described methods for disulfide bond containing proteins. 
[36]
 The gene coding for the human 
FGFR2-Ig2 (residues 147-255) was amplified via PCR and subcloned into pRHO vector using 
the EcoR I and Hind III clone sites. Transformed E. Coli BL21(DE3)-SS cells were grown in 
minimal media at 37ºC to an A600 of 0.7, and then the cultures were induced with 1 mM 
isopropyl-D-thiogalactopyranoside and further cultivated at 37ºC for 16h. The harvested cell 
suspension was centrifuged for 10 min at 30,000  g(6000-7000rpm), obtaining the protein in 
the supernatant. 
15
N- and 
13
C/
15
N-labelled proteins were purified from cells grown in M9 
medium containing either 
15
NH4Cl as the sole nitrogen source or (
13
C6)-D-glucose and 
15
NH4Cl 
as the sole carbon and nitrogen sources, respectively. These highly expressed proteins were 
purified first, by DEAE Sepharose and secondly, heparin affinity chromatography (GE 
Healthcare) under native conditions and eluted with buffer containing 1M NaCl. It was 
concentrated by ultracentrifugation with Vivaspin (Amicon Co., USA) and stored at -80ºC until 
use. In all the cases, the final purification yield averaged 5mg/L minimal medium culture. 
NMR Spectroscopy 
All NMR experiments were acquired at 298 K on Bruker Avance 600 and 800 MHz 
spectrometers equipped with cryogenically cooled HCN-probes with z-axis gradients. All the 
NMR samples were prepared in the same buffer (20 mM sodium phosphate, 100 mM NaCl, 
and 90% H2O/10% D2O at pH 6.0). Chemical shifts were referenced relative to 3-trimethylsilyl-
propionate. For sequential assignment of the protein 3D HNCACB and CBCA(CO)NH 
experiments were carried out by using 1mM concentration protein prepared in the standard 
buffer. For oligosaccharide titration experiments, 
1
H-
15
N HSQC spectra were acquired at 600 
MHz with 2048 points in the 
1
H dimension (t2) and 128 points in the 
15
N dimension (t1). All 
spectra were processed and analyzed using TOPSPIN2.0 (Bruker Biospin, Karlsruhe, 
Germany) and CARA version1.8.4 (Keller and Wuthrich 2004) softwares, respectively. 
Titration experiments 
Titrations were performed by stepwise addition of the oligosaccharides (using stock solutions 
at high concentration) into 
15
N-labeled proteins (FGFR-Ig2 or FGF, typically at a concentration 
of 0.1-0.3 mM) to a final 1- to 2-fold excess, and 
1
H-
15
N HSQC spectra were acquired for each 
titration point. The molar ratios of FGFR Ig2 to oligosaccharide were 1:0, 1:0.25, 1:0.5, 1:1, 
1:1.5, 1:2. Titrations were continued until no further chemical shift changes were observed. 
Minimal changes in pH were ensured throughout the sample preparations. 
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Mapping of the interaction surface 
Backbone amide HSQC cross-peaks of the proteins were monitored for each titration point of 
every experiment with both oligosaccharides. An average chemical shift change (av) for 
each residue was calculated as the weighted average of the 
1
H (HN) and 
15
N (N) chemical 
shift changes as given in equation 1, as follows. 
av={[(HN)
2+(N/5)
2]}1/2  (Eq. 1) 
Calculation of Dissociation Constants (Kd) 
Dissociation constants were determined by fitting with non-linear regression the average 
chemical shift change of all non-overlapping residues versus ligand concentration to the 
equation:  
    av= max {(KD + [L0] + [P0]) – ([KD + [L0] + [P0])
2 -4[L0][P0]]
1/2}/2[P0]
          (Eq. 2) 
Where av is the average chemical shift change, max the total chemical shift change at 
saturation, [L0] and [P0] the ligand and protein concentrations, respectively. 
Biological Assays 
Cell Culture and in Vitro Mitogenesis Assays—BaF3/FR1c-11 cells were provided by D. M. 
Ornitz (Washington University) and were cultured as described, 
[33]
 except that conditioned 
media from AX63 plasmacytoma cells transfected with plasmid BMGNeo mIL3 were used as 
source of interleukin-3. 
[37]
 Proliferation assays were carried out as described by Ornitz et al. 
[33]
 except that the cell number was determined by monitoring the reduction of 2,3-bis[2-
methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT; Roche Molecular 
Biochemicals, cell proliferation kit II), and heparin was omitted. Incubation times in the 
proliferation assays were 48 h unless otherwise indicated, with XTT being added 6 h before 
the end of this period in all the cases. The experiments were done in quadruplicate. 
AutoDock and Molecular Dynamic simulations 
The first set of structures for the penta and octasaccharide were constructed with the reported 
heparin structures by Mulloy et al (PDB code 1HPN) 
[38]
. Only the 
2
SO conformation of L-
iduronate rings were taken into account, in agreement with the experimental data (manuscript 
II), calculated the partial charges with Gaussian 03 (Frisch et al 2004) and minimized in explicit 
solvent with AMBER package. 
[23]
 The starting coordinates for the proteins FGFR-Ig2 and 
FGF1 were obtained separately from the crystal structure corresponding to the Protein Data 
Bank entry 1E0O. Then two models of our ternary complexes (with penta and octasaccharide) 
were constructed in a similar fashion to the crystal structure corresponding to the Protein Data 
Bank entry 1FQ9, creating two models in agreement with our experimental results. 
Additionally, the protein complex without heparin was also analysed. 
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The corresponding binary (FGFR-Ig2/pentasaccharide, FGF1/pentasaccharide, FGFR-Ig2/ 
FGF1) and ternary complexes (FGFR-Ig2/pentasaccharide/FGF1, FGFR-Ig2/octasaccharide 
/FGF1) were firstly docked with AUTODOCK. AutoDockTools package was used to generate 
all the necessary input files and the docking grids, employing the Lamarckian genetic 
algorithm search and maintaining the ligand rigid. 
[39]
 
Furthermore, the best docked solutions were submitted to molecular dynamic simulations. The 
proteins were defined by the ff99 and gaff parameter sets in AMBER force field, whereas the 
sugar ligands were defined with Glycam06 parameters and with parameters computed for the 
sulfo and sulfamo groups 
[40]
, to accurately simulate the conformational behaviour of the sugar 
moieties, respectively. Due to the highly negative charged ligands, the use of explicit solvent 
was absolutely required to get realistic conformers of the heparin-like oligosaccharides. A 
TIP3P cubic box with at least 8 Å distance around the complex was used under periodic 
boundary conditions (PBC). The full complexes were solvated by 21186 and 21175 TIP3P 
water molecules and neutralized with 18 Cl
-
 and 6Cl
-
 counter ions for the penta and the 
octasaccharide complexes, respectively. And the truncated complex was solvated by 23230 
TIP3P water molecules and 38Cl
-
 were added to neutralize the system.  
The AMBER 10 molecular dynamics simulation program (Case et al., 2008) allowed us to 
performed 3-6 ns MD simulations. The Shake algorithm 
[41]
 was applied to all hydrogen-
containing bonds, and 1fs integration step was used. The electrostatic interactions were 
represented using the smooth particle mesh Ewald method, 
[42-43]
 with a grid spacing of 1Å. 
Each system was gently annealed from 100 to 300 K over a period of 25 ps. The systems 
were then maintained at a temperature of 300 K during 50 ps with a solute restraint and 
progressive energy minimizations, gradually releasing the restraints of the solute followed by a 
20 ps heating phase from 100 to 300 K, where restraints were removed. Coordinate 
trajectories were recorded each 2 ps throughout all equilibration and production runs, which 
yielded an ensemble of 1500 structures of each complex for further analysis. MD trajectories 
were analyzed using a combination of AMBER and VMD packages.  
 
Discussion 
To date, many key contributions have focused on understanding the ternary complex 
FGFR/HS/FGF architecture and interactions. As discussed above, two crystallographic 
structures have been published, which are dramatically different.  
Herein, we have investigated the molecular interactions of the ternary complex composed of 
FGFR2-Ig2, FGF1 and two active heparin oligosaccharides in solution, by NMR 
1
H-
15
N HSQC 
titration experiments. We herein have reported, for the first time, the recombinant expression 
of this Ig2 protein domain in a soluble, active form, which has been subsequently used for 
interaction studies with FGF1 and heparin oligosaccharides. 
The synthetic antithrombin-binding heparin pentasaccharide and an octasaccharide of the 
regular region of heparin were chosen for this study. Both molecules contain the 6-OSO3 and 
the 2-OSO3 groups reported to be necessary for the interaction with FGFRs to induce 
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mitogenecity. 
[44]
 Our octasaccharide, with the structural motif of the major region of heparin, is 
similar in length to that recently employed by Saxena et al. 
[16] 
However, a difference with our 
octasaccharide exists, since the non reducing end starts with GlcN, N-SO3 6-SO3, instead of 
GlcA,2-SO3. Both octasaccharides contains the internal Ido2S(L-iduronic acid 2-O-sulphate)-
GlcNS6S(N-sulpho-D-glucosamine 6-O-sulphate)- Ido2S(L-iduronic acid 2-O-sulphate) 
trisaccharide motif, which has been reported to display the highest affinity for FGF1. 
[45]
 In 
addition, different assays in our labs have shown that both penta- and octasaccharide 
molecules used in this study are able of promoting efficient FGF signalling, more effectively in 
the case of the octasaccharide, as seen in Figure 7. 
As mentioned above, the GAG binding surface on FGFR-Ig2 was characterized using 
15
N-
labeled protein and both heparin oligosaccharides. The resulting chemical shift perturbations 
clearly showed interaction with both oligosaccharides, thus indicating, in a non ambiguous 
manner, that this receptor binds GAGs without necessity of the presence of FGF. The detailed 
analysis of the HSQC titrations showed that the binding surface described by the NMR studies 
for FGFR-Ig2 is largely the same region of the protein for both oligosaccharides (Figure 3), 
containing both the basic residues K16 and K19, as well as E15, M17, E18, N28, F32, S70, 
L71 and S75 residues. The pentasaccharide-induced chemical shift perturbation was 
significantly higher in than that for the octasaccharide, indicating that the pentasaccharide 
binds more strongly to FGFR-Ig2. This fact is likely related to the additional O-sulfation at 
position 3 in the internal D-glucosamine residue of the pentasaccharide.  
In addition, for both cases, a clear loss of intensity of most N-H resonances was observed over 
the titration course. Moreover, some residues at region of Ig2 different of the heparin binding 
site deduced in the X-ray crystallographic models were affected (Figure 3). We interpreted 
these observations in terms of a dimer process formation, which takes place in presence of 
both GAGs. This process is supported by the symmetric two-end model structure 
[19]
, where 
direct receptor-receptor contacts involve the A’-B and E-F loops of both receptors. This 
dimerization hypothesis was further confirmed by NMR DOSY experiments of the free and 
bound protein to the pentasaccharide, suggesting the trend of this receptor to form dimers in 
the presence of certain GAGs, without requirement of the occurrence of FGF1 in solution. Our 
results also indicate that FGF1 is able to bind to FGFR2 Ig2 in the absence of heparin 
oligosaccharides, in agreement with Kochoyan et al. 
[15]
 This fact is in contrast with the work of 
Saxena et al, 
[16] 
in which it was shown that FGF1 and FGF2 were not capable to bind to 
FGFR-4 in absence of heparin. In our case, the ―HAV‖ motif is again responsible for the 
binding (Figure 10). Other works have also reported on the existence of binding in the absence 
of heparin for other protein preparations. 
[15] 
 
The ternary complex was then studied. Heparin binds tightly to FGFs, having dissociation 
constants ranging from 100 nM to 10 uM, 
[46]
 while few investigations have reported on the 
interactions between FGFRs and GAGs. 
[47-50]
 For the pentasaccharide, we have estimated a 
Kd value 10 µM for FGFR-Ig2 binding.  
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Further titration studies with the 
15
N labelled FGFR2 Ig2/pentasaccharide sample were 
performed by addition of unlabelled FGF1. A clear intensity decay of several resonances in the 
titration process was observed, which have been explained by the existence of additional 
protein-protein interactions. In fact, the most affected residues are located at the D2-FGF1 
interaction surface (Figure 5). For instance, residues H22, A23 and V24 of FGFR2, highly 
affected in the titration, correspond to the ―HAV‖ (-His-Ala-Val-) conserved motif in all cell 
adhesion molecules. These residues, either in the crystal structures and in our model, are 
clustered together at the protein interface and form a hydrophobic patch that is believed to be 
responsible for the high affinity of the interaction between the two proteins. 
[11,19,51]
  
Different studies have reported that GAGs increases the affinity of FGF1 for FGFR2. 
[13,48]
 Our 
titration results with the FGFR2/octasaccharide complex, upon addition of FGF1, have shown 
that the affinity to the complex is much higher than to the single Ig2 domain, and the ternary 
FGFR-FGF-heparin complex is more stable. These data are in agreement with previous 
investigations by using SPR by Zhang et al 
[52]
 and Ibrahimi et al,  
[13]
 and are in contrast with 
the data presented by Hung et al. with SOS. They suggested that SOS per se does not 
promote formation of the Ig2-hFGF1 binary complex, but merely stabilizes the preformed 
receptor-ligand complex. 
[14]
 However, it should be considered that SOS is not a 
glycosaminoglycan molecule. 
Further NMR titration experiments with 
15
N-labelled FGF1 were performed by addition of the 
heparin ligands and/or non-labelled FGFR-Ig2, which permitted to further characterize the 
GAG binding surface on FGF1, previously studied by us, employing a different 
hexasaccharide. 
[22]
   
The comparison of our NMR solution state data with the interaction surfaces of the two 
polypeptides in the available X-ray crystal structures was then performed to try to discriminate 
between both possibilities. While in the asymmetric model structure, the FGF1-FGFR2 contact 
site contains the following residues of FGF1: Y15, G20, F22, R35, R37, L89, Y94, L133, P134 
and L135 (Y29, G34, F36, R49, R51, L103, Y108, L147, P148 and L149, in the nomenclature 
used here) 
[11]
, some additional residues of FGF2 are exclusively found in the secondary 
binding site of the 3D structure of the symmetric model: H138, Y139, E104, L144, L145 and 
T110. Additionally, in absence of heparin, residues G140, Q141 and K142 of the FGF interact 
with Ig2 only in this latter model. 
When the perturbed resonances of 
15
N-FGFR2-Ig2/heparin/FGF1 and 
15
N-FGF1/heparin/ 
FGFR-Ig2 titrations were mapped onto the three-dimensional crystal structures, a 
complementary binding site was identified for most of the highlighted residues, as shown 
schematically in Figure 8. Nevertheless, it is clearly shown that the secondary site interaction 
surface identified on both proteins provides a much better fit with the spatial arrangement 
shown in the symmetric model. Several key residues that mediate the specific binding of the 
two proteins when in the ternary complex were identified as in the secondary binding site from 
both approaches. Our results allow us to propose that the symmetric model is the one that 
takes places in solution. 
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Figure 8. Both crystal structures (pdb codes 1FQ9 and 1EO0) with the interaction surfaces based on 
chemical shift perturbations and intensity decays observed in the NMR titration experiments of 
15
N-labelled 
FGFR2-Ig2 with heparin and unlabelled FGF1 and vice versa. The surface color code is as follows: yellow, 
residues of the proteins perturbed upon addition of the pentasaccharide separately; magenta, residues of 
the proteins affected when the binary complex with the heparin is formed and upon addition of the third 
protein component. The interaction surface identified on both proteins is complementary. The symmetric 
model better fits the data (see the secondary binding site, not present in the asymmetric model, 
highlighted in a white circle). Note that in the 1FQ9 structure, the proteins have been slightly separated for 
sake of clarity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Snapshot model of the ternary complex taken from the MD simulation trajectory. Mapping of the 
experimental data on the model. The surface color code is as follows: magenta, residues of the proteins 
affected upon addition of the third protein component when the binary complex with the heparin has been 
previously formed. The electrostatic surface representation of the complex is also shown on the left. The 
views in the lower panels are the molecules rotated by 90º to allow for viewing of the interaction surfaces. 
FGFR2 and FGF1 are coloured in cyan and dark blue respectively.  
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This fact is interesting, because although there are amino acid differences in the sequences of 
FGF1 and FGF2, and FGFR1 and FGFR2 of both crystal structures, with pdb codes 1EO0 
(―asymmetric‖) and 1FQ9 (―symmetric‖), we should emphasize that the protein components in 
our study correspond to those of the 1EO0 structure. However, our NMR data in solution fit 
better with the alternative symmetric structure described in 1FQ9.  
Then, on the basis of the chemical shift mapping experiments and the X-ray structure of the 
symmetric model, 
[19]
 a 3D structure that fitted the experimental data for the ternary complex 
FGFR2-Ig2/pentasaccharide/FGF1 interactions was built. Those residues that experienced 
chemical shift perturbation and intensity decrease were placed at the interface of the three 
molecules. By using AutoDock and MD simulations, the relative orientation of the three 
molecules was optimized, maximizing the interaction surfaces and contacts between the 
oppositely charged residues.  
Molecular dynamics simulations can provide a good idea of how these proteins behave in a 
solution environment. In this case, the overall binding orientation was maintained throughout 
the simulation. For the different MD trajectories, the analysis of the protein backbone rmsd 
showed that the protein complexes were stable along the simulation time (see the Supporting 
Information for graphs).  
In the derived structure, the heparin pentasaccharide interacts with both FGFR-Ig2 and FGF1 
in the ternary complex. Although in the symmetric model a hexasaccharide was the smallest 
oligosaccharide shown to be effective, 
[19]
 the results shown herein indicate that a 
pentasaccharide can still make effective contacts with both FGFR and FGF1 in the ternary 
complex, as can be seen in Figure 10.  
 
 
 
 
 
 
 
 
Figure 10. The binding orientation of the 
FGFR/FGF1/pentasaccharide complex and hydrogen 
bonding network between the two proteins and those 
with the pentasaccharide are shown as result of the 
MD simulation. 
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The pentasaccharide via its nonreducing end is stabilized by the hydrogen bonding network 
shown in Figure 10, in a similar manner to the symmetric model, where the first six sugar 
residues at the nonreducing end of the decasaccharide make 30 hydrogen bonds, including 9 
with FGFR1, 16 with FGF2 in the same half-complex, and 5 with FGFR1 in the vicinal half-
complex.  
A superimposition of different snapshots along the MD trajectory is shown in the supporting 
information. Also the superimposition of our structure with the crystallographic analogue from 
Schlessinger et al is shown in the Supporting Information, indicating the large degree of 
similarity.  
Conclusions 
The ternary complex FGFR2 Ig2-heparin-FGF1 has been analyzed by NMR methods in 
solution. The interactions have been analyzed at the atomic level, using biologically active, 
short length and highly homogeneous penta- and octasaccharide heparin fragments and its 
associated FGFR2 Ig2 and FGF1 proteins. For the first time, the recombinant expression of 
the Ig2 protein domain in E. coli has been achieved in a soluble, active form. Experimental 
NMR studies have been performed to try to better understanding the molecular basis of the 
FGF-FGFR-heparin interactions that contribute in the FGF signalling process.  
The observed carbohydrate-protein and protein-protein interactions have been mapped in the 
previously reported crystallographic structures by using NMR 
1
H-
15
N HSQC experiments. 
15
N 
labelled FGFR Ig2 and 
15
N labelled FGF1 have been alternatively used to characterize FGFR 
Ig2 domain and FGF1 interactions with two heparin oligosaccharides. Our data point out that 
15
N FGFR can bind both oligosaccharides in a similar mode, in a fast exchange regime, but 
with higher affinity for the pentasaccharide. In addition, our results suggest the presence of 
Ig2-Ig2 interactions in the presence of both GAGs, even in the absence of FGF1. 
Moreover, NMR titration studies with the three components have provided experimental 
evidence that the ternary complex is formed in solution. The highly sulfated chain of the 
shorter ligand, even being a pentasaccharide, is also competent to form the ternary complex. 
In addition, the results clearly show the existence of two FGF1 binding sites at FGFR-Ig2 
surface, which are located at opposite faces of the protein, as well as two receptor binding 
sites at the FGF1 surface. All these data are in agreement with the presence of the ―two end‖ 
symmetric model architecture of the ternary complex in solution. 
A computational model was also built, where heparin interacts via its nonreducing end with 
both FGF and FGFR, and found to reproduce accurately the behavior of the ternary complex 
in agreement with the NMR experimental data. The results of the MD simulations showed that 
the ternary complex model is stable along the simulation, and provided an accurate 
representation of the FGFR2-Ig2/oligosaccharide/FGF1 complex. 
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Introduction 
Microtubules are the basic components of the eukaryotic cell cytoskeleton and are involved in 
many cellular processes, including cell division, cell elongation, intracellular transport, cell 
motility and the control of cell shape. 
[1]
  
Over the past years, the discovery of natural products that attenuate cell growth by acting as 
inhibitors of cellular microtubules has resulted in the development of clinically-important drugs 
in cancer chemotherapy. 
[2]
 Now is known that tubulin-binding drugs can dramatically interfere 
with the tubulin-microtubule polymerization equilibrium and therefore exhibit profound cytotoxic 
activity.  
One of the most important clinical anticancer drugs is the natural product paclitaxel (Taxol®), 
which inhibits human cancer cell growth through the stabilization of cellular microtubules. Over 
the last few years a diverse set of other (non-taxane) natural products from a variety of 
sources have been established to share the taxanes ability to stabilize microtubules, including 
epothilones A and B, discodermolide, dyctiostatin and eleutherobin. 
[3]
 In addition, in an effort 
to overcome drug resistance, which limits, for instance, taxol application, other novel 
microtubule-stabilizing agents (MSAs), either semi-synthetic derivatives or fully synthetic 
derivatives, with a more favorable activity profile have been appeared in the last years. 
Although, many efforts have been dedicated to understand the mechanism of the 
conformational control exerted by these small organic molecules on the protein tubulin, 
however, limited information is known about the molecular basis of the recognition of these 
molecules by their target protein, tubulin. As for taxol and other biomimetics, two different 
binding sites have been recently described, at the lumen (internal site, at the tubulin β-subunit) 
and at the pore of the microtubules (external site, involving α- and β-subunits of different 
heterodimers). It has been proposed that these ligands first bind to the external site, thus 
facilitating internalization to the luminal site. 
[4]
 
In addition, a question of obvious importance is whether these MSAs are also capable of 
binding -tubulin heterodimers, when tubulin is present in a non polymerized form. 
Here, we have studied the basis of the interplay between tubulin and several potent 
microtubule stabilizing agents (MSAs). These include docetaxel, discodermolide and a novel 
epothilone analogue termed as azathilone 
[5]
.  
The scope of this work was the NMR-based characterization of the binding of MSA-type drugs 
to assembled microtubules, including the number and location of the binding sites; the NMR-
based characterization and understanding, at the molecular level, of the binding of these 
microtubule-stabilizing agents to tubulin  heterodimers, when tubulin is present in a non 
polymerized state; and the elucidation of the geometry of the binary complex formed by the 
different MSAs and tubulin heterodimers by a combined NMR and modeling approach. 
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Results 
With the aim of providing a framework to understand the mechanism of the conformational 
control exerted by these MSAs on the tubulin polymerization equilibrium, the present work, 
condensed in publications IV and V, has been carried out in collaboration with the group of Dr. 
Fernando Díaz at CIB. Herein, we describe the binding interactions of three MSAs to 
unassembled -tubulin heterodimers and microtubules, by using biochemical and NMR 
techniques. 
NMR is particularly suited for this purpose, as tubulin is a highly dynamic molecule, which so 
far escaped crystallization in a physiologically relevant form. 
In this context, I have been directly involved in the characterization of the conformation of the 
different MSAs studied by using NMR (analysis and interpretation) and molecular modeling 
(validation of the models with the NMR data). In particular, in the computational aspects, I 
have also participated in the generation of 3D models of the complexes with tubulin and in the 
calculation of the experimental and theoretical STD effects of these models to validate the 
docking procedures. 
4.2.1 Chemical assignment of the ligands 
For the free ligands, the standard homo- and heteronuclear 2D NMR experiments were 
employed for the assignment of NMR chemical shifts, (Figure 4.2.1 A-C) including 2D 
COSY/TOCSY, NOESY, ROESY and HSQC experiments. COSY/TOCSY and 
NOESY/ROESY experiments were used to establish the connectivity of the molecular frames, 
through chemical bonds and distances in space, respectively. HSQC experiments 
complemented the homonuclear data by providing the corresponding one-bond heteronuclear 
chemical shift correlations. 
 
 
4.2.1.A 
1
H NMR Chemical shifts (δ, ppm) for docetaxel in the bound state in D2O at 298 K 
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Proton δ (ppm) Proton δ (ppm) 
H2 5.60 H17 1.11 
H2’ 4.39 H18 1.87 
H3 3.77 H19 1.67 
H3’ 5.17 H20 4.24/4.28 
HN 5.43 H22 2.39 
H5 5.00 t-Bu 1.38 
H6 1.99/2.56 o-Ar 7.41 
H7 4.19 m-Ar 7.50 
H10 5.36 p-Ar 7.29 
H13 6.11 o-OBz 8.10 
H14 2.31 m-OBz 7.70 
H16 1.19 p-OBz 7.81 
 
 
 
4.2.1.B 
1
H NMR Chemical shifts (δ, ppm) for discodermolide in the bound state D2O at 298 K 
 
12
1517
24
9
7
53
19
32 31 30 29
28
27
26
25
 
 
Proton δ (ppm) Proton δ (ppm) Proton δ (ppm) 
H2 2.82 H12 2.25 H23 6.74 
H3 3.83 H13 5.01 H24a 5.30 
H4 1.93 H15a 1.53 H24b 5.39 
H5 4.57 H15b 1.76 H25 1.28 
H6a 1.49 H16 1.80 H26 1.11 
H6b 1.99 H17 3.31 H27 1.07 
H7 4.57 H18 1.80 H28 0.95 
H8 5.57 H19 4.70 H29 1.60 
H9 5.74 H20 3.17 H30 0.79 
H10 2.77 H21 5.52 H31 0.83 
H11 3.26 H22 6.23 H32 1.02 
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4.2.1.C 
1
H NMR Chemical shifts (δ, ppm) for azathilone in D2O at 310 K 
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Proton δ (ppm) Proton δ (ppm) 
H2 2.58   
H3 4.46 H14 2.31 
H6 3.53 H15 5.94 
H7 3.80 H17 7.69 
H8 1.71 H21 2.68 
H9a 1.48 H22 1.46 
H9b 1.79 H23 1.08 
H10a 1.46 H24 1.20 
H10b 1.56 H25 1.09 
H11a 3.26 H27 7.44 
H11b 3.40 H28 7.61 
H13a 3.29 H31 3.86 
H13b 3.57 H33 1.44 
 
4.2.2 Sample preparation and NMR experiments 
Tubulin heterodimers samples (using a 30:1 ligand receptor molar ratio) and microtubule 
samples (using a 15:1 ligand receptor molar ratio) were prepared in the laboratory of Dr. 
Fernando Díaz at CIB, as described in publication IV and V. The biochemical assays were 
also performed in their laboratory. 
Therefore, with the samples at hand, I recorded the NMR spectra at 298 K for the -tubulin 
heterodimer samples and at 310 K for the microtubule samples on a Bruker AVANCE 500 
MHz spectrometer. In a first approach, I recorded the 2D NOESY experiments for the free 
ligands. NOESY cross-peaks were basically zero at room temperature for the three MSAs in 
the free state, and ROESY permitted to obtain positive cross-peaks in the case of the 
azathilone, as can be seen in publication V.  
           Molecular recognition of MSAs by tubulin 
 
 
143 
 
For the samples with the complexes, I recorded STD experiments with 0.5, 1 and 2s saturation 
times (by concatenation of 50 ms Gaussian pulses separated by 1 ms). I also performed the 
2D tr-NOESY experiments with non polymerized -tubulin heterodimers and microtubules 
with mixing times of 50, 100, 200, 250 and 300 ms. In both cases, in contrast to the free state, 
strong negative NOE cross peaks were observed, indicating binding of the ligands to both 
aggregation states of the protein. Then, I carried out the analysis of Saturation Transfer 
Difference profiles, obtaining the ligand binding epitope, which allowed to identify those 
protons that are closer to the protein in each case. Comparison of the STD profiles for each 
ligand when bound to -tubulin heterodimers and microtubules showed a similar profile, but 
not identical, as can be seen in the figures 3 in publications IV and V. 
From an exhaustive analysis of the tr-NOESY experiments, the bioactive 3D structures of the 
different MSAs bound to -heterodimers were elucidated and compared to those bound to 
microtubules, as reported with more detail in publications IV and V. Since the bioactive 
conformation of docetaxel and azathilone will be discussed with detail in publications IV and V 
respectively, only the conformation of discodermolide in the bound state to non polymerized 
-tubulin heterodimers will be explained next. 
From the analysis of tr-NOESY experiments (Figure 4.2.2), the bioactive 3D structure of 
discodermolide when bound to α/β-heterodimers was elucidated and compared to that bound 
to microtubules previously described by our group. 
[6]
 
 
4.2.2 Expansion of TR-NOESY spectra (mixing time: 300 ms) of discodermolide in the presence of 
nonpolymerized tubulin α/β-heterodimer (D2O, 298 K). 
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According to the NOE cross-peaks intensities, it could be deduced (see Table 4.2.3) that the 
observed values in the bound conformation to α/β tubulin heterodimer are in agreement with a 
half-chair form conformation for the six-membered ring (see Figure 4.2.4 A), due to the 
weakness of the H2-H5 cross-peak, as well as the intensities of the key NOEs from the CH325 
and CH326 signals. Also, the strong H4-CH325 NOE peak (corresponding distance 2.5 Å) 
could only be explained by a half-chair conformer. 
We found that the observed cross-peaks were very similar to the data previously described by 
our group for the bound conformer to microtubules (these data are also shown in Table 4.2.3). 
In this previous work, the obtained NMR data indicated that microtubules recognize 
discodermolide through a conformational selection process, in which the half-chair conformer 
(and not the predominant in water solution, the skew boat form) of the lactone moiety is bound 
to the receptor. 
[6]  
 
 
Predicted for 
the skew 
form 
conformer 
(OPLS 
2005) 
Predicted for 
the half-
chair form 
conformer 
(OPLS 
2005) 
Reported 
for the 
free 
state in 
D2O
[a] 
 
Experimental 
distances 
for the 
bound state 
to dimeric 
tubulin 
Reported for the 
bound state to 
microtubules
[a] 
 
H2-H3 3.0 2.6 2.8 s, 2.8 2.6 
H2-H4 3.8 3.8 - m, 3.4 - 
H2-H5 2.5 3.9 3.4 w (overlap) >3.7 
H3-H4 2.2 2.4 2.5 s, 2.4 2.5 
H3-CH325 2.8 2.6 2.4 s, 2.6 2.4 
H3-CH326 3.4 2.8 2.5 s, 2.7 2.2 
H3-CH331 3.0 4.1 - w, > 3.4 - 
H4-H18 2.5 2.3 2.8 s (overlap) 2.8 
H4-CH325 4.6 2.9 2.8 2.5 2.5 
H4-CH326 2.1 2.1 - 2.3 - 
H4-CH331 2.4 2.3 - 2.7 - 
H5-H7 3.0 3.0 overlap overlap overlap 
H5-CH326 2.6 2.8 2.6 2.7 2.5 
H6S-H6R 1.7 1.7 - 1.7 - 
H6S-H7 3.0 3.0 - 3.0 - 
H6R-H8 2.5 2.7 2.7 s, 2.7 3.1 
H6S-H15a 2.4 2.2 2.3 s (overlap) 2.3 
H7-H8 3.1 3.1 - 3.2 - 
H7-H10 2.1 2.2 2.0 2.5 2.3 
H7-CH327 3.6 3.3 2.8 3.4 2.9 
H8-H9 2.3 2.3 - 2.2 - 
H8-H22 3.1 2.4 2.7 2.7 2.8 
H9-H10 3.1 3.0 - m, 3.3 - 
H9-H12 3.0 2.9 2.6 s, 2.7 2.9 
H10-H11 2.5 2.5 2.3 2.4 2.4 
H10-H12 3.0 3.0 - 2.9 - 
H10-CH327 2.1 2.1 2.4 2.4 2.4 
H11-H12 3.0 3.0 3.1 3.0 3.0 
H11-CH327 2.7 2.7 2.4 2.4 2.4 
H11-CH328 2.8 2.8 2.5 2.5 2.5 
H12-H15b 2.6 2.5 2.0 2.2 2.1 
H12-CH328 2.1 2.1 - 2.4 - 
H12-CH330 3.6 3.7 3.2 3.5 3.2 
H15a-H15b 1.7 1.7 - 1.9 - 
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H15a-CH331 3.2 3.2 - 2.9 - 
H16-CH329 2.9 2.9 2.2 2.1 2.4 
H16-CH331 2.8 2.8 2.0 2.2 2.3 
H17-H18 2.5 2.5 2.4 2.4 2.4 
H17-H20 2.2 2.2 2.1 s (overlap) 2.3 
H17-H21 4.1 4.0 - 3.7 - 
H17-H23 2.3 2.4 2.5 s, 2.4 2.6 
H17-CH330 2.8 2.7 2.5 2.4 2.5 
H18-H20 3.2 3.2 3.0 3.1 3.1 
H18-H21 3.1 2.9 2.8 2.7 3.0 
H20-H21 3.1 3.1 3.1 3.2 3.1 
H20-H23 2.1 2.1 2.1 s, 2.1 2.2 
H20-CH332 2.1 2.1 - 2.4 - 
H21-H22 2.3 2.3 - 2.2 - 
H21-CH332 2.8 2.9 2.6 2.6 2.5 
H22-H24b 2.5 2.5 2.4 2.0 2.5 
H24-H28   
not 
observed 
3.7 not observed 
[a] See reference [6]. 
Table 4.2.3 Analysis of the estimated interproton distances for discodermolide in the bound state to 
non polymerized tubulin. For the bound state, the experimental distances, r [Å], were estimated 
according to a full matrix-relaxation approach, with a CORCEMA-based analysis of the TR-NOESY data. 
The H21-H22 distance (2.2 Å) was taken as internal reference. The estimated experimental errors are ± 
10%. The reported data for the free state in aqueous solution and bound to microtubules are also 
given.
[6]
 Key NOEs are underlined. 
 
The analysis of the conformational search results permitted the determination of the 
discodermolide conformation bound to the non-polymerized tubulin α/β-heterodimer. The best 
fit to the NMR data was provided by a half-chair geometry for the six-membered ring (see 
Figure 4.2.4 A), very similar to the structure mentioned above for binding to microtubules (see 
Figure 4.2.4 C). The hairpin backbone is basically identical, with a slight change in the 
orientation of the lactone chain. Nevertheless, this minor variation could also be due to the 
different force fields used for the calculations (OPLS 2005 and MM3, respectively), as recently 
discussed by Jogalekar et al. 
[7]
 
In contrast, there are some diferences in our deduced dimeric tubulin-bound conformation with 
respect to that described by Carlomagno et al., 
[8]
 for binding to non-assembled tubulin. 
(Figure 4.2.4 D and E). Although Carlomagno’s structure 
[8]
 also shows a chair for the six-
membered ring, its relative orientation to the molecular backbone is rather different to ours. 
Nevertheless, the presentation mode of the polar and non polar areas of the molecule are still 
remarkably similar. 
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A)      
 
 
 
 
B)              C)                                  D)                 E) 
 
 
 
 
 
Figure 4.2.4 Conformational analysis of disdodermolide. A) The bound conformer to dimeric tubulin, as 
deduced by TR-NOESY experiments. B) Superposition of the half-chair and skew-boat conformers of 
discodermolide obtained by OPLS 2005 calculations. C) Superimposition of the deduced form with that 
described by Canales et al. 
[6]
 for DDM bound to microtubules. D) Superimposition of the deduced 
form with that described by Carlomagno et al. 
[8]
 for DDM bound to non polymerized tubulin. E) 
Superposition of the three different bound conformers. 
 
Additionally, STD experiments were performed on the same NMR samples. The saturation 
intensities obtained for the discodermolide-dimeric tubulin complex are given in Table 4.2.5. 
proton % saturation proton % saturation 
H2 100% (8,98) H18 overlap with 16                          
H3 55%  (4,95) H19    overlap with water            
H4 59%   (5,3) H20 44%  (3,92) 
H5 overlap with H7                          H21 64%  (5,78) 
H6a 45%  (4,07) H22 70%  (6,31) 
H6b 48%  (4,28) H23 77%  (6,96) 
H7 overlap with H5                          H24a 93%  (8,41) 
H8 59%  (5,3) H24b 60%  (5,71) 
H9 51%  (4,58) CH3 25 85% (7,68) 
H10 60%  (5,4) CH3 26 52%  (4,72) 
H11 90%  (8,07) CH3 27 68% (6,08) 
H12 74%  (6,64) CH3 28 82% (7,39) 
H13 77% (6,9) CH3 29 86% (7,76) 
H15a 50%  (4,54) CH3 30 81% (7,25) 
H15b 49%  (4,4) CH3 31 72% (6,51) 
H16 overlap with 18                          CH3 32 58% (5,2) 
H17 54%  (4,86)   
 
Table 4.2.5 STD intensities of the discodermolide-non polymerized tubulin complex. 
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The STD spectra showed clear enhancements for some methyl groups of the central part of 
the hairpin (methyls 28, 29 and 30). It is also remarkable that H2 provided the most significant 
STD enhancement, along with the methyl group at the lactone moiety, and H24, at the side 
chain. These results also match with those STD data obtained by us for discodermolide bound 
to microtubules. 
[6] 
4.2.3 Computational approach  
Our computational approach (more detailed in Publication IV) to obtain a structural model of 
the complex between the different MSAs and tubulin consisted of three steps: first, we 
generated 100 docking models for each of the ligands complexed with -tubulin 
heterodimers and microtubules in order to explore the conformational space of each MSA in 
the taxane binding pocket of each tubulin aggregate, docking solutions where energy 
minimized with Macromodel to avoid close contacts between atoms; second, we calculated the 
theoretical STD values for each ligand-receptor complex solution with CORCEMA-ST 
program, as described on section 3.2.2 in Material and Methods; third, we rejected or retained 
structures depending on the NOE R-factor, a scoring function that best reproduces the 
experimental data. 
Docking procedures 
For the docking calculations we used the -tubulin dimer coordinates obtained from the 
Protein Data Bank 1JFF code. Model tetramer coordinates were kindly provided by Prof. M. 
Botta. 
[9]
 The bioactive 3D structure for the ligand in each case as deduced from the tr-NOESY 
experiments was maintained rigid along the simulation. 
CORCEMA-ST calculations 
An in-house script, which employs custom-made programs written in Fortran90 developed by 
Javier Rodríguez-Salarichs, permitted to rebuild the output files of Autodock and prepare for 
CORCEMA-ST analysis. In addition, other new script, (to be published) was used to perform 
an exhaustive file treatment in order to score the docked conformations using the CORCEMA-
ST program 
[10]
 to predict the STD values for a given ligand-receptor complex. 
The results presented herein, in publications IV and V, point to a complex network of binding 
events and conformational changes, which regulates the tubulin polymerization equilibrium.  
In contrast to some previous biological data, which fail to detect the binding of the MSAs to 
non-polymerized protein, our data show that there is binding of the MSAs used in this study to 
soluble -tubulin heterodimers. In this work we have determined the conformation of the 
MSAs bound to non-polymerized tubulin and to microtubules and the binding mode of the drug 
to the protein. Moreover, the combination of experimental TRNOE and STD NMR data with 
CORCEMA-ST calculations indicates that docetaxel, discodermolide and the azathilone target 
an additional binding site at the pore of the microtubules, which is different to the internal 
binding site at the lumen previously determined by electron crystallography. 
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Main results are detailed in the following publications (Publication IV and V). 
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The discovery of natural products that attenuate cell growthby acting as inhibitors of cellular microtubules has resulted in
the development of clinically important drugs in cancer chemo-
therapy.13 A particularly valuable class of such antimitotic
compounds preferentially binds to assembled microtubules over
unassembled tubulin, thus stabilizing the polymer and impairing
the dynamics. Through this mechanism of action, the dividing
tumor cells become blocked in the G2/M phase of the cell cycle,
resulting in apoptosis. These microtubule-stabilizing agents
(MSAs) can be classiﬁed into two groups, depending on their
competition for three distinct known microtubule-binding sites.
The ﬁrst group includes paclitaxel and its biomimetics (doce-
taxel, epothilones, discodermolide, dictyostatin, cyclostreptin,
etc.).4 These molecules competitively bind to one or both
binding sites present in the lumen (internal site of the tubulin
β-subunit) and at the pore of the microtubules (external site,
involving the R and β subunits of diﬀerent heterodimers). It is
proposed that these ligands bind to this external site and this
facilitates transport to the luminal site. In support of this
hypothesis, a ﬂuorescent taxoid (hexaﬂutax) was able to bind
only to the external site on microtubules. It was shown that
binding to this pore site was suﬃcient to induce microtubule
assembly.5,6 Moreover, the binding of cyclostreptin (a MSA that
covalently binds tubulin) with microtubules was characterized by
mass spectrometry, showing that this ligand binds to both the
inner and the pore sites.7
At present, it is not yet established if microtubule-stabilizing
agents that target the paclitaxel binding site bind only to the
inner, only to the outer, or to both binding sites. However, their
strict 1:1 stoichiometry with respect to the R/β-tubulin hetero-
dimer indicates that binding to both sites is mutually exclu-
sive.4,8,9 Furthermore, indirect evidence supports the presence of
a binding site with moderate aﬃnity for MSAs. It is known that
fast kinetics of dissociation in the relaxation time scale are required
to observe TR-NOESY signals. As it was possible to obtain strong
TR-NOESY signals of docetaxel and discodermolide bound to
Received: March 23, 2011
Accepted: May 3, 2011
ABSTRACT: The binding interactions of two antitumor agents that target the
paclitaxel site, docetaxel and discodermolide, to unassembled R/β-tubulin
heterodimers and microtubules have been studied using biochemical and NMR
techniques. The use of discodermolide as a water-soluble paclitaxel biomimetic
and extensive NMR experiments allowed the detection of binding of microtubule-
stabilizing agents to unassembled tubulin R/β-heterodimers. The bioactive 3D
structures of docetaxel and discodermolide bound to R/β-heterodimers were
elucidated and compared to those bound to microtubules, where subtle changes
in the conformations of docetaxel in its diﬀerent bound states were evident.
Moreover, the combination of experimental TR-NOE and STD NMR data with
CORCEMA-ST calculations indicate that docetaxel and discodermolide target an additional binding site at the pore of the
microtubules, which is diﬀerent from the internal binding site at the lumen previously determined by electron crystallography.
Binding to this pore site can then be considered as the ﬁrst ligand-protein recognition event that takes place in advance of the drug
internalization process and interaction with the lumen of the microtubules.
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microtubules,10 it is likely that a binding site with a lower aﬃnity
than the luminal binding site is also involved in the recognition of
these compounds.
The second group of microtubule-stabilizing agents includes
laulimalide and peloruside, which compete for a diﬀerent binding
site that has not yet been fully characterized.11,12
Microtubule structure determination both in the presence and
in the absence of MSAs remains a challenge for structural
biology. The complexity of this system, where diﬀerent aggrega-
tion states of the R/β-heterodimer can coexist in solution, has
precluded the crystallization of microtubules. Therefore, only 4 Å
resolution X-ray structures of RB3-tubulin complexes are
available.13 Moreover, only a few drugs that target tubulin have
been crystallized with the protein, also leading to relatively
limited resolution (3.5 Å) structures.14,15
In 1998, Nogales et al. reported the ﬁrst structural data for
tubulin in the presence of a microtubule-stabilizing agent.16 The
structure of Zn-stabilized tubulin sheets in the presence of
paclitaxel was determined by electron crystallography, which
enabled the location of the paclitaxel binding site within the
tubulin β-subunit, establishing interactions with residues at the
H6-H7 loop, H7 helix, B7-H9, M, and B9-B10 loops. However,
the resolution of the structure precluded the complete character-
ization of the ligand bound conformation, and additional com-
putational studies were needed to reﬁne the ligand orientation
and elucidate the key drugprotein interactions.17 Subsequently,
Nettles et al. reported the structure of the complex of epothilone
A bound to zinc-stabilized tubulin sheets by electron crystal-
lography.18 This work conﬁrmed that the binding site of this
paclitaxel mimetic was located within the same region of the
tubulin β-subunit as the paclitaxel site previously described by
Nogales. Despite these ﬁndings, the aggregation state of this
system (Zn-induced sheets) lacks the interprotoﬁlament inter-
actions present in microtubules, and therefore, the precise
mapping of the binding site of taxoids and paclitaxel mimetics
to microtubules, as well as a detailed knowledge of the molecular
recognition process, remains elusive.
In this context, we have focused on determining the binding
modes of docetaxel and discodermolide to microtubules in
aqueous solution by using an integrated NMR and computa-
tional approach. Since the action of these molecules probably
involves a multistep mechanism, with diﬀerent recognition
events, we have also studied the binding of these two paclitaxel
mimetics to the nonpolymerized tubulin R/β-heterodimer, in
order to check if the protein is able to recognize the drugs in this
nonaggregated state. Although this event seems to be an essential
step for the promotion ofmicrotubule formation from tubulinR/
β-heterodimers by MSA,19 as far as we know, there is no direct
biochemical evidence in support of the binding of paclitaxel and
its biomimetics to unassembled tubulin.
In previous work, the use of cyclostreptin, a drug that
covalently binds to tubulin, allowed the detection of a weak inter-
action with nonpolymerized tubulin R/β-heterodimers at the
external pore site.7 This region had been predicted to be the
transient location for paclitaxel in its way toward the luminal
site.5,20 Surprisingly, cyclostreptin was found to bind to poly-
meric tubulin both at the inner luminal and at the pore site.
However, for nonpolymerized tubulinR/β-heterodimers, it was only
bound to the pore site, thus providing the ﬁrst direct identiﬁcation of
those residues of the external site present in unassembled tubulin. In
contrast, the luminal site has been proposed as the binding site on
the basis of docking and INPHARMAanalysis of epothilones bound
to unpolymerized tubulin.21
Herein, we provide experimental evidence for the binding of
docetaxel and discodermolide to unassembled tubulin. These
compounds promote tubulin polymerization under conditions in
which tubulin itself is not able to undergo assembly, i.e. with
GDP bound to the exchangeable site.8 These results imply that
paclitaxel mimetics not only stabilize the microtubule when it is
already formed but also can promote microtubule formation. In
this work, two key questions related to the mechanism of
recognition and stabilization of tubulin by MSA are addressed:
the number and location of the binding sites involved in the drug
recognition event by microtubules, and the characterization of
the binding of these MSAs to nonpolymerized tubulin.
’RESULTS
Characterization of the Binding of the MSAs to Nonpoly-
merized States of the Protein. Binding of Discodermolide to
Tubulin r/β-Heterodimer. Microtubule-stabilizing agents in-
duce microtubule assembly under conditions in which tubulin
itself is unable to assemble (GDP-bound and absence of magne-
sium). Therefore, it is likely that they bind to unassembled
tubulin R/β-heterodimer. In practice, the binding of paclitaxel
and docetaxel to tubulin in the absence of Mg2þ has been
previously studied,19 using concentrations up to 10 μM of pacli-
taxel and 50 μM of docetaxel. However, under these conditions,
no binding was detected, indicating that the limit for the
dissociation constant should be in the millimolar range. In recent
years, structurally novel microtubule-stabilizing agents with
better solubility and higher affinity for microtubules, as is the
case for discodermolide, have been discovered. Thus, higher
concentrations of these ligands can be assayed for tubulin
binding. The centrifugation assays indicated that discodermolide
cosediments with the nonpolymerized tubulin R/β-heterodimer
in the absence of Mg2þ (conditions in which R/β-tubulin is not
polymerized22). However, given the low binding affinity ob-
served (in the range of 104 M1), it was not possible to reach
saturation at the maximum possible ligand concentrations and
the stoichiometry of the interaction could not be quantified.
Nevertheless, since Scatchard analysis of the data indicates 0.85(
0.22 sites, we have assumed a 1:1 stoichiometry for the interaction
that results in a binding constant of 2.0 ( 0.7  104 M1
(Figure 1).
In order to check the speciﬁcity of the process, competition
experiments were performed. In particular, discodermolide and
epothilone B, at 55 μM concentrations, were incubated, both
separately and together, in D2O with 45 μM tubulin in 10 mM
NaPi, 0.1 mMGTP and pH/ (direct reading in a D2O solution of
the H2O calibrated pH-meter)
38 7.0. While 0.35 mol epothilone
B and 0.17 mol discodermolide per mol of tubulin were found to
be bound to tubulin when the ligands were incubated separately,
the stoichiometries were reduced to 0.21 and 0.09, respectively,
when the ligands were incubated together. This result indicates
that they compete (at least partially) for the same site. Control
repeats in H2O of the corresponding experiments gave the same
results.
Puriﬁed tubulin is an unstable protein known to rapidly
denature in aqueous solution. D2O has been reported to stabilize
tubulin against deactivation and aggregation,23 as well as to
stabilize protein assemblies, including microtubules.24 In order
to determine the oligomerization state of tubulin in our experiments
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and to rule out any possible changes due to the presence of D2O
or to ligand binding, samples containing 13 and 45 μM tubulin in
10 mM NaPi, 0.1 mM GTP in D2O, pH
/ 7.0, at 25 C, were
analyzed by sedimentation velocity in an analytical ultracentri-
fuge. These samples were found to contain over 90% of 5.8 S R/
β-tubulin heterodimers, 2 h after equilibration in the D2O buﬀer.
Incubation with 55 μM docetaxel or discodermolide did not
induce tubulin R/β-heterodimer aggregation under these experi-
mental conditions. Thus, the nonpolymerized state of the tubulin
R/β-heterodimer was conﬁrmed.
Conformation of Microtubule-Stabilizing Agents Bound
to Nonpolymerized Tubulin r/β-Heterodimer and Microtu-
bules. The bound conformation of docetaxel and discodermo-
lide to the tubulin R/β-heterodimer was deduced by analysis of
the TR-NOESY cross peaks, as shown in Figure 2A and B,
respectively (expanded versions are shown in Supplementary
Figures 2 and 3, respectively). Extremely weak NOEs were evi-
dent between both aromatic moieties (2-OBz and 30-Ar), resem-
bling the results obtained for docetaxel bound to microtubules.25
These data indicate that the so-called “polar conformation” is not
significantly populated in the bound state.
In contrast, strong NOEs were detected between the 4-OAc
methyl group and both aromatic rings. The tert-butoxy protons
also showed clearNOEcontacts with both aromatic rings, although
signiﬁcantly weaker than those detected for the 4-OAc group.
Notably, this result contrasts with the observations described
for docetaxel when bound to microtubules.25 In that case, the
NOEs between the tert-butoxy and 2-OBz meta protons were
signiﬁcantly stronger than those between the 2-OBz meta
protons and the 4-OAc group. The ratio of NOE intensities
between the key proton pairs was estimated. Thus, the intensity
of the Hmeta 2-OBz (two protons)-tert-butoxy (nine protons)
cross peak was compared to that between the Hmeta 2-OBz (two
protons)-4-OAc (three protons) equivalent. The corresponding
ratio clearly changed from 2.1 to 1.3, when the NOESY spectra
recorded in the presence of microtubules was compared to that
with nonpolymerized tubulin R/β-heterodimer. This change in
intensity ratio could be correlated with a change in the con-
formation and thus in the relative orientation of the key pendant
groups. Furthermore, the data suggest that the nonpolymerized
tubulin R/β-heterodimer-bound conformation of docetaxel pre-
sents amore open arrangement between the hydrophobic groups
(2-OBz and tert-butoxy) than that adopted when it is bound to
microtubules (Figure 2C).
The analysis of the molecular modeling results permitted the
determination of the docetaxel conformation bound to nonpoly-
merized tubulin R/β-heterodimer with the best ﬁt to the NMR
data as deﬁned by improper torsion angle values for OC2
C30NBz (φ1) and OC2C30C(Ph) (φ2) of 98 and40,
respectively. In contrast, the corresponding torsion angles are 77
Figure 1. Chemical structures of docetaxel and discodermolide. Scatchard plot of binding of discodermolide to nonpolymerized R/β-tubulin
heterodimer in 10 mM sodium phosphate, 0.1 mM GTP, pH 7.0 at 25 C.
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and80 for the docetaxel conformation bound to microtubules.
Therefore, the microtubule bound docetaxel conformation as
deduced byNMR is intermediate between the so-calledT-paclitaxel
geometry, described by Snyder et al.17 (deﬁned by φ1 80 and
φ2 58) and the nonpolar geometry (with improper torsion
angles φ1 42, φ285). On the other hand, the docetaxel con-
formation bound to nonpolymerized tubulin R/β-heterodimer
approximates closely to the T-paclitaxel conformation.17
In contrast, the REDOR-based paclitaxel conformation26 does
not account for the observed NOEs under our experimental con-
ditions, neither for dimeric tubulin nor for microtubules. The
REDOR-based conformation displays the C30 aromatic ring atta-
ched to the amide moiety pointing out to the opposite direction
of the taxane ring, far apart from the 2-OBz aromatic ring. This
geometry cannot satisfy the observed NOE contacts between
tert-butoxy and 2-OBz protons.
On the other hand, no signiﬁcant diﬀerences were found
between the conformation of discodermolide when bound to
nonpolymerized tubulin R/β-heterodimer or to microtubules.
Thus, for discodermolide, the bound conformation in both states
corresponds to that previously described.10
Saturation Transfer Difference (STD) Analysis of Com-
pounds Bound to Nonpolymerized Tubulin r/β-Heterodi-
mer and to Microtubules. In order to gain insight into the
mechanisms employed by microtubule-stabilizing agents to induce
microtubule assembly, the binding of these compounds to
nonpolymerized tubulin R/β-heterodimer and to microtubules
was studied using saturation transfer difference analysis. STD-
NMR experiments detect magnetization transfer from a given
protein to a bound ligand. Only bound ligands show STD signals,
and as in any NOE-type experiment, the observed STD effect
depends on the distance between the protein and ligand protons,
thus providing a useful tool to detect the ligand epitope and to
probe the pharmacophore region. Additionally, STD also depends
on the exchange rate, binding affinity, concentrations of ligand
and receptor, rotational correlation times, and spectrometer
frequency. Binding of docetaxel and discodermolide to nonpo-
lymerized tubulin R/β-heterodimer in D2O, 10 mM NaPi,
0.1 mM GTP and pH/ 7.0 could be easily detected by STD
(Figure 3A,B). The addition of an excess of discodermolide to a
sample containing tubulin and docetaxel reduced the character-
istic STD signals of docetaxel, (the peak at 7.50 ppm for the 30-Ar
protons is shown as example in Figure 3C). This result indicates
that they compete, at least partially, for the same binding site, as
also deduced from the ultracentrifugation experiments (see
above). However, given the difference of more than 1 order of
magnitude between the estimated binding constants for those
molecules (ca. 2.0  104 M1 for discodermolide and less than
Figure 2. TR-NOESY spectra (mixing time: 300 ms) of the diﬀerent ligands in the presence of nonpolymerized tubulin R/β-heterodimer (D2O,
298 K): (A) docetaxel and (B) discodermolide. (C) Red color: docetaxel conformation when bound to microtubules. Blue color: docetaxel
conformation bound to nonpolymerized tubulin R/β-heterodimer.
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1  103 M1 for docetaxel19), an even more drastic decrease of
the docetaxel STD signals in the presence of discodermolide
would have been expected. This finding suggests the presence of
additional binding sites for docetaxel binding (see below for
further discussion).
The comparison of the STD proﬁles of docetaxel bound to
unassembled tubulin and to microtubules allowed us to identify
those protons that are closer to the protein in each aggregation
state of the system. It can be observed (Figure 3D) that the
proﬁles are similar, although not identical. As expected, the
absolute value of the detected STD eﬀect on docetaxel protons
was higher in the presence of microtubules. This result merely
reﬂects that the ligand is bound to a larger receptor in the case of
microtubules. In both cases, the protons with the higher STD
values were the aromatic ones of the groups at positions 2 and 30.
In the case of discodermolide, STD eﬀects have smaller values
than the ones for docetaxel. In addition, the eﬀects are quite uniform
within the molecule for both microtubules and nonpolymerized
tubulin R/β-heterodimer samples. The protons with the highest
STD eﬀect are H11 and 25-CH3 in the presence of microtubules
and H2, H11 in the case of unassembled tubulin heterodimers.
Modeling of the Bioactive Conformations in the Binding
Sites.TheNMR data obtained were then employed tomodel the
tubulin-bound conformations of discodermolide and docetaxel.
First, docking of the ligands in the luminal binding site (PDB
code1JFF)27was performed, as previously described.10The resulting
docetaxel binding mode at the luminal site (Figure 4A) was fairly
similar to that reported for paclitaxel using electron crystal-
lography, as shown in Figure 4B. The discodermolide binding
model involving the luminal binding site has already been descri-
bed in our previous work.10
Additional docking calculations were also performed for the
pore site. Initially, the model described by Magnani and co-
workers was employed.28 In this case, two binding modes were
found (Figure 5A). In the ﬁrst one, docetaxel was placed between
the tubulin β-subunit, close to the luminal site (β1, following the
Magnani nomenclature), and the R-subunit of the next dimer in
the protoﬁlament (R2, see Figure 5A, cyan structure). In this
case, the location of the binding site was similar to that described
by Magnani. However, the binding pose of docetaxel was rather
diﬀerent to that described by Magnani for paclitaxel. This dis-
crepancy could be due to the diﬀerent chemical nature of the
ligand side chains at C13 and/or to the diﬀerent docking protocols
employed. Magnani treated paclitaxel as a ﬂexible entity, searching
for the best pose with no experimental constraints. In contrast, we
Figure 3. (A) Oﬀ-resonance NMR experiment (500 MHz) (lower line) and STD spectra (upper line) of docetaxel bound to nonpolymerized tubulin
R/β-heterodimer. (B) Oﬀ-resonance NMR experiment (500 MHz) (lower line) and STD spectra (upper line) of discodermolide bound to
nonpolymerized tubulin R/β-heterodimer. Protons with higher STD are labeled. (C) Decrease of the STD signals of docetaxel with discodermolide
concentration. The peak at 7.50 ppm (30-aryl protons) is evaluated. (D) Comparison between the STD proﬁles of docetaxel bound to microtubules
(dashed line) and nonpolymerized tubulin R/β-heterodimer (solid line).
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considered the experimental NOE-based docetaxel conformation
for the docking protocol.
In the second solution, docetaxel was bound in the bottom
part of the pore, close to subunits β1 and β4 (see Figure 5A,
magenta structure), in a location similar to that described by
Freedman et al.29 However, as in the former case, the obtained
binding pose of the ligand relative to this site was diﬀerent from
that described by Freedman.
Docking of discodermolide to the pore site (the geometries of
the bound conformers to nonpolymerized tubulin R/β-hetero-
dimers and to microtubules are essentially identical) resulted in a
preference for the ligand to occupy the lower part of the pore
(Figure 5B), near subunits β1 and β4, as described above for the
second solution found for docetaxel.
Corcema-ST Calculations. Paclitaxel Mimetics Bound to
Microtubules. The theoretical STD profiles of the docking
models described above were calculated by using the CORCE-
MA-ST program and compared to the experimental data. In the
case of microtubules, the best fit between the experimental and
calculated STD values was obtained when the docking solutions
located at the pore site were considered (Figure 5A). For
docetaxel, the blue conformer (Figure 5A) provided the best
fitting (Figure 6A), with a NRMSD = 9.9%. In contrast, the pink
structure at the pore (Figure 5A) and the geometries docked at
the internal site (Figure 4A) did not satisfactorily reproduce the
experimental data (see Figure S1 in the Supporting Information.
Values of NRMDS = 56.5% and NRMSD = 42.6% were found,
respectively).
In the best binding pose (STD- and trNOESY-based), the tert-
butoxy group of docetaxel is located in the proximity of the CH3
groups of the side chains of β1 Thr220 and β1 Thr221. In fact,
Thr220 is the nucleophile residue that reacts with cyclostreptin,
and is in a peptide protected for hydrogen/deuterium exchange
(HDX) in paclitaxel-induced microtubules.30 The hydroxyl
group at position 7 of docetaxel is engaged in hydrogen bonds
with β1 Glu207 and β1 Lys176 (also protected from HDX),
while the aryl group at the C13 side chain occupies the hydro-
phobic pocket close to β1 Y210 and to the CH3 of β1 Thr223.
The benzoyl group of docetaxel is located in the vicinity of the
CH3 of R2 Ala289.
In the case of discodermolide bound to microtubules, the best
ﬁt between the experimental NMR data and the docking solu-
tions (Figure 6B NRMSD = 22.4%) was found for the pore site.
In this case, the C11 hydroxyl of discodermolide is engaged in
two hydrogen bonds with residues β1 Lys218 and β1 Phe214
while the C7 hydroxyl forms a hydrogen bond with β1 Thr220.
One additional hydrogen bond is established between the β4
Val93 backbone carbonyl and the hydroxyl moiety at position 17.
Me30 is close to β4 Phe92, while the carbamate moiety of the
ligand forms a hydrogen bond with the backbone carbonyl group
of β4 Phe94. The docked solutions located at the internal site
provided a much poorer ﬁt with the STD experimental data, as
deduced from the high NRMSD = 61.6%.
Therefore, the combined NMR/docking protocol employed
herein provides support for the major binding site of both
paclitaxel mimetics docetaxel and discodermolide bound to
microtubules to be located at the pore of the microtubules.
Paclitaxel Mimetics Bound to Nonpolymerized Tubulin R/β-
Heterodimers. First, it is important to note that the observed
STD signals obtained with unassembled tubulin R/β-hetero-
Figure 4. (A) Docetaxel binding at the luminal binding site. (B) Electron crystallography structure of paclitaxel bound to microtubules (PDB code 1JFF).
Figure 5. (A) Solutions found for the docking of the microtubule bound form of docetaxel into the pore type I of microtubules. The four tubulin
heterodimers forming the pore are labeled 1 (gray), 2 (blue), 3 (green), and 4 (orange); docetaxel pose beween heterodimers 1 and 2 is labeled in cyan,
and docetaxel pose between heterodimers 1 and 4 is labeled in magenta. (B) Docking of the microtubule bound form of discodermolide into pore type I
of microtubules. Discodermolide is labeled in light green.
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dimer preparations cannot be due to interactions with the
complete pore site. Indeed, this cavity is only present in micro-
tubules since it is formed by interactions of different hetero-
dimers. Therefore, in order to obtain a structural view of the
interaction of the paclitaxel mimetics with a partially formed
pore, additional docking models were evaluated. The first model
employed contained only the β1 subunit. This is the region that
provided the best fit between the experimental NMR and the
CORCEMA-ST predictions for microtubules, as described above
(blue structure, Figure 5A). A second model was also calculated
by considering only the β4 subunit, which shows major interac-
tions with the C13 side chain of docetaxel, at the pore site (pink
structure, Figure 5A). Additional models of docetaxel and
discodermolide bound to tubulin R/β-heterodimer in the inter-
nal binding site were also evaluated.
Altogether, the ﬁtting procedures between the experimental
data and the CORCEMA-ST calculations were carried out
evaluating the three putative binding sites: the internal binding
site, the external semisite at β1, and the external semisite at β4.
The theoretical STD eﬀects calculated for docetaxel bound at the
internal binding site (red thin line in Figure 7A) provided a fair
agreement with those experimentally observed in the presence of
nonpolymerized R/β-tubulin heterodimer, NRMSD = 22.1%.
However, some protons in this model produced STD values
higher than those experimentally observed (o-Ar,m-Ar, p-Ar, and
H7). Alternatively, the docking pose at the β1 semisite also
provided a reasonable ﬁt to the observed STD proﬁle for
the taxane core protons, NRMSD = 25.5% (green thin line in
Figure 7A), but failed to reproduce the STD proﬁle of most of the
protons at the C13 side chain, including those of the aryl and
benzoyl rings. Finally, the calculated STD proﬁle for the partially
formed pore site at β4 gave a poor ﬁt with the experimental data,
NRMSD = 40.16% (Supplementary Figure 1B). Thus, no single
solution gave a satisfactory match with all the experimental STD
data. In practice, a linear combination between the STD values
obtained for the luminal binding site with those obtained from
the partially formed pore site at β1 gave the best agreement with
the experimental data (NRMSD = 16.7% dashed line Figure 7A).
For discodermolide, neither the previously reported docking
model at the luminal site, NRMDS = 27.6% (red thin line in
Figure 7B),10 nor the partially formed pore bound structures,
NRMDS = 55.5% (green thin line in Figure 7B), provided a good
ﬁt between the calculated and the experimental STD values. As
for docetaxel, a linear combination between the STD proﬁles
calculated for both possible binding poses resulted in the best ﬁt,
with a NRMSD = 19.5%.
Figure 6. Comparison between experimental and theoretical STD data (CORCEMA-ST) for docetaxel and discodermolide in the presence of
microtubules. (A) The experimental STD eﬀects (solid line and circles) for docetaxel, compared with the calculated ones (dashed line and squares) for
this MSA at the pore of microtubules (blue structure, Figure 5A). (B) The experimental STD eﬀects (solid line and circles) for discodermolide,
compared with the calculated ones (dashed line and squares) for this MSA (green structure, Figure 5B). The parameters employed in the CORCEMA
calculations were the following: bound correlation time, 100 ns; koﬀ, 100 s
1; and kon, 10
8 s1 M1, for diﬀusion-controlled binding.
Figure 7. Comparison between experimental and theoretical STD data (CORCEMA-ST) for docetaxel and discodermolide in the presence of
nonpolymerized tubulin R/β-heterodimers. (A) The experimental STD eﬀects (thick line and black circles) for docetaxel compared with the calculated
ones for the docking pose at the semisite at β1 (green circles and thin line, koﬀ = 10
5 s1), and for the docking pose at the luminal site (red circles and thin
line, koﬀ = 10
5 s1). The best agreement is found for the combination of these two poses (dashed thick line and black squares) using diﬀerent koﬀ values of
125,000 and 200,000 s1, respectively. (B) The experimental STD eﬀects (solid line and circles) for discodermolide when bound to tubulin dimers,
compared with the calculated ones when docked at the semisite at β4 (green circles and thin line) and with those estimated when bound at the luminal
site (red circles and thin line). The best agreement is found for the combination of these two poses (dashed thick line and black squares). For
discodermolide, the koﬀ values described above were employed for each particular case. All CORCEMA calculations for dimeric tubulin employed a
bound correlation time of 60 ns and a kon value of 10
8 s1 M1, for diﬀusion-controlled binding.
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’DISCUSSION
Although ligand binding to unassembled tubulin is essential
for explaining the mode of action of microtubule-stabilizing
agents,4,9,19 the unequivocal experimental demonstration of its
existence has proved elusive. Indeed, it has been previously observed
only by covalent labeling of the pore site7 employing cyclo-
streptin. Up to now, the reversible interaction of microtubule-
stabilizing agents with R/β-tubulin heterodimer in its nonpoly-
merized state had never been directly observed. In order to
stabilize microtubules, it is required that the binding aﬃnity of
the compound for the assembled state is much higher than that
for the unassembled form, thus displacing the assembly equilib-
rium toward the polymer. Therefore, the existence of low aﬃnity
of MSAs for unassembled R/β-tubulin heterodimers can be
predicted. This low aﬃnity precluded the previous detection of
binding of MSAs to nonpolymerized R/β-tubulin heterodimers
using centrifugation techniques.19 Notably, in the present work,
the use of TR-NOESY and STD experiments with discodermo-
lide as microtubule-stabilizing agent, with higher aqueous solu-
bility, has allowed the ﬁrst experimental detection of binding to
nonpolymerized tubulin R/β-heterodimers, as well as the bio-
chemical and structural characterization of the interaction.
Two diﬀerent binding sites in microtubules have been des-
cribed for paclitaxel biomimetics, the pore site to which binding
of cyclostreptin7 and hexaﬂutax6 take place and the internal
luminal site, where paclitaxel itself interacts.16,31 When micro-
tubules are formed, it is expected that paclitaxel and its mimetics
should be mostly bound to the high aﬃnity luminal site. In
principle, the existence of a very high aﬃnity site precludes the
use of ligand-based NMR techniques such as TR-NOESY and
STD for monitoring interactions due to the requirements of fast
dissociation rate of the ligands for these experiments to succeed.
Therefore, it is highly probable that the binding events associated
with this high aﬃnity luminal site are TR-NOESY- and STD-
silent. However, these experiments produced clear-cut NMR
signals for discodermolide and docetaxel in the presence of
microtubules. Therefore, it seems very likely that the observed
TR-NOESY and STD signals arise from an alternative binding
event, probably a prerelease conformation. In practice, the best
ﬁtting of the experimental STD eﬀects to distinct binding mode
geometries was obtained when the interaction of the ligands to
the pore site was considered, suggesting that the experimental
NMR signals of paclitaxel mimetics bound to microtubules arise
from the ligand that has been just released from themicrotubules.
This ﬁnal release step complies with the kinetic requirements of
TR-NOESY and STD, because it should be fast enough in the
relaxation time scale.
Thus, according to our experimental data, MSAs bind and
dissociate from/to microtubules following a two-step mecha-
nism.32 The ﬁrst binding event is assigned to the binding to the
external pore site,7 from which the dissociation kinetics is fast.32
The second, the slow step, should be the internalization toward
the luminal site. Subsequently, in the dissociation process, the
events are reversed. The ﬁrst is the slow step, assigned to the
transportation from the internal luminal to the external pore site,
while the second fast step corresponds to the release of the ligand
to themedium. Thismechanism implies that the ﬁnal release step
of MSAs from microtubules takes place from the pore. Alter-
natively, the two steps involved in binding could be due to a
conformational rearrangement of the luminal site, resulting in the
release of the ligand by diﬀusion to the medium through the ends
of the microtubule. However, this diﬀusion process should be
expected to be rather slow33,34 and, therefore, not compatible
with the observed fast release of radioactive paclitaxel and
docetaxel from assembled microtubules. It has been demon-
strated that this phenomenon occurs within 2 min35 and that the
rate-limiting step is the ﬁrst slow step of dissociation.
The analysis of the NMR data has indicated the existence of
structural diﬀerences in the bioactive conformations of docetaxel
when bound to microtubules versus nonpolymerized R/β-tubu-
lin heterodimer. The resulting 3D models of the ligand-protein
complexes (combining docking and CORCEMA-ST calculations)
indicated that His229 of the tubulin β-subunit at the luminal site,
which simultaneously interacts with the 2-OBz and the C13 side
chain in the internal binding site and therefore makes them
spatially separated (Figure 4), does not play any key role in the
recognition process at the pore site. Indeed, the corresponding
experimental NOEs between the meta protons of the 2-OBz
moiety and the tert-butoxy protons at the C13 side chain are
signiﬁcantly diﬀerent when the TR-NOESY spectra of docetaxel
are recorded in the presence of microtubules or nonpolymerized
R/β-tubulin heterodimer. Therefore, the combined NMR/model-
ing data strongly suggest that, whenmicrotubules are employed, it is
the pore site that is observed by TR-NOESY and STD.
With this information in hand, there is still the question of the
actual site (or sites) that is interacting with docetaxel in non-
polymerized R/β-tubulin heterodimers. Thus, the experimental
data were analyzed and compared to the predictions of COR-
CEMA-ST for all the possible binding sites described above. The
best ﬁt was obtained when the internal binding site was con-
sidered, indicating that this is the most plausible binding site for
docetaxel in unassembled tubulin (Figure 4). Nevertheless, the ﬁt
between the experimental and predicted data considerably im-
proved when the contribution of the β1 semisite was additionally
considered. In fact, the coexistence of two binding sites is in
agreement with the observations of the competition experiments
which suggested the existence of two simultaneously binding
sites for dimeric tubulin. Thus, at the initial stages of the process,
and when no polymer has been yet formed, these paclitaxel
mimetics mainly interact at the luminal and β1 binding sites, which
then further evolves to form the complete pore binding site.
The results presented in this work have allowed the detection
of the interaction of docetaxel and discodermolide with non-
polymerized R/β-tubulin heterodimers. The interaction has
been biochemically characterized, clarifying the manner in which
microtubule-stabilizing agents induce microtubule assembly
from R/β-heterodimers. These data show that MSAs play a dual
role since they not only stabilize microtubules once they are
formed but also promote tubulin polymerization. In addition, the
bioactive conformations and the binding epitopes for docetaxel
and discodermolide when bound to nonpolymerized R/β-tubu-
lin heterodimers have been determined by NMR. Moreover, the
binding epitopes of these compounds when bound to micro-
tubules have been also described by using STD data. CORCE-
MA-ST calculations were carried out taking into account the two
possible binding sites located at the pore and at the lumen of
microtubules to discriminate among the diﬀerent binding poses.
The observed NMR ﬁndings can be satisfactorily explained by
binding of these MSAs at the pore of the microtubules. The
existence of this interaction mode therefore suggests that the
recognition process of docetaxel and discodermolide by micro-
tubules takes place following a two step mechanism. First,
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binding to the pore occurs, and then internalization to the lumen
takes place.
Finally, the existence of conformational variations in the
bound geometry of docetaxel when bound to microtubules and
to nonpolymerized tubulin R/β-heterodimers has been shown.
These observations suggest that the binding of microtubule-
stabilizing agents to the tubulin R/β-heterodimer mainly involves
the region where the luminal binding site in microtubules will be
located. However, the partially formed pore site also participates
in ligand recognition.
’METHODS
Proteins and Ligands. Purified calf brain tubulin and chemicals
were obtained as previously described.8,36Docetaxel (Taxotere) (Figure 1)
was kindly provided by Rho^ne Poulenc Rorer, Aventis. Discodermolide
(Figure 1) was synthesized as described.37 All compounds were diluted in
99.8% d6-DMSO (Merck) to a final concentration of 20 mM and stored
at 20 C.
Binding of Microtubule-Stabilizing Agents to Nonpoly-
merized Tubulinr/β-Heterodimers. The binding of microtubule-
stabilizing agents to unassembled tubulin heterodimers was determined
by centrifugation. Samples containing 50 μM discodermolide in D2O
containing 10 mM sodium phosphate, 0.1 mM GTP pH/ 38 7.0 (or the
same buffer in H2O pH 7.0) were incubated with increasing concentra-
tions of tubulin up to 40 μM at 25 C. The samples were centrifuged at
100,000 rpm in a TLA 100.2 rotor in a Beckman Optima TLX
ultracentrifuge for 120 min. The upper and lower 500 μL were carefully
collected, and the pellets were resuspended in 10 mM sodium phos-
phate, 0.1 mMGTP buffer pH 7.0. The concentration of tubulin in both
parts of the tube and in the pellet was determined spectrophotome-
trically, using an extinction coefficient of 107,000 M1 cm1 at 275 nm,
in 10 mM phosphate buffer 1% SDS,39 by employing a Thermo
Evolution 300 LC spectrophotometer. To 300 μL of each sample was
added 10 μMdocetaxel as internal standard. The samples were extracted
three times with an excess volume of dichloromethane, dried in vacuum,
and redissolved in 25 μL of 60%methanol. The amount of discodermolide
in the sampleswas analyzed in anAgilent 1100HPLC, employing a Zorbax
Eclipse XDB-C18 developing a gradient from 60% to 70% methanol in
water (v/v) at 1 mL/min (5 min 60% 15 min gradient 5 min 70%).
Analytical Ultracentrifugation. The oligomerization state of the
tubulin samples for the NMR experiments was analyzed by sedimenta-
tion velocity in a Beckman Optima XL-I analytical ultracentrifuge
equipped with interference and absorbance optics, using an An50Ti
rotor and double sector cells, at 43,000 or 50,000 rpm, 25 C. The
differential sedimentation coefficient distributions, c(s), were calculated
by least-squares boundarymodeling of sedimentation velocity data using
the program SEDFIT.40,41 The weight average sedimentation coefficient
values measured in the D2O buffer at 25 C were corrected for solvent
composition and temperature to H2O at 20 C, s20w, using SEDN-
TERP, retrieved from the RASMB server.42
NMR Sample Preparation and Experiments. The samples of
the ligands bound to nonpolymerized tubulin R/β-heterodimers were
prepared in NMR tubes using a 300 μM concentration of the desired
compound and 10 μM of tubulin in D2O, 10 mM NaPi, 0.1 mM GTP
pH/ 7.0. The tubulin samples were prepared by removing sucrose,
Mg2þ, and H2O from the storage buffer of a 10 mg sample of frozen
tubulin, by chromatography using a Sephadex G-25 medium column
(25 0.9 cm) equilibrated in D2O, 10 mMNaPi, 0.1 mMGTP pH/ 7.0.
Tubulin was centrifuged for 10 min at 50,000 rpm in a TLA 120 rotor in
an Optima TLX centrifuge to remove aggregates, and its concentration
was determined spectrophotometrically by employing an extinction
coefficient of 107,000M1 cm1 in 10 mMphosphate buffer containing
1% SDS.39 The samples were incubated at 25 C for 30 min prior to
measurement.
The samples of the ligands bound to microtubules were prepared in
NMR tubes using a 300 μMconcentration of the desired compound and
20 μMof tubulin in D2O, 10 mMKPi, 0.1 mMGMPCPP, 6 mMMgCl2
pH/ 6.7. The tubulin samples were prepared by removing sucrose,
Mg2þ, and H2O from the storage buﬀer of a 20 mg sample of frozen
tubulin using a two-step procedure by chromatography in a drained
centrifuge column of Sephadex G-25 medium (6  1 cm) equilibrated
in D2O, 10 mM KPi, 10 μM GTP pH
/ 7.0 in the cold, followed by a
second chromatography using another Sephadex G-25 medium column
(15  0.9 cm) equilibrated in D2O, 10 mM KPi, pH/ 7.0. Tubulin was
centrifuged, and its concentration was measured as above. Tubulin was
diluted to 20 μM and GMPCPP 0.1 mM and 6 mM MgCl2 (ﬁnal pH
/
6.7) added prior to the drug addition. The samples were then incubated
at 37 C for 30 min prior to measurement.
NMR spectra were then recorded at 298 K (dimeric tubulin samples)
or 310 K (polymeric tubulin samples) in D2O on a Bruker AVANCE
500 MHz spectrometer equipped with a triple-channel cryoprobe.
NOESY43 cross peaks were basically zero at RT for both docetaxel and
discodermolide, and moderately positive at 310 K for free discodermolide.
For the bound ligands, STD and TR-NOE experiments were
performed as described,44 using a 30:1 ligand receptor molar ratio for
the interaction experiments with nonpolymerized tubulin R/β-hetero-
dimers, and employing a 15:1 ligand receptor molar ratio for the inter-
action experiments with microtubules. STD experiments were per-
formed with 0.5, 1, and 2 s saturation times (by concatenation of
50 ms Gaussian pulses separated by 1 ms). TR-NOESY experiments
with nonpolymerized tubulin R/β-heterodimers were performed with
mixing times of 50, 100, 200, 250, and 300 ms. No purging spin lock
period to remove the NMR signals of the background macromolecule
was employed, since they were basically not observable due to the huge
size of the receptor. First, line broadening of the ligand protons was
monitored after the addition of the protein. Strong negative NOE cross
peaks were observed, in contrast to the free state, indicating binding of
the ligands to the nonpolymerized tubulin R/β-heterodimer or micro-
tubule preparation. The theoretical analysis of the TR-NOEs of the
ligand protons was performed using a full relaxation matrix approach
with exchange45 as implemented in the CORCEMA program. Diﬀerent
exchange-rate constants were employed to obtain the optimal match
between experimental and theoretical results of the intraresidue cross
peaks of the ligands, which has a relatively ﬁxed geometry. Given the
protein/ligand ratio, the overall correlation time τc for the free state was
always set to 0.25 ns, since NOESY cross peaks for the free molecule
were essentially zero at RT and 500MHz, and the τc for the bound state
was set to 60 ns for nonpolymerized tubulin R/β-heterodimers (τc
calculated with HYDROPRO46).
The theoretical STD eﬀects for ligands bound to nonpolymerized
tubulin R/β-heterodimers and microtubules were calculated using the
CORCEMA-ST program. The overall correlation time τc for the free
state was always set to 0.25 ns, and the average rotational motion
correlation time, τc, for the bound state was set to 60 ns for nonpoly-
merized tubulin R/β-heterodimers, and 100 ns for microtubules. An
order parameter S2 = 0.85 was employed to account for the fast rotation
of the methyl groups, as implemented in CORCEMA-ST.
In order to ﬁt the experimental STD eﬀects and TR-NOE intensities,
oﬀ-rate constants between 100 and 200,000 s1 were tested. Optimal
agreement was achieved for koﬀ = 100 s
1 in the case ofmicrotubules and
a combination of Koﬀ = 200,000 s
1 for the pore semisite and Koﬀ =
125,000 s1 for the luminal binding site, in the case of nonpolymerized
tubulin R/β-heterodimers.
Conformational Search of Ligands. The calculations were
performed using the MacroModel/Batchmin47 package (version 9.6)
and the OPLS2005 all-atom force field as implemented in the program
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Macromodel 9.6. Bulk water solvation was simulated using Macro-
Model’s generalized Born GB/SA continuum solvent model.48 The
conformational searches were carried out using the torsional sampling
MCMM search method implemented in the Batchmin program, and
20,000 Monte Carlo step runs were performed. Extended nonbonded
cutoff distances (a van der Waals cutoff of 8.0 Å and an electrostatic
cutoff of 20.0 Å) were used. PR conjugate gradient (PRCG) minimiza-
tion (2000 steps) was used in the conformational search.
Docking Calculations. Docking of the ligands was performed
using the AutoDock 4.0 program.49 During an AutoDock 4.0 simulation,
multiple Lamarckian Genetic Algorithm runs occurred, each one
providing one predicted binding mode, and cluster analysis was per-
formed at the end of the simulation. Atomic coordinates for the ligands
were obtained from the NMR data assisted by molecular mechanics
calculations (see above). The R/β-tubulin dimer coordinates were
obtained from the Protein Data Bank 1JFF code. Model tetramer
coordinates were kindly provided by Prof. M. Botta.28
Grids of probe atom interaction energies and electrostatic potential
were generated by the AutoGrid program present in AutoDock 4.0. Grid
spacing of 0.375 Å were used. For each calculation, one job of 100
docking runs was performed using a population of 200 individuals and an
energy evaluation number of 3  106. Autodock structures were
minimized by using Macromodel 9.6, by several steps of Polak-Ribiere
conjugate gradient (PRCG) until the energy gradient become lower
than 0.001 kJ Å1 mol1.
Since the scoring function implemented in the Autodock program
was not useful to select a docking pose compatible with the experimental
NMR results, a new scoring function was implemented, based on the
diﬀerence between the experimental and theoretical saturation transfer
diﬀerence (STD) of each ligand’s proton (SF-STD). An in-house script
which employs custom-made programs written in Fortran90 (to be
published) was used to perform exhaustive ﬁle treatment in order to
score the docked conformations using the CORCEMA-STD program50
to predict the STD values for a given ligandreceptor complex. Brieﬂy,
the output ﬁles of Autodock were rebuilt and prepared for CORCEMA-
STD analysis. In this way, the structural information required for each
ligandreceptor complex was prepared for calculating the theoretical
STD. Protein residues located inside a sphere of 8 Å around the ligand
were considered for the calculations. Finally, the set of docked con-
formations was ordered according to the normalized root-mean-square
deviation (NRMSD) values calculated between the theoretical and the
experimental STD values measured for each proton of the ligand.
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Manuscript V: 
Insights into the interaction of the MSA azathilone with tubulin 
by using a combined NMR and computational approach 
 
Abstract 
A combined approach of NMR experimental data and Monte Carlo conformational searches 
have been employed to determine the tubulin bound conformation of the microtubule-
stabilizing agent azathilone 1, an hypermodified epothilone analogue that showed low 
nanomolar IC50 values to inhibit the growth of different types of drug-sensitive human cancer 
cell lines, similar to those of EpoA. In addition, docking protocols and subsequent CORCEMA 
validation procedures were successfully combined to explore the possible binding of this 
epothilone analogue to both the internal luminal site on  tubulin subunit and the external 
pore site on the outside of microtubules.    
Introduction 
Microtubule stabilizing agents (MSAs) comprise a chemically and structurally diverse variety of 
small molecules, which promote tubulin polymerization into microtubules, blocking microtubule 
dynamics and leading to abnormal mitosis and subsequent cell apoptosis. 
[1-2]
 
Among these MSAs, epothilones are a promising class of antimitotic agents, being epothilones 
A and B the most extensively investigated. (i. e. reviews 
[3-6]
) These polyketide-based bacterial 
natural products have shown to exhibit potent antiproliferative activity both in vitro and in vivo, 
[7-8]
 through the same mechanism of action as paclitaxel, a well known clinical anticancer drug 
(Taxol). 
[7]
 However, in contrast to taxol, epothilones appear to be extremely poor substrates 
for P-glycoprotein drug efflux pump, showing a low propensity to induce multidrug resistance. 
[7,9]
 They also are considerably more water-soluble than taxol. 
[10]
 
Based on these properties, over the past decade, epothilones have served as lead structures 
for the development of a new generation of anticancer drugs.
[5,11-12]
 These efforts have 
included the search for semi-synthetic derivatives and fully synthetic analogues 
[13-17]
 with 
improved pharmacological profiles. Extensive structure-activity relationship (SAR) studies 
[6,11,18]
 have also been carried out for a detailed understanding of the structural requirements 
for their biological activity. In this context, a new chemotype dubbed “azathilones” or “aza-
epothilones”, based on the replacement of a backbone carbon atom by nitrogen in the 
macrocycle, has shown promising antiproliferative activity. 
[14,19-20]
 Especially, the azathilone-
type compound shown in Scheme 1, which has a dimethyl benzimidazole side chain, instead 
of the thiazole moiety of the natural product, was found to inhibit the growth of different types 
of drug-sensitive human cancer cell lines with low nanomolar IC50 values, comparable to the 
potency described for epothilone A. 
[14,19]
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Although epothilones A and B competitively inhibit taxol binding to microtubules 
[21]
 and a 
common pharmacophore for epothilone and taxanes has been described 
[22]
, limited 
information is known about the molecular basis of the recognition of these molecules and 
analogues by their target protein, tubulin. As for taxol and other biomimetics, two different 
binding sites have been recently described, at the lumen (internal site, at the tubulin β-subunit) 
and at the pore of the microtubules (external site, involving α- and β-subunits of different 
heterodimers). It has been proposed that these ligands first bind to the external site, thus 
facilitating internalization to the luminal site.
[23]
 
As antecedents, in 2003, Carlomagno et al. described the conformation of epothilone A bound 
to unpolymerized tubulin by using NMR spectroscopy.
[24]
 The structure of the complex of Epo 
A with β-tubulin in Zn
2+
-stabilized tubulin polymer sheets was later determined by electron 
crystallography (EC) at 2.89 Å resolution. 
[25]
 Despite these findings, the aggregation state of 
this system (Zn-induced sheets) lacks the interprotofilament interactions present in 
microtubules and, therefore, the precise mapping of the binding site of taxoids and paclitaxel 
mimetics to microtubules, as well as a detailed knowledge of the molecular recognition 
process, remains elusive. 
Hence, an understanding of the underlying molecular mechanism of the interaction of these 
MSAs with tubulin may be essential for rationally driving new therapeutic approaches. With 
this purpose, NMR-based molecular recognition methods have been developed in the last few 
years to characterize the binding process at the molecular level. For the structural 
determination of binding ligands, a NMR combined approach, using transferred Nuclear 
Overhauser Effect (TR-NOE) experiments 
[26-27]
 and Saturation Transfer Difference (STD) 
methods 
[28-29]
, has been successfully applied in a variety of cases to investigate the bound 
conformation of different ligands and to determine the ligand binding epitope. 
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Scheme 1. Chemical structure and atomic numbering of the ‘non-natural’ azathilone 1, with promising IC50 
values for inhibition of human cancer cell growth. 
[19]
 
Herein, we report on the determination of the conformation of azathilone 1, in its free state and 
when bound to tubulin, both in its unpolymerized and polymerized states, by employing NMR 
spectroscopy and computational methods.  
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Results and Discussion 
NMR and modeling studies in the free state 
As the initial step, the conformation of the free molecule in water solution was deduced. NMR 
experiments in D2O were carried out at 500 MHz and 310K. A complete assignment of the 
1
H 
NMR resonance signals of compound 1 was achieved on the basis of 1D 
1
H, 2D TOCSY and 
ROESY experiments.  
Due to the intermediate size of the compound 1, which displays near-zero longitudinal NOE 
effects, the conformational information in the free state was derived from 2D ROESY 
experiments. At 500 MHz and 310 K, weak cross peaks were observed in the ROESY spectra 
(see Figure S2 of Supporting Information). Some of the NOE derived distances from key cross 
peaks are shown in Table 1.  
Table 1. Analysis of the NOE-derived Interproton Distances for azathilone 1 in the free state
a
  
proton pair 
observed NOE 
intensity (free 
state, D2O) 
NOE-based 
exp. 
distance r (Å) 
Conformer A  Conformer B 
2-23 strong 3.1 2.9 2.9 
3-22 med strong 2.8 2.8 2.8 
3-6 strong 2.4 2.9 2.9 
6-9a s, overlap 2.3 2.1 2.1 
6-22 s, overlap 2.3 2.5 2.5 
6-25 w, overlap 3.9 4.3 4.3 
6-23 w, overlap 3.9 4.1 4.1 
7-24 medium 3.0 2.8 2.8 
7-25 medium 2.8 2.7 2.7 
8-25 strong 2.2 2.1 2.1 
9b-25 medium 2.8 2.9 2.9 
15-17 medium 2.9 3.7 2.4 
15-27 medium 3.1 2.5 3.7 
21-31 medium 3.0 3.0 3.0 
28-27 strong 2.5 2.5 2.5 
a
The experimental distances (r, Å;±10%) were estimated according to a full matrix relaxation approach 
from a build up curve analysis of the ROESY data. Distances were calculated from NOEs with a reference 
distance of 1.75 Å for the geminal protons. 
 
NMR experiments were further assisted by molecular mechanics and dynamics methods. A 
restrained-free Monte Carlo conformational search was performed using the OPLS_2005 all-
atom force field, as implemented in the program Macromodel, as described in the 
experimental section. An ensemble of 250 structures was obtained from the conformational 
search. The lowest energy solutions from the calculations pointed out the presence of two 
conformational families, in agreement with most of the NOE-derived distances (see below). 
These structures present a fairly similar conformation for the macrocyclic ring, showing a 
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preferred conformation for the torsions in the C6-C10 region that would remain free of syn-
pentane interactions, as the major conformer reported previously by Taylor et al. for 
Epothilones A and B in organic solvents. 
[30]
 The main difference between the families is the 
relative orientation of the dimethylbenzimidazole side chain relative to the macrocyclic ring 
(See Figure S2 of Supplementary information). 
 
Conformer A     Conformer B 
Figure 1. Conformational analysis of 1.  The two low-energy conformations of azathilone 1 in water 
solution. 
As can be seen in Figure 1 (H15-H17 and H15-H27 distances), conformer A shows close 
proximity between the 15-27 proton pair (2.48 Å), while conformer B shows the opposite 
situation, with close proximity between the 15-17 proton pair (2.44 Å). Remarkably, both H17-
H15 and H27-H15 cross peaks display similar intensities in the ROESY spectrum (see Figure 
S3 of Supporting Information), suggesting the fast rotation in the NMR chemical shift time 
scale around the C15-C16 bond and therefore the presence of a conformational equilibrium of 
both A and B conformers in water solution.  
Azathilone tubulin recognition. NMR and modeling studies.  
As a further step, the bioactive conformation of azathilone 1, bound to unanssembled and 
assembled tubulin, was then studied. NMR experiments in D2O were carried out at 500 MHz at 
temperatures ranging from 298K (tubulin heterodimer) to 310K (microtubules). The bound 
conformation and the ligand epitope, in each case, were deduced from the TR-NOESY cross-
peaks and the analysis of the STD NMR experiments. 
TR-NOESY NMR experiments: 
TR-NOESY studies allowed the comparison of the structures of azathilone bound to tubulin 
 heterodimers and to microtubules. Strong negative cross-peaks were observed in the 
presence of the protein at 298 K (tubulin heterodimers) and at 310 K (microtubules), as 
expected for the ligand when it is bound to the receptor (Figure 2).  
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 Figure 2. TR-NOESY spectra. A) TR-NOESY spectrum (mixing time: 300 ms) of ligand 1 in the presence 
of tubulin heterodimers (D2O, 298 K). B) TR-NOESY spectrum (mixing time: 200 ms) of ligand 1 in the 
presence of microtubules (D2O, 310 K). Key NOE cross-peaks that define the NOE contacts between the 
protons at the macrocycle and the protons at the aromatic side chain can be observed in the expansion at 
the right handside. 
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Table 2. Analysis of the NOE-derived Interproton Distances for azathilone 1 in the bound state
a
  
proton pair 
NOE-based exp. 
distance (Å) 
dimeric 
NOE-based exp. 
distance
a
 (Å) 
microt 
Atomic distance (Å) 
Conformer A Conformer B 
2-3 2.8 3.1 2.9 2.9 
2-7 4.2 4.1 4.3 4.3 
2-22 4.4 3.9 4.3 4.3 
2-23 3.1 3.1 3.0 3.0 
3-6 2.9 4.0 2.9 3.0 
3-7 >3.5 n.o. 4.4 4.4 
3-22 2.7 2.7 2.8 2.8 
3-23 3.6 3.6 3.5 3.5 
6-7 3.1 3.2 3.0 3.0 
6-8 3.8 3.2 3.1 3.1 
6-9a s, overlap s, overlap 2.1 2.1 
6-22 s,overlap s,overlap 2.5 2.5 
6-23 4.1 4.2 4.1 4.1 
6-24 3.0 2.9 2.7 2.7 
7-8 3.2 3.2 2.5 2.5 
7-9b 3.0 n.o. 3.8 3.8 
7-24 3.1 3.2 3.2 3.2 
7-25 3.1 3.7 2.7 2.7 
8-24 4.0 n.o. 4.2 4.2 
8-25 3.1 3.3 2.1 2.1 
9b-25 3.4 n.o. 2.9 2.9 
13a-15 3.6 n.o. 3.7 3.7 
13b-15 4.0 4.2 3.9 3.9 
14-15 3.1 3.0 2.5 2.5 
14-17 3.9 3.6 4.3 2.8/4.0 
27-14 3.8 n.o. 3.3 > 4.0 
15-17 3.0 2.7 3.7 2.4 
15-27 3.3 3.5 2.5 3.7 
21-31 3.0 2.9 3.0 3.0 
22-23 3.5 3.4 2.5 2.5 
22-24 3.6 3.7 3.6 3.6 
27-28 2.5 2.5 2.5 2.5 
28-31 3.2 3.0 3.1 3.1 
a
The experimental distances (r, Å;±10%) were estimated according to a full matrix relaxation approach 
from a build up curve analysis of the TR-NOESY data. Distances were calculated from NOEs with a 
reference distance of 1.75 Å for the geminal protons. n.o.: not observable 
 
No significant differences were found between the conformation of the macrocyclic moiety 
deduced in the bound state to that existing in the free unbound form (Table 2), thus showing 
that the geometry of the macrocycle is fairly preorganized in the free state. In contrast, the 
comparison of the intensities of the key cross peaks H15-H17 and H15-H27 (see expansion in 
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Figure 2) reveal differences between the spectra. Conformer B is the most populated in both 
cases, when bound to tubulin  heterodimers or microtubules. However, the equilibrium is 
more driven towards conformer B in the case of microtubules. Fittingly, H27-H15 is weaker 
than in the spectrum of  heterodimers and H27-H14 is not observed. 
The tert-butoxy protons also showed NOE contacts with the aromatic ring that support 
conformer B as the major conformer in the bound state. Extremely weak NOEs were observed 
between H27 and H28 with the tert-butoxy protons Bu
t
-33, while a stronger peak was found 
between H17 and Bu
t
-33.  
A transannular H3-H6 NOE cross peak was detected in both spectra, pointing out that the 
minor conformer described by Taylor et al, in organic solvent is also present in the bound state 
of azathilone to tubulin. In the case of tubulin  heterodimers this conformer seems to be the 
major recognized by the protein (NOE-determined distance 2.9 Å). This fact is also in 
agreement with the epothilone conformation described by Carlomagno et al. in the presence of 
non-polymerized tubulin.
[24]
 In contrast, in the presence of microtubules, a weaker NOE was 
detected, suggesting the existence of additional flexibility around the C2-C5 torsion angle in 
this case.  
STD NMR experiments: 
STD-NMR experiments allowed the determination of binding epitopes of azathilone 1 when 
bound to both unassembled and assembled tubulin. The STD method is based on the 
magnetization transfer from a given protein to the ligand protons, a fact that can only take 
place when the ligand indeed binds to the protein. Only bound ligands show STD signals, 
being the ligand protons nearest to the protein the most likely to be highly saturated. 
Therefore, these protons display the strongest signals in the STD spectrum. In contrast, the 
ligand protons located further away are saturated to a lower degree, and their STD intensities 
are weaker. Therefore, the degree of saturation of individual ligand protons reflects their 
proximity to the protein surface, and can be used as a binding epitope-deducing method to 
describe the protein-ligand interactions. 
STD experiments (2s saturation time) were performed for azathilone either in the presence of 
tubulin heterodimers or in the presence of stabilized microtubules (with ca. 1:15 and 1:30, 
molar ratios, respectively) (Figure 3). The STD intensities of the individual proton resonances 
are plotted in Figure 3, in the form of saturation profiles. 
The comparison of the STD profiles for azathilone 1 bound to unassembled tubulin and to 
microtubules allowed us the identification of those protons which are closer to the protein in 
each aggregation state of the system. As can be seen in figure 3, the profiles are similar, 
although not identical. The absolute values of the detected STD effects are higher for 
microtubules. This evidence is due to the fact that the ligand is bound to a larger receptor in 
this case. The strongest signals in both cases correspond to the H17 and H28 aromatic 
protons, suggesting that these protons are in more intimate contacts with the protein.  
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Figure 3. Bottom. 
1
H STD NMR studies for azathilone in the presence of microtubules. Off-resonance 
spectrum (upper line) and STD spectrum (lower line) of azathilone bound to microtubules. Top. 
Comparison between the STD profiles of azathilone bound to microtubules and to dimeric tubulin. 
 
Modeling of the bioactive conformation in the binding sites 
In a first attempt, a rigid docking protocol was performed in the luminal binding site (PDB code 
1JFF)
[31]
, as previously described 
[32]
. In particular, the major tubulin-bound conformation of the 
azathilone, determined by transferred-NOEs (TR-NOE), was kept rigid throughout the docking 
calculations. In the following step, we allowed the C15-C16 bond of the ligand to be flexible in 
the binding pocket (Figure 4). Then, the best-scored found conformations were used for further 
analysis. 
In the case of the microtubules, the tetramer model described by Magnani and co-workers was 
employed for the docking calculations 
[33]
. This model resembles the geometrical situation 
existing in microtubules better than that found for Zn-stabilized sheets. 
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Figure 4. 3D views of the azathilone-tubulin complex models that better reproduce the experimental data. 
Left) Best docking pose, where flexibility around C15-C16 bond was allowed during the calculation. Right) 
Superimposition of the best docking pose in magenta (major conformer according to NMR data) with the 
pose obtained for the minor conformer (green).  
 
The best binding pose (STD- and TR-NOESY based) was obtained when flexibility around 
C15-C16 bond was allowed during the calculations. In this case, the local docking for 1 
tubulin suggested that there is a preferred azathilone-binding region within this conformer, 
since most of the 100 structures could be gathered in the lowest energy cluster. In fact, this 
binding site corresponds to the taxol-binding site, involving residues 1-31 and 217-233, as 
determined by electron crystallography. 
[31]
 The dimethyl benzimidazole ring occupies the 
hydrophobic pocket close to residues K19, V23 and F83 of the 1 subunit, and it is stabilized 
by short contacts with the methylene groups present in the side chains of E22 and D26. The 
tert-butoxy group of azathilone is located in the proximity of the side chains of V23, I24, P360 
and G370 of the 1 tubulin subunit. The carbonyl group at C5 of the ligand is engaged in a 
hydrogen bond with M-loop residue R278. Also, the hydroxyl group at position 3 is forming a 
hydrogen bond with H229, and the hydroxyl group at position 7 makes a hydrogen bond with 
the backbone carbonyl group of 1 P274 of the M-loop. In the best docking pose, H27 of the 
aromatic side chain is very close to H229 (<2.5 Å), in contrast in the minor conformer, H17 is 
the one closer to H229. 
 
The resulting azathilone binding mode at the pore site takes place at its bottom part, close to 
subunits β1 and β4 (see Figure 5), in a fairly similar location to that described by Freedman et 
al. 
[34]
 and to that recently reported by us for discodermolide. 
[35]
 In this case, the C3 hydroxyl 
of azathilone is engaged in one hydrogen bond with residue 1-K218, while the C7 hydroxyl 
forms a hydrogen bond with the backbone carbonyl group of 4-F94. 
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Figure 5. The azathilone binding pose at the pore type I site of microtubules.  
 
The theoretical STD profiles of the docking models described above were then calculated by 
using the CORCEMA-ST program, and compared to the experimental data (Figure 6). In the 
case of α,β tubulin heterodimers, the theoretical STD effects  calculated for the major 
conformer of azathilone bound at the  internal binding site (Figure 6A) provided a fair 
agreement with those experimentally observed in the presence of non-polymerized -tubulin 
heterodimer. However, it is worth noting that a single structure was not able to reproduce the 
complete experimental STD profile for the aromatic protons, since both NMR conformers had 
to be taken into account. In fact, the linear combination between the STD values obtained for 
the major and minor conformers at the luminal binding site gave the best agreement with the 
experimental data (Figure 6B), thus supporting the presence of both conformers bound to the 
heterodimer.  
 
In the case of microtubules, the best fit between the experimental and calculated STD values 
was obtained when the docking solutions located at the pore site were considered (Figure 6C). 
 
Discussion 
The development of libraries of many synthetic epothilone analogues has contributed, during 
the last years, to extensively map structure-activity relationship (SAR) profiles of epothilones. 
By employing this protocol, the key interactions between the ligand and microtubules have 
been then deduced. 
Whereas it has been shown that most of the functional groups of the macrocycle have to 
remain for keeping a significant biological activity, it has been demonstrated that the epoxide 
ring is not essential and may be replaced by other groups that provide the same rigid 
conformation of the C11/C14 ring segment, thus stabilizing the required conformation of the 
entire macrocycle. In addition, the replacement of the thiazole moiety retains the bioactivity as 
long as the nitrogen stays in its place. This fact has been deduced by employing a pyridine-
containing epothilone analogue. 
[36]
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Figure 6. Upper panel: dark blue, azathilone experimental STD effects; magenta, CORCEMA-ST 
calculation with both coordinates (major and minor conformers) of the azathilone at the lumen of tubulin 
heterodimer. Medium panel: dark blue, azathilone experimental STD effects; magenta, CORCEMA-ST 
calculation with the coordinates of the major conformer of the azathilone at the lumen of tubulin 
heterodimer (Rfactor 0.75, with K 10
3
). Lower panel: green, azathilone experimental STD effects; red, 
CORCEMA-ST calculation with the coordinates of the azathilone at the pore of microtubules (Rfactor 
0.46). All CORCEMA calculations for dimeric tubulin employed a bound correlation time of 60 ns and a kon 
value of 10
8
 s
-1
 M
-1
 for diffusion-controlled binding. 
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In the present work, we have studied the conformational and binding properties of a novel 
compound, where both the epoxide and the thiazole substituents have been modified, while 
keeping the bioactivity. 
[14,19]
 
The use of TR-NOESY and STD experiments with this azathilone, as microtubule-stabilizing 
agent, has allowed detection of its binding features to both non-polymerized tubulin -
heterodimers and microtubules. Remarkably, the modified side chains display interactions with 
tubulin in both aggregation states, suggesting that the new substituents play an important role 
in protein recognition. 
Previous SAR studies proved that N12-unsubstituted compounds were completely inactive, 
whereas the N12-alkyl derivatives behaved as microtubule stabilizing agents, being the tert-
butoxycarbonyl-containing compound a more potent inducer of tubulin polymerization than the 
N12-ethoxycarbonyl analogue. 
[19]
 These findings are in agreement with our experimental data, 
since the t-butoxy protons are receiving important saturation from the protein in the STD 
experiments. In fact, the t-butoxy group is the second substituent with the largest STD effect.  
One of the key structural features of epothilones under discussion refers to the disposition of 
the 3-OH group and its role on providing interactions with the receptor. The first NMR studies 
in organic solvents described the presence of a conformational equilibrium between two low 
energy conformers in this region (defined by the C2-C5 torsion angle). 
[30]
 The determined X-
ray structure of the free compound agreed with the presence of one of these conformers, 
which displays the OH group pointing towards the inner part of the macrocycle.
[37]
 Later, 
Carlomagno et al, in their first work with epothilone A bound to tubulin, reported a different 
conformation with the 3-OH pointing outside of the macrolide ring. This orientation makes the 
oxygen a potentially better acceptor of hydrogen bonding of tubulin side chains. 
[24]
 In fact, 
according to the EC-derived structure, this OH group is involved in protein recognition by the 
formation of a hydrogen bond with T274 of β-tubulin. 
[25]
  
However, additional investigations carried out with the 3-deoxy-Epo A analogue, and the 
corresponding unsaturated derivative 3-deoxy-2,3-didehydro-Epo A showed intriguingly potent 
antiproliferative activity against human cancer cell lines. 
[38]
 According to the structural features 
described above, the bioactivity of these 3-deoxy derivatives would be expected to be 
significantly reduced as compared with the parent natural product. Therefore, the 3-OH group 
does not seem to be crucial for epothilone-tubulin interaction. 
Our experimental results agree with the bound NMR conformation of EpoA proposed by 
Carlomagno, rather than with the X-ray structure of free EpoA. Indeed, the 3-OH points 
towards the outside of the macrolide ring. In our model of azathilone interaction with -
tubulin heterodimer, this OH is engaged in a hydrogen bond with H229, while it is engaged in 
one hydrogen bond with residue 1 K218 in the case of microtubules. It would be interesting to 
synthesize 3-deoxy-azathilone derivatives that might provide access to similar SAR studies for 
comparison with epothilones.   
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A comparison of the dihedral angles of the tubulin-bound structure of EpoA proposed by 
Carlomagno with the major conformer determined in this work is shown in Fig. 7. As can be 
seen in the table, the C5-C11 sections closely overlap, and the substitution of the thiazole 
moiety by the dimethylbenzimidazol side chain locates the nitrogens at nearly identical 
positions. The main difference between the two molecules is found in the C11-C1 region 
(where the structural modifications are located). 
Dihedral angle EpoA-bound 
conformation 
[24]
 
Free 
X-ray 
conformation
[37]
  
 
Azathilone-bound 
Major NMR 
conformer (B) 
C1-C2-C3-C4 -152.5 165.4 156.8 
C2-C3-C4-C5 -51.7 73.0 -67.3 
C3-C4-C5-C6 -43.0 -75.9 -94.79 
C4-C5-C6-C7 156.4 145.6 130.4 
C5-C6-C7-C8 -70.0 -64.0 -61.1 
C6-C7-C8-C9 -74.8 -79.2 -65 
C7-C8-C9-C10 164.1 159.0 164.5 
C8-C9-C10-C11 -171.9 176.8 -169.7 
C9-C10-C11-C12 -178.0 174.8 171.6 
C10-C11-C12-C13 -129.2 -112.8 -68.03 
C11-C12-C13-C14 4.1 -1.9 104.5 
C12-C13-C14-C15 76.3 93.6 -164.5 
C13-C14-C15-O1 -62.6 -82.6 57.8 
C14-C15-O1-C1 179.5 159.6 77.22 
C15-O1-C1-C2 176.3 174.2 -178.5 
O1-C1-C2-C3 -124.3 156.7 59.7 
C14-C15-C16-C17 -129.7 -118.5 -84.7 
C15-C16-C17-C18 180.0 176.0 178.2 
C16-C17-C18-N 180.0 -7.6 179.9 
 
Figure 7. Table with dihedral angles of the structure of tubulin-bound Epo A as it was derived from NMR 
experiments by Carlomagno et al. 
[24]
  with the X-ray structure of Epo A.
[37]
  
 
The internal site 
The combined docking and CORCEMA-ST approach for the non-polymerized -tubulin 
heterodimers has indicated that the major interaction with the azathilone,  using the major 
NMR-based conformation, takes place at the luminal site of the tubulin -subunit. 
Nevertheless, the fit between the experimental and predicted data considerably improved 
when the contribution of a minor conformer was also considered, suggesting that the protein 
binding pocket could accommodate both conformers. This evidence also agrees with the TR-
NOESY data. 
In both binding poses, the benzimidazole side chain is fairly close to the key H229 residue, as 
also occurs in the electron crystallography structural model, where a hydrogen bond is formed 
between His229 and the thiazole nitrogen. In our case, for the non-polymerized tubulin, no 
hydrogen bonds are seen between the benzimidazole side chain and H229. Instead, 
depending on the conformer, the aromatic H17 and H27 protons alternatively interact with this 
aminoacid residue.   
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Figure 8. Superposition of azathilone and EC structure of tubulin-bound Epo A with -tubulin surface of the 
epothilone-bound protein as background.  
 
A representation of our azathilone model docked into its binding site on -tubulin, 
superimposed with the EC-derived structure of epothilone A bound to the same site on tubulin, 
is shown in Fig. 8. The shared binding pocket on -tubulin is clearly visible. Nevertheless, the 
mode of binding of the two entities is strikingly different with regard to their pharmacophore 
features. Our binding model accommodates the dimethyl benzimidazol side chain in a different 
manner to that of the corresponding moiety of EpoA, at the left of the histidine 229. In contrast, 
for Epo A, the thiazole ring is at the right hand side. 
[25]
 A similar behavior has been proposed 
for the interactions of different taxoid side chains with different forms of tubulin, as described 
for the C3’ benzamido of taxol. 
[31]
 In our case, our observations could be explained by the 
steric effects induced by the replacement of the epoxide subsituent by the bulky tert-butoxy 
group. 
The external site 
In the case of the microtubules, the best binding pose was found at the pore site, close to 
subunits 1 and 4, similar to that reported by us for discodermolide 
[35]
, and nearly identical to 
that found for epothilone B (unpublished results). In fact, the C3 hydroxyl of azathilone is 
engaged in one hydrogen bond with residue 1 K218, while the C7 hydroxyl forms a hydrogen 
bond with the backbone carbonyl group of 4 F94. These residues are also involved in 
hydrogen bonding with discodermolide when bound to microtubules (the residues have been 
numbered as in the 1JFF pdb structure). In this binding mode, the hydrophobic pocket at the 
1/4 interface is mainly occupied by the dimethyl benzimidazol ring of the azathilone, which 
establishes favorable hydrophobic interactions with 1 F214, R215 and K218 residues, and 
with 4 residues S117, D120, V121, K123. In the case of microtubules, the rotation around the 
C15-C16 bond seems to be rather limited by the presence of the hydrogen bond formed by the 
nitrogen at the imidazol moiety and the β1 K16 residue. This fact also supports the existence 
of one preferred conformer, as deduced by the TR-NOESY experiments.  
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Conclusions 
In summary, a combination of NMR and modeling methods has allowed us to deduce the 
bioactive conformation of azathilone when bound to tubulin  heterodimers and to 
microtubules. The NMR data have shown that the molecule adopts a preferred conformation in 
presence of the protein. Distinct binding modes of the ligand, either at the internal luminal site, 
or at the external transient binding site of tubulin, have been proposed based on STD data 
acquired for tubulin  heterodimers and microtubules, respectively. 
Taken together, these data corroborate the recently proposed model of existence of an 
external binding site on microtubules for MSAs, and provide the molecular basis for the 
location of the putatives sites in both tubulin  heterodimers and in microtubules binding 
interfaces. 
Experimental procedures 
Proteins and ligands 
Purified calf brain tubulin and chemicals were obtained as previously described. 
[39-40]
 
Azathilone 1 (Scheme 1) was synthesized as described. 
[19]
 This compound was diluted in 
99.8% D6-DMSO (Merck, Darmstad, Germany) to a final concentration of 20 mM and stored at 
-20 ºC.  
NMR sample preparation and experiments  
The samples of the ligand bound to non-polymerized tubulin -heterodimers were prepared 
in 200 L NMR tubes using a 300 μM concentration of the desired compound and 10 μM of 
tubulin in D2O, 10 mM NaPi, 0.1 mM GTP pH* 7.0. The tubulin sample was prepared by 
removing sucrose, Mg
2+
, and H2O from the storage buffer of a 10 mg sample of frozen tubulin, 
by chromatography using a Sephadex G-25 medium column (25x0.9 cm) equilibrated in D2O, 
10 mM NaPi, 0.1 mM GTP pH* 7.0. Tubulin was centrifuged for 10 minutes at 50.000 in a 
TLA120 rotor in an Optima TLX centrifuge to remove aggregates, and its concentration was 
determined spectrophotometrically by employing an extinction coefficient of 107000 M
-1
 cm
-1
 in 
10 mM phosphate buffer containing 1% SDS
[41]
. The samples were incubated at 25 ºC for 30 
min prior to measurement. 
The sample of the ligand bound to microtubules was prepared in a 200 L NMR tube using a 
300 μM concentration of the desired compound and 20 μM of tubulin in D2O, 10 mM KPi, 0.1 
mM GMPCPP, 6 mM MgCl2 pH* 6.7. The tubulin sample was prepared by removing sucrose, 
Mg
2+
, and H2O from the storage buffer of a 20 mg sample of frozen tubulin using a two-step 
procedure by chromatography in a drained centrifuge column of Sephadex G-25 medium (6x1 
cm) equilibrated in D2O, 10 mM KPi, 10 μM GTP pH* 7.0 in the cold, followed by a second 
chromatography using another Sephadex G-25 medium column (15x0.9 cm) equilibrated in 
D2O, 10 mM KPi, pH* 7.0. Tubulin was centrifuged and its concentration measured as above. 
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Tubulin was diluted to 20 μM and GMPCPP 0.1 mM and 6 mM MgCl2 (final pH* 6.7) added 
prior to the drug addition. The samples were then incubated at 37 ºC for 30 min prior to 
measurement. 
NMR spectra were then recorded at 298 K (dimeric tubulin samples) or 310 K (polymeric 
tubulin samples) in D2O on a Bruker AVANCE 500 MHz spectrometer equipped with a triple-
channel cryoprobe. NOESY
[42]
 cross peaks were moderately positive at 310 K for free 
azathilone.  
For the bound ligand, STD and TR-NOE experiments were performed as described
[43]
, using a 
30:1 ligand receptor molar ratio for the interaction experiments with non-polymerized tubulin 
-heterodimers, and employing a 15:1 ligand receptor molar ratio for the interaction 
experiments with microtubules. STD experiments were performed with 0.5, 1, and 2 s 
saturation times (by concatenation of 50 ms gaussian pulses separated by 1 ms). TR-NOESY 
experiments with non-polymerized tubulin -heterodimers were performed with mixing times 
of 50, 100, 200, 250 and 300 ms. No purging spin lock period to remove the NMR signals of 
the background macromolecule was employed, since they were basically not observable due 
to the huge size of the receptor. First, line broadening of the ligand protons was monitored 
after the addition of the protein. Strong negative NOE cross peaks were observed, in contrast 
to the free state, indicating binding of the ligands to the non-polymerized tubulin -
heterodimer or microtubule preparation. The theoretical analysis of the TR-NOEs of the ligand 
protons was performed using a full relaxation matrix approach with exchange
[44]
 as 
implemented in the CORCEMA program. Different exchange-rate constants were employed to 
obtain the optimal match between experimental and theoretical results of the intraresidue 
cross peaks of the ligands, which has a relatively fixed geometry. Given the protein/ligand 
ratio, the overall correlation time c for the free state was always set to 0.25 ns, since NOESY 
cross peaks for the free molecule were essentially zero at room temperature and 500 MHz, 
and the c for the bound state was set to 60 ns for non-polymerized tubulin -heterodimers 
(c calculated with HYDROPRO 
[45]
).  
The theoretical STD effects for ligands bound to non-polymerized tubulin -heterodimers 
and microtubules were calculated using the CORCEMA-ST program. The overall correlation 
time c for the free state was always set to 0.25 ns and the average rotational motion 
correlation time, c, for the bound state was set to 60 ns for non-polymerized tubulin -
heterodimers, and 100 ns for microtubules. An order parameter S
2
=0.85 was employed to 
account for the fast rotation of the methyl groups, as implemented in CORCEMA-ST.  
In order to fit the experimental STD effects and TR-NOE intensities, off-rate constants 
between 100-200000 s
-1 
were tested. Optimal agreement was achieved for koff = 100 s
-1
 in the 
case of microtubules and Koff = 100000 s
-1 
for the non-polymerized tubulin -heterodimer. 
Conformational search of ligands. 
The calculations were performed using the MacroModel/Batchmin
[46]
 package (version 9.6) 
and the OPLS2005 all-atom force field as implemented in the program Macromodel 9.6. Bulk 
water solvation was simulated using MacroModel's generalized Born GB/SA continuum 
solvent model
[47]
. The conformational searches were carried out using the torsional sampling 
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MCMM search method implemented in the Batchmin program, and 20,000 Monte Carlo step 
runs were performed.
 
Extended non-bonded cutoff distances (a van der Waals cutoff of 8.0 Å 
and an electrostatic cutoff of 20.0 Å) were used. PR conjugate gradient (PRCG) minimization 
(2000 steps) was used in the conformational search. 
Docking calculations.  
Docking of the ligand was performed using the AutoDock 4.0 program
[48]
. During an AutoDock 
4.0 simulation, multiple Lamarckian Genetic Algorithm runs occurred, each one providing one 
predicted binding mode, and cluster analysis was performed at the end of the simulation. 
Atomic coordinates for the ligand was obtained from the NMR data assisted by molecular 
mechanics calculations (see above). The -tubulin dimer coordinates were obtained from 
the Protein Data Bank 1JFF code. Model tetramer coordinates were kindly provided by Prof. 
M. Botta
[33]
. 
Grids of probe atom interaction energies and electrostatic potential were generated by the 
AutoGrid program present in AutoDock 4.0. Grid spacing of 0.375 Å were used. For each 
calculation, one job of 100 docking runs was performed using a population of 200 individuals 
and an energy evaluation number of 3 × 10
6
. Autodock structures were minimized by using 
Macromodel 9.6, by several steps of Polak-Ribière conjugate gradient (PRCG) until the energy 
gradient become lower than 0.001 kJ Å
-1
 mol
-1
. 
Since the scoring function implemented in the Autodock program was not useful to select a 
docking pose compatible with the experimental NMR results, a new scoring function was 
implemented, based on the difference between the experimental and theoretical saturation 
transfer difference (STD) of each ligand's proton (SF-STD). An in-house script which employs 
custom-made programs written in Fortran90 (to be published) was used to perform exhaustive 
file treatment in order to score the docked conformations using the CORCEMA-ST program
[49]
 
to predict the STD values for a given ligand-receptor complex. Briefly, the output files of 
Autodock were rebuilt and prepared for CORCEMA-ST analysis. In this way, the structural 
information required for each ligand-receptor complex was prepared for calculating the 
theoretical STD. Protein residues located inside a sphere of 8 Å around the ligand were 
considered for the calculations.  
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6. Conclusions 
In view of the experiments presented throughout the previous chapters the conclusions of the 
present PhD Thesis are the following: 
 
Chapter I: Insights into the molecular recognition of heparin by FGF 
and FGFR based on NMR and computational studies 
 We have successfully characterized the conformational and dynamic properties of 
uniformly labeled 
15
N, 
13
C heparin oligosaccharides and its precursors in solution 
using NMR spectroscopy in combination with Molecular Dynamics simulations. 
Isotopic enrichment of GAGs was found to provide well resolved spectra and this 
novel strategy may be interesting for further study of the interaction of heparin with 
proteins. 
 We have successfully developed a novel protocol for the expression of soluble 
FGFR-Ig2, in its native state. In addition, we have over-expressed and purified FGF1, 
as previously reported by Canales et al. Later, we have been able to efficiently 
incorporate 
15
N and 
15
N, 
13
C in the target proteins by means of uniform labeling 
strategies to suit our experimental needs. Uniform labeling was achieved using an E. 
Coli host and standard methods, and have proved able to monitor binding events on 
our model complexes FGFR-Ig2 – heparin and FGFR-Ig2 – heparin – FGF1. 
  As prerequisite for the investigation of FGFR-Ig2, suitable combinations of three-
dimensional NMR spectra have been set up for the assignment of the NMR backbone 
resonances of the protein, obtaining the protein assignment almost to completion. 
Efficient calculation of the three-dimensional structure of FGFR-Ig2 from distance and 
torsion angle constraints was performed by torsion angle dynamics-driven simulated 
annealing, as implemented in CYANA software. 
 
13
C-filtered experiments and a series of 
15
N-
1
H HSQC experiments were used for the 
conformational analysis of a heparin pentasaccharide, capable to stimulate FGF1 
mediated mitogenic activity, and the study of its interactions when bound to FGFR-
Ig2.  As a result, the protein showed to selectively recognize the 
2
SO twisted-boat 
conformation for the iduronate ring of the GAG. This experimental data, together with 
Docking and MD simulations has let us to propose a model for the mutual recognition 
of these molecules. 
 The successful characterization of the protein binding surfaces involved in the 
interactions of the ternary complex FGF-heparin-FGFR in solution have been 
achieved by HSQC-based titration experiments. A comparison to previously 
described X-ray crystallography structures revealed that the so-called symmetric 
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model is the one occurring in solution. Finally, together with the experimental data, a 
three-dimensional model for the ternary complex FGF1-heparin-FGFR2-Ig2 has been 
proposed by using Docking methods and MD simulations. 
 
Chapter II: Insights into the interaction of Microtubule-stabilizing 
agents with non-polymerized tubulin  heterodimers and 
microtubules by using an integrated NMR and computational 
approach 
 A combined STD, tr-NOESY, and molecular modelling approach has allowed the 
characterization of the binding of Microtubule-stabilizing agents by assembled 
microtubules, including the ligand binding epitope, bioactive conformation, and the 
number and location of the binding sites involved in the recognition. As a result, an 
additional binding site at the pore of the microtubules, different to the internal binding 
site at the lumen has been observed. This scheme was successfully applied to 
screen and identify the binding of different Microtubule-stabilizing agents. 
 An in-house script was built to perform exhaustive file treatment in order to score the 
docked conformations using the CORCEMA-ST program to predict the STD values 
for a given ligand-receptor complex. 
 We have characterized, for the first time, the binding of these microtubule-stabilizing 
agents to non polymerized states of the protein in solution by NMR and MD 
simulations. These results have permitted a better understanding of the molecular 
basis of the recognition of MSAs by tubulin  heterodimers, showing that MSAs 
play a dual role since they not only stabilize microtubules once they are formed, but 
also promote tubulin polymerization.  
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Conclusiones 
A la vista de los resultados presentados en los capítulos anteriores, las conclusiones de la 
presente Tesis doctoral son las siguientes: 
Capítulo I: Estudios experimentales de RMN, y computacionales, del 
reconocimiento molecular de heparina por las proteínas FGF y 
FGFR. 
 Se han caracterizado las propiedades conformacionales y dinámicas de 
oligosacáridos de heparina uniformemente marcados con 
15
N y 
13
C y sus precursores 
en solución, con un método combinado de RMN y cálculos de Dinámica Molecular. 
El marcaje isotópico de los GAG ha proporcionado espectros bien resueltos y esta 
novedosa estrategia será de gran interés para el estudio de interacción de GAGs con 
proteínas.  
 Se ha desarrollado con éxito un nuevo protocolo para la expresión de FGFR-Ig2, 
soluble, en su estado nativo. Además, se ha expresado y purificado FGF1, siguiendo 
el método previamente descrito por A. Canales, en nuestro grupo. Se han podido 
implementar estrategias eficientes para el marcaje de forma uniforme de dichas 
proteínas con 
15
N y 
15
N, 
13
C usando E. coli como huésped y métodos estándar de 
marcaje, que han servido para monitorizar procesos de unión en los complejos 
FGFR-Ig2 – heparina y FGFR-Ig2 – heparina – FGF1. 
 Como prerrequisito para los estudios del dominio Ig2 de FGFR, se ha puesto a punto 
una combinación adecuada de experimentos tridimensionales de RMN para la 
asignación de las resonancias de la cadena principal de la proteína, obteniéndose la 
proteína asignada, casi al completo. El cálculo de la estructura tridimensional de la 
proteína a partir de restricciones de distancia y ángulos torsionales, fue llevado a 
cabo con el programa CYANA. 
 Se han realizado experimentos filtrados en 
13
C y una serie de 
15
N-
1
H HSQC para el 
análisis conformacional y la caracterización de las interacciones de un pentasacárido 
de heparina, capaz de estimular la actividad mitogénica mediada por FGF1, unido a 
FGFR-Ig2. Como resultado, la proteína reconoce selectivamente una conformación 
de tipo bote torcido 
2
SO en el anillo del ácido idurónico en el GAG. Estos resultados 
experimentales, junto con cálculos de Docking y de Dinámica Molecular, nos han 
permitido proponer un modelo del complejo FGFR-Ig2 – GAG. 
 Se han caracterizado las superficies de unión de las proteínas que interaccionan en 
el complejo ternario FGF-heparina-FGFR en solución mediante un protocolo de 
valoración basado en experimentos HSQC. La comparación con las estructuras 
cristalográficas, previamente descritas, reveló que el llamado modelo simétrico es el 
que tiene lugar en solución. Finalmente, se ha propuesto un modelo tridimensional 
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para el complejo ternario FGF1-heparina-FGFR2-Ig2, mediante datos 
experimentales, métodos de Docking y cálculos de Dinámica Molecular. 
 
Capítulo II: Estudios sobre la interacción de agentes estabilizantes 
de microtúbulos con el heterodimero de  tubulina 
despolimerizado, y con microtúbulos, usando una aproximación 
integrada de métodos de RMN y computacionales. 
 Se ha caracterizado la unión de agentes estabilizantes de microtúbulos a tubulina 
ensamblada en forma de microtúbulos, mediante una aproximación combinada de 
experimentos de RMN STD, tr-NOESY y de modelado molecular. Se ha determinado 
el epítopo de unión del ligando, la conformación bioactiva del mismo, y el número y 
localización de los sitios de unión involucrados en el reconocimiento. Se ha 
observado un sitio de unión adicional en el poro del microtúbulo que es diferente al 
sitio interno en el lumen. Este protocolo se ha aplicado con éxito para identificar y 
estudiar varios agentes estabilizantes de microtúbulos. 
 Se ha desarrollado un programa para asegurar el tratamiento adecuado de los 
resultados y priorizar adecuadamente las soluciones de Docking usando los cálculos 
CORCEMA-ST, que predicen los valores de STD para un determinado complejo 
ligando-receptor.  
 Además, se ha caracterizado, usando métodos de RMN en disolución, la unión de 
estos agentes estabilizantes de microtúbulos a heterodímeros de  tubulina. Los 
resultados han permitido una mayor comprensión de las bases moleculares de la 
unión de agentes estabilizantes de microtúbulos a estados no polimerizados de la 
proteína, mostrando que los MSA tienen un doble papel ya que no solo estabilizan 
los microtúbulos una vez formados sino que también promueven la formación de 
microtúbulos a partir del heterodímero sin polimerizar.  
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